:: CLDF ::

Home | Contact Us | Bookmark

HBV

HCC

HCV

Centers of Educational Expertise

Live CME Meetings Webcasts Slide Library Abstract Library

Conference Highlights

HCV | Abstract Library

The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.

Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs

Llaneras J¹, Riveiro-Barciela M², Lens S³, Diago M⁴, Cachero A⁵, García-Samaniego J⁶, Conde I⁷, Arencibia A⁸, Arenas J⁹, Gea F¹⁰, Torras X¹¹, Luis Calleja J¹², Antonio Carrión J¹³, Fernández I¹⁴, María Morillas R¹⁵, Miguel Rosales J¹⁶, Carmona I¹⁷, Fernández-Rodríguez C¹⁸, Hernández-Guerra M¹⁹, Llerena S²⁰, Bernal V²¹, Turnes J²², González-Santiago JM²³, Montoliu S²⁴, Figueruela B²⁵, Badia E²⁶, Delgado M²⁷, Fernández-Bermejo M²⁸, Iñarrairaegui M²⁹, Manuel Pascasio J³⁰, Esteban R², Mariño Z³, Buti M³¹. J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]

2.	Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection
	Williams N¹, Bossert N¹, Chen Y², Jaanimägi U¹, Markatou M³, Talal AH⁴. J Subst Abuse Treat. 2019 Jul;102:33-39. doi: 10.1016/j.jsat.2019.04.009. Epub 2019 May 2.

3.	Clinical evaluation of a hepatitis C antibody rapid immunoassay on self-collected oral fluid specimens
	Kimble MM¹, Stafylis C², Treut P¹, Saab S³, Klausner JD⁴. Diagn Microbiol Infect Dis. 2019 May 25. pii: S0732-8893(19)30117-8. doi: 10.1016/j.diagmicrobio.2019.05.010. [Epub ahead of print]

4.	Hepatitis C Competency and Outreach of Occupational Health Nurses
	Surjadi M¹, Nuchols B², Souza D, Wolfe L³, Burgel B¹. Workplace Health Saf. 2019 Jun 10:2165079919841637. doi: 10.1177/2165079919841637. [Epub ahead of print]

5.	Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors
	Frager SZ¹, Dhand A², Gass A³, Levine A³, Spielvogel D⁴, Nog R², Wolf DC⁵, Bodin RI⁵. Cardiol Rev. 2019 Jul/Aug;27(4):179-181. doi: 10.1097/CRD.0000000000000255.

6.	Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
	McGlynn EA¹, Adams JL², Kramer J², Sahota AK³, Silverberg MJ⁴, Shenkman E⁵, Nelson DR⁶. JAMA Netw Open. 2019 Jun 5;2(6):e194765. doi: 10.1001/jamanetworkopen.2019.4765.

7.	A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY)
	Wilson E¹, Covert E², Hoffmann J¹, Comstock E¹, Emmanuel B¹, Tang L¹, Husson J¹, Chua J¹, Price A¹, Mathur P¹, Rosenthal E¹, Kattakuzhy S¹, Masur H³, Kottilil S¹. J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307-1. doi: 10.1016/j.jhep.2019.05.021. [Epub ahead of print]

8.	Willingness to participate in hepatitis C vaccine trials among socially marginalized people who use drugs
	Yakovenko I¹, Hyshka E¹, Tyrrell L², Wild TC³. J Subst Abuse Treat. 2019 Jun;101:67-71. doi: 10.1016/j.jsat.2019.03.010. Epub 2019 Mar 27.

9.	Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs
	Jost JJ¹, Tempalski B², Vera T³, Akiyama MJ⁴, Mangalonzo AP⁵, Litwin AH^6,7. Int J Environ Res Public Health. 2019 Jun 2;16(11). pii: E1958. doi: 10.3390/ijerph16111958.

10.

Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study

Persico M¹, Aglitti A¹, Milella M², Coppola C³, Messina V⁴, Claar E⁵, Gentile I⁶, Sogari F⁷, Pierri P⁸, Surace LA⁹, Morisco F¹⁰, Tundo P¹¹, Brancaccio G¹², Serviddio G¹³, Gatti P¹⁴, Termite AP¹⁵, Di Costanzo GG¹⁶, Caroleo B¹⁷, Cozzolongo R¹⁸, Coppola N¹⁹, Longo A²⁰, Fontanella L²¹, Federico A²², Rosato V^1,5, Terrenato I²³, Masarone M¹. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14170. [Epub ahead of print]

11.	The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance
	Stopka TJ¹, Jacque E², Kelso P³, Guhn-Knight H⁴, Nolte K⁵, Hoskinson R Jr⁴, Jones A³, Harding J⁶, Drew A⁷, VanDonsel A³, Friedmann PD⁴. Prev Med. 2019 May 31:105740. doi: 10.1016/j.ypmed.2019.05.028. [Epub ahead of print]

12.	Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs
	Coffin PO^1,2, Santos GM^1,2, Behar E¹, Hern J¹, Walker J¹, Matheson T¹, Kinnard EN^1,3, Silvis J¹, Vittinghoff E², Fox R², Page K². PLoS One. 2019 Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019.

13.	Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic
	Lazenby GB¹, Orr C¹, Guille C¹, Meissner EG¹. South Med J. 2019 Jun;112(6):325-330. doi: 10.14423/SMJ.0000000000000988.

14.	Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States - a Rural and Urban Comparison
	Fraser H¹, Vellozzi C², Hoerger TJ³, Evans JL⁴, Kral AH³, Havens J⁵, Young AM^5,6, Stone J¹, Handanagic S⁷, Hariri S⁸, Barbosa C³, Hickman M¹, Leib A⁹, Martin NK^1,10, Nerlander L⁷, Raymond HF¹¹, Page K¹², Zibbell J³, Ward JW^8,13, Vickerman P¹. Am J Epidemiol. 2019 May 31. pii: kwz097. doi: 10.1093/aje/kwz097. [Epub ahead of print]

15.	Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users
	Lier AJ¹, Smith K², Odekon K³, Bronson S², Taub E³, Tharakan M³, Kelly GJ⁴, Patel P⁵, Marcos LA². Infect Dis Ther. 2019 May 25. doi: 10.1007/s40121-019-0249-y. [Epub ahead of print]

16.	Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study
	Williams B¹, Howell J², Doyle J³, Thompson AJ⁴, Draper B⁵, Layton C⁶, Latham N⁷, Bramwell F⁶, Membrey D⁶, Mcpherson M⁸, Roney J⁹, Stoové M⁵, Hellard ME¹⁰, Pedrana A¹¹. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30134-3. doi: 10.1016/j.drugpo.2019.05.012. [Epub ahead of print]

17.

Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs

Latham NH^1,2, Doyle JS^1,3, Palmer AY¹, Vanhommerig JW¹, Agius P^1,4, Goutzamanis S^1,4, Li Z¹, Pedrana A^1,5, Gottfredsson M^6,7,8, Bouscaillou J⁹, Luhmann N⁹, Mazhnaya A^10,11, Altice FL^12,13, Saeed S¹⁴, Klein M¹⁵, Falade-Nwulia OO¹⁶, Aspinall E^17,18, Hutchinson S^17,18, Hellard ME^1,3,5,19, Sacks-Davis R^1,4,20. Liver Int. 2019 May 24. doi: 10.1111/liv.14152. [Epub ahead of print]

18.	Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles
	Fuster D¹, Gelberg L^2,3. J Community Health. 2019 May 24. doi: 10.1007/s10900-019-00679-w. [Epub ahead of print]

19.	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project
	Rojas Rojas T¹, Di Beo V¹, Delorme J², Barre T¹, Mathurin P³, Protopopescu C¹, Bailly F⁴, Coste M¹, Authier N², Carrieri MP⁵, Rolland B⁶, Marcellin F¹. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30135-5. doi: 10.1016/j.drugpo.2019.05.013. [Epub ahead of print]

20.	The Swiss Hepatitis Strategy as a model for facing future health policy challenges
	Blindenbacher R¹, Maeschli B², Bruggmann P³. Health Policy. 2019 May 16. pii: S0168-8510(18)30417-2. doi: 10.1016/j.healthpol.2019.05.010. [Epub ahead of print]

21.	Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs
	Gutkind S¹, Schackman BR¹, Morgan JR², Leff JA¹, Agyemang L³, Murphy SM¹, Akiyama MJ³, Norton BL³, Litwin AH^4,5, Linas BP^2,6. Clin Infect Dis. 2019 May 16. pii: ciz384. doi: 10.1093/cid/ciz384. [Epub ahead of print]

22.	Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons
	Assoumou SA^1,2, Tasillo A¹, Vellozzi C³, Yazdi GE¹, Wang J¹, Nolen S¹, Hagan L⁴, Thompson W⁴, Randall LM⁵, Strick L^6,7, Salomon JA⁸, Linas BP^1,2,9.

23.	Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE
	Teixeira PA¹, Bresnahan MP², Laraque F², Litwin AH³, Shukla SJ³, Schwartz JM³, Reynoso S³, Perumalswami PV⁴, Weiss JM⁴, Wyatt B⁴, Schackman BR¹. Learn Health Syst. 2018 Jul;2(3). pii: e10056. doi: 10.1002/lrh2.10056. Epub 2018 May 10.

24.	Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
	Luo A¹, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Medicine (Baltimore). 2019 May;98(20):e15626. doi: 10.1097/MD.0000000000015626.

25.	Utilizing Electronic Laboratory Reporting Data to Assess the Burden of Hepatitis C in Arizona
	Tsang CA¹, Khan MA, Brady SM, Erhart LM, Komatsu KK. J Public Health Manag Pract. 2019 May 14. doi: 10.1097/PHH.0000000000001011. [Epub ahead of print]

26.	Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response
	Williams J¹, Lucarelli N², Nicoll A^1,2, Lubel J^1,2. Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.

27.	Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort)
	Costa M^1,2, Rojas Rojas T^1,2, Lacoste D³, Villes V^1,2, Aumaitre H⁴, Protopopescu C^1,2, Yaya I^1,2, Wittkop L^5,6, Krause J⁷, Salmon-Céron D^8,9, Marcellin F^1,2, Sogni P^8,10,11, Carrieri MP^1,2; ANRS CO13 HEPAVIH Study Group. Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]

28.	The Global State of Harm Reduction in Prisons
	Sander G¹, Shirley-Beavan S¹, Stone K¹. J Correct Health Care. 2019 Apr;25(2):105-120. doi: 10.1177/1078345819837909.

29.	Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates
	Moore MS¹, Greene SK², Bocour A³, Brown CM⁴, Coyle JR⁵, Kuncio D⁶, Onofrey S⁷, Patel MT⁸, Winters A⁹. J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124. [Epub ahead of print]

30.	Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors
	Sise ME¹, Strohbehn IA², Bethea E², Gustafson JL², Chung RT². Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.

31.	Treatment of patients with HIV or hepatitis C by pharmacist clinicians in a patient-centered medical home
	Ryan KL¹, Jakeman B², Conklin J³, Pineda LJ⁴, Deming P⁵, Mercier RC⁵. Am J Health Syst Pharm. 2019 May 4. pii: zxz059. doi: 10.1093/ajhp/zxz059. [Epub ahead of print]

32.	Hepatitis C Update and Expanding the Role of Primary Care
	Simoncini GM¹, Koren DE². J Am Board Fam Med. 2019 May-Jun;32(3):428-430. doi: 10.3122/jabfm.2019.03.180286.

33.	Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017
	Bartholomew TS^1,2, Grosgebauer K², Huynh K³, Cos T^3,4. Infect Dis (Auckl). 2019 Apr 28;12:1178633719841381. doi: 10.1177/1178633719841381. eCollection 2019.

34.	Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
	Pearlman B¹, Perrys M², Hinds A³. Am J Gastroenterol. 2019 May 8. doi: 10.14309/ajg.0000000000000248. [Epub ahead of print]

35.	Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States
	Mukhtar NA¹, Ness EM¹, Jhaveri M¹, Fix OK¹, Hart M¹, Dale C¹, Pratt C², Kowdley KV³. Ann Hepatol. 2019 Mar - Apr;18(2):360-365. doi: 10.1016/j.aohep.2018.12.003. Epub 2019 Apr 17.

36.	Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships
	Hahn JA¹, Tully DC², Evans JL³, Morris MD³, Briceno A³, Bean DJ⁴, Allen TM⁴, Page K⁵. Open Forum Infect Dis. 2019 Apr 25;6(4):ofz125. doi: 10.1093/ofid/ofz125. eCollection 2019 Apr.

37.	The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration
	Gidwani-Marszowski R^1,2,3, Owens DK^4,5, Lo J⁶, Goldhaber-Fiebert JD⁵, Asch SM^4,7, Barnett PG^6,4,5. Appl Health Econ Health Policy. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print]

38.	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures
	Pawlotsky JM^1,2. Semin Liver Dis. 2019 Apr 30. doi: 10.1055/s-0039-1687823. [Epub ahead of print]

39.	High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial
	Varajic B¹, Cavallazzi R², Mann J², Furmanek S³, Guardiola J², Saad M². J Crit Care. 2019 Apr 15;52:186-192. doi: 10.1016/j.jcrc.2019.04.006. [Epub ahead of print]

40.	Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment
	Voils CI^1,2, King HA^3,4,5, Thorpe CT^6,7, Blalock DV^3,8, Kronish IM⁹, Reeve BB⁴, Boatright C³, Gellad ZF^3,10. Dig Dis Sci. 2019 Apr 29. doi: 10.1007/s10620-019-05621-7. [Epub ahead of print]

41.	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study
	Trickey A¹, Fraser H², Lim AG², Peacock A³, Colledge S³, Walker JG², Leung J⁴, Grebely J⁵, Larney S³, Martin NK⁶, Hickman M⁷, Degenhardt L³, May MT⁸, Vickerman P⁷. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30085-8. doi: 10.1016/S2468-1253(19)30085-8. [Epub ahead of print]

42.	Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs
	E Williams B¹, Nelons D², Seaman A³, Witkowska M⁴, Ronan W⁵, Wheelock H⁵, Zaman A³, Garcia J². Int J Drug Policy. 2019 Apr 15. pii: S0955-3959(19)30074-X. doi: 10.1016/j.drugpo.2019.03.015. [Epub ahead of print]

43.	Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study
	Bajis S¹, Grebely J¹, Cooper L², Smith J², Owen G², Chudleigh A², Hajarizadeh B¹, Martinello M¹, Adey S³, Read P⁴, Gilliver R⁴, Applegate T¹, Treloar C⁵, Maher L¹, Dore GJ¹. J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112. [Epub ahead of print]

44.	Quantitative evaluation of an integrated nurse model of care providing hepatitis Ctreatment to people attending homeless services in Melbourne, Australia
	Harney BL¹, Whitton B², Lim C³, Paige E², McDonald B⁴, Nolan S⁵, Pemberton D⁵, Hellard ME⁶, Doyle JS⁶. Int J Drug Policy. 2019 Apr 10. pii: S0955-3959(19)30077-5. doi: 10.1016/j.drugpo.2019.02.012. [Epub ahead of print]

45.	Liver Fibrosis Determination
	Lai M¹, Afdhal NH². Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.

46.	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis
	Weinberg EM¹, Palecki J¹, Reddy KR¹. Semin Liver Dis. 2019 May;39(2):195-208. doi: 10.1055/s-0039-1679934. Epub 2019 Apr 12.

47.	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis
	Back D¹, Belperio P², Bondin M³, Negro F⁴, Talal AH⁵, Park C³, Zhang Z³, Pinsky B³, Crown E³, Mensa FJ³, Marra F¹. J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110. [Epub ahead of print]

48.	Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned
	Younis IR^1,2, Lakota EA^1,3, Volpe DA¹, Patel V¹, Xu Y¹, Sahajwalla CG¹. J Clin Pharmacol. 2019 Apr 11. doi: 10.1002/jcph.1405. [Epub ahead of print]

49.	Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES
	Butt AA^1,2,3, Yan P¹, Aslam S¹, Shaikh OS¹, Abou-Samra AB^2,3. Clin Infect Dis. 2019 Apr 12. pii: ciz304. doi: 10.1093/cid/ciz304. [Epub ahead of print]

50.	Hepatitis C in pregnant American Indian and Alaska native women; 2003-2015
	Nolen LD¹, O'Malley JC², Seeman SS¹, Bruden DJT¹, Apostolou A^3,4, McMahon BJ⁵, Bruce MG¹. Int J Circumpolar Health. 2019 Dec;78(1):1608139. doi: 10.1080/22423982.2019.1608139.

51.	HIV and HCV screening among trauma patients
	Simoncini GM¹, Oyola-Jimenez J¹, Singleton D¹, Volgraf J², Ramsey FV³, Goldberg A⁴. Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590. [Epub ahead of print]

52.	Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2
	Rogal SS^1,2,3, Yakovchenko V⁴, Waltz TJ^5,6, Powell BJ⁷, Gonzalez R⁸, Park A⁹, Chartier M¹⁰, Ross D¹⁰, Morgan TR⁸, Kirchner JE¹¹, Proctor EK¹², Chinman MJ^13,14. Implement Sci. 2019 Apr 8;14(1):36. doi: 10.1186/s13012-019-0881-7.

53.	Health implications of sex trading characteristics in Long Beach, California, USA
	Clingan SE¹, Fisher DG^2,3, Hardan-Khalil K⁴, Reynolds GL^3,5, Huckabay L⁴, Costa C⁴, Pedersen WC², Johnson ME⁶. Int J STD AIDS. 2019 Apr 8:956462419828138. doi: 10.1177/0956462419828138. [Epub ahead of print]

54.	Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting
	Overton K¹, Clegg J², Pekin F², Wood J², McGrath C², Lloyd A³, Post JJ⁴. Int J Drug Policy. 2019 Apr 6. pii: S0955-3959(19)30078-7. doi: 10.1016/j.drugpo.2019.02.013. [Epub ahead of print]

55.	Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston
	Beiser ME¹, Smith K², Ingemi M³, Mulligan E⁴, Baggett TP⁵. Int J Drug Policy. 2019 Apr 5. pii: S0955-3959(19)30079-9. doi: 10.1016/j.drugpo.2019.03.017. [Epub ahead of print]

56.	Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey
	Kasting ML¹, Giuliano AR², Reich RR³, Roetzheim RG⁴, Duong LM⁵, Thomas E⁶, Nelson DR⁷, Shenkman E⁸, Vadaparampil ST⁹. Cancer Epidemiol. 2019 Apr 3;60:112-120. doi: 10.1016/j.canep.2019.03.007. [Epub ahead of print]

57.	Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois
	McLuckie C^1,2, Pho MT^3,4, Ellis K⁵, Navon L^6,7, Walblay K⁸, Jenkins WD⁹, Rodriguez C¹⁰, Kolak MA¹¹, Chen YT¹², Schneider JA¹³, Zahnd WE^14,15. Int J Environ Res Public Health. 2019 Mar 19;16(6). pii: E989. doi: 10.3390/ijerph16060989.

58.	Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study
	Simmons R^1,2, Ireland G^1,2, Ijaz S^3,2, Ramsay M¹, Mandal S^1,2; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections. J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096. [Epub ahead of print]

59.	Quality of Life, Functioning, and Coping in HCV Patients Continuing Versus Ceasing Alcohol Use
	Sims OT^1,2, Oh H³, Pollio DE¹, Hong BA⁴, Pollio EW¹, North CS^5,6. Health Promot Pract. 2019 Mar 21:1524839919837968. doi: 10.1177/1524839919837968. [Epub ahead of print]

60.	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
	Casey JL¹, Feld JJ^2,3, MacParland SA^4,5. Cells. 2019 Apr 5;8(4). pii: E317. doi: 10.3390/cells8040317.

61.	Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated
	Morris MD¹, Mirzazadeh A², Evans JL³, Briceno A³, Coffin P⁴, Hahn JA⁵, Page KA⁶. Drug Alcohol Depend. 2019 Feb 27;198:133-135. doi: 10.1016/j.drugalcdep.2019.02.008. [Epub ahead of print]

62.

Abara WE¹, Trujillo L², Broz D², Finlayson T², Teshale E¹, Paz-Bailey G², Glick S³, Al-Tayyib AA⁴, Robinson WT⁵, Masiello-Schuette S⁶, Sey EK⁷, Anderson BJ⁸, Poe J Infect Dis. 2019 Mar 27. pii: jiz142. doi: 10.1093/infdis/jiz142. [Epub ahead of print]

J⁹, Braunstein S¹⁰.

63.	Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans
	Bendich I¹, Takemoto S², Patterson JT¹, Monto A³, Barber TC¹, Kuo AC². J Arthroplasty. 2019 Mar 9. pii: S0883-5403(19)30208-6. doi: 10.1016/j.arth.2019.02.052. [Epub ahead of print]

64.	Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
	Eckardt P¹, Niu J², Savage A¹, Griffin T¹, Sherman E^1,3. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219835590. doi: 10.1177/2325958219835590.

65.

Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia

Doyle JS^1,2, Scott N^2,3, Sacks-Davis R², Pedrana AE^2,3, Thompson AJ^4,5, Hellard ME^1,2,3; Eliminate Hepatitis C Partnership. Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15210. [Epub ahead of print]

Collaborators (10)

66.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Thabut D¹, Bureau C², Layese R³, Bourcier V⁴, Hammouche M⁴, Cagnot C⁵, Marcellin P⁶, Guyader D⁶, Pol S⁷, Larrey D⁸, De Lédinghen V⁹, Ouzan D¹⁰, Zoulim F¹¹, Roulot D¹², Tran A¹³, Bronowicki JP¹⁴, Zarski JP¹⁵, Goria O¹⁶, Calès P¹⁷, Péron JM¹⁸, Alric L¹⁹, Bourlière M²⁰, Mathurin P²¹, Blanc JF²², Abergel A²³, Serfaty L²⁴, Mallat A³, Grangé JD²⁵, Attali P²⁶, Bacq Y²⁷, Wartelle-Bladou C²⁸, Dao T²⁹, Pilette C³⁰, Silvain C³¹, Christidis C³², Capron D³³, Bernard-Chabert B³⁴, Hillaire S³⁵, Di Martino V³⁶, Sutton A³⁷, Audureau E³, Roudot-Thoraval F³, Nahon P⁴; ANRS CO12 CirVir group.

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]

67.	Comparative effectiveness of pharmacist care delivery models for hepatitis Cclinics
	Naidjate SS¹, Zullo AR², Dapaah-Afriyie R¹, Hersey ML¹, Marshall BDL³, Winkler RM¹, Berard-Collins C⁴. Am J Health Syst Pharm. 2019 Mar 15. pii: zxz034. doi: 10.1093/ajhp/zxz034. [Epub ahead of print]

68.	Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
	Younossi ZM¹, Henry L¹, P Ong J², Tanaka A³, Eguchi Y⁴, Mizokami M³, Lim YS⁵, Dan YY⁶, Yu ML⁷, Stepanova M⁸. Aliment Pharmacol Ther. 2019 Mar;49(6):644-653. doi: 10.1111/apt.15131. Epub 2019 Feb 13.

69.	The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment
	Woodward EN^1,2, Matthieu MM^3,4, Uchendu US⁵, Rogal S^6,7,8, Kirchner JE^3,9,10. Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.

70.	Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program
	Jones EA¹, Linas BP², Truong V³, Burgess JF¹, Lasser KE^2,3. PLoS One. 2019 Mar 14;14(3):e0213745. doi: 10.1371/journal.pone.0213745. eCollection 2019.

71.	Increasing access for veterans with hepatitis C by enhancing use of clinical pharmacy specialists
	Ourth HL, Groppi JA, Morreale AP, Jorgenson T, Himsel AS, Jacob DA. J Am Pharm Assoc (2003). 2019 Mar 7. pii: S1544-3191(19)30028-7. doi: 10.1016/j.japh.2019.01.018. [Epub ahead of print]

72.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]

73.	Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population
	Mokkarala S^1,2, Johnson C³, Sarkar S³, Rudas RJ⁴. J Correct Health Care. 2019 Mar 13:1078345819832875. doi: 10.1177/1078345819832875. [Epub ahead of print]

74.	Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017
	Bixler D¹, Annambholta P², Abara WE¹, Collier MG¹, Jones J², Mixson-Hayden T¹, Basavaraju SV², Ramachandran S¹, Kamili S¹, Moorman A¹. Am J Transplant. 2019 Mar 12. doi: 10.1111/ajt.15352. [Epub ahead of print]

75.	Fibrosis reversal after hepatitis C virus elimination
	Rockey DC¹. Curr Opin Gastroenterol. 2019 Mar 6. doi: 10.1097/MOG.0000000000000524. [Epub ahead of print]

76.	Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
	Park A¹, Gonzalez R¹, Chartier M¹, Rogal S¹, Yakovchenko V¹, Ross D¹, Morgan TR¹. Fed Pract. 2018 Jul;35(7):24-29.

77.	Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review
	Francis-Graham S^1,2,3, Ekeke NA⁴, Nelson CA⁵, Lee TY⁵, Haj SE⁴, Rhodes T⁶, Vindrola C⁷, Colbourn T⁸, Rosenberg W^9,4,10. BMC Health Serv Res. 2019 Mar 8;19(1):152. doi: 10.1186/s12913-019-3970-z.

78.	Short-term budget affordability of hepatitis C treatments for state Medicaid programs
	Chou JW¹, Silverstein AR², Goldman DP². BMC Health Serv Res. 2019 Feb 28;19(1):140. doi: 10.1186/s12913-019-3956-x.

79.	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers
	Sandmann L^1,2, Dörge P^1,2, Wranke A^1,2, Vermehren J^3,2, Welzel TM^3,2, Berg CP^4,2, Grottenthaler JM^4,2, Weiss KH^5,2, Langel J^5,2, Sterneck M^6,2, von Wulffen M^6,2, Manns MP^1,2, Wedemeyer H^1,7,2, Hardtke S^1,2, von Hahn T^1,2. Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]

80.	Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
	Dellay B¹, Sexter A², Wang JH³, Hess GP^4,5, Kim WR⁶, Israni AK^3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]

81.

Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study

Ide T¹, Koga H², Nakano M¹, Hashimoto S³, Yatsuhashi H³, Higuchi N⁴, Nakamuta M⁴, Oeda S⁵, Eguchi Y⁵, Shakado S⁶, Sakisaka S⁶, Yoshimaru Y⁷, Sasaki Y⁷, Honma Y⁸, Harada M⁸, Seike M⁹, Maeshiro T¹⁰, Miuma S¹¹, Nakao K¹¹, Mawatari S¹², Ido A¹², Nagata K¹³, Matsumoto S¹⁴, Takami Y¹⁵, Sohda T¹⁶, Kakuma T¹⁷, Torimura T¹. Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2. [Epub ahead of print]

82.	Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
	Wei L¹, Kumada H², Perumalswami PV³, Tanwandee T⁴, Cheng W⁵, Heo J⁶, Cheng PN⁷, Hwang P⁸, Mu SM⁹, Zhao XM⁹, Asante-Appiah E⁸, Caro L⁸, Hanna GJ⁸, Robertson MN⁸, Haber BA⁸, Talwani R⁸. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]

83.	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
	Lawitz E¹, Gane E², Cohen E³, Vierling J⁴, Agarwal K⁵, Hassanein T⁶, Mantry PS⁷, Pockros PJ⁸, Bennett M⁹, Kemmer N¹⁰, Morelli G¹¹, Zha J³, Wang D³, Shulman NS³, Cohen DE³, Reddy KR¹². Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.

84.	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation
	Latt NL¹. Gastroenterol Hepatol (N Y). 2018 Dec;14(12):687-705.

85.

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

Bernstein DE¹, Tran A², Martin P³, Kowdley KV⁴, Bourliere M⁵, Sulkowski MS⁶, Pockros PJ⁷, Renjifo B⁸, Wang D⁸, Shuster DL⁸, Cohen DE⁸, Jacobson IM⁹. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

86.	Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
	Park A¹, Gonzalez R¹, Chartier M¹, Rogal S¹, Yakovchenko V¹, Ross D¹, Morgan TR¹. Fed Pract. 2018 Jul;35(7):24-29.

87.	Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
	Dellay B¹, Sexter A², Wang JH³, Hess GP^4,5, Kim WR⁶, Israni AK^3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]

88.	Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
	Wei L¹, Kumada H², Perumalswami PV³, Tanwandee T⁴, Cheng W⁵, Heo J⁶, Cheng PN⁷, Hwang P⁸, Mu SM⁹, Zhao XM⁹, Asante-Appiah E⁸, Caro L⁸, Hanna GJ⁸, Robertson MN⁸, Haber BA⁸, Talwani R⁸. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]

89.	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
	Lawitz E¹, Gane E², Cohen E³, Vierling J⁴, Agarwal K⁵, Hassanein T⁶, Mantry PS⁷, Pockros PJ⁸, Bennett M⁹, Kemmer N¹⁰, Morelli G¹¹, Zha J³, Wang D³, Shulman NS³, Cohen DE³, Reddy KR¹². Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.

90.	Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
	Bernstein DE¹, Tran A², Martin P³, Kowdley KV⁴, Bourliere M⁵, Sulkowski MS⁶, Pockros PJ⁷, Renjifo B⁸, Wang D⁸, Shuster DL⁸, Cohen DE⁸, Jacobson IM⁹. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

91.	Vitamin D deficiency and health-related quality of life in chronic hepatitis C
	Palazzo D¹, Biliotti E¹, Esvan R¹, Volpicelli L¹, Franchi C¹, Fontanelli Sulekova L¹, Spaziante M¹, Santori M¹, Rugova A¹, Rucci P², Taliani G¹. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076. [Epub ahead of print]

92.	Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
	Day E¹, Broder T², Bruneau J³, Cruse S¹, Dickie M⁴, Fish S⁴, Grillon C⁵, Luhmann N⁵, Mason K⁶, McLean E⁷, Trooskin S⁸, Treloar C⁹, Grebely J¹⁰. Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]

93.	Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs
	Childs E¹, Assoumou SA², Biello KB^3,4,5, Biancarelli DL^1,6, Drainoni ML^1,2,6,7, Edeza A^3,4, Salhaney P³, Mimiaga MJ^3,4,5,8, Bazzi AR⁹. Harm Reduct J. 2019 Feb 11;16(1):14. doi: 10.1186/s12954-019-0286-6.

94.	Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
	Kumthekar A¹, Shull S², Lovejoy TI^2,3, Morasco BJ^2,3, Chang M^2,3, Barton J^2,3. Int J Rheum Dis. 2019 Feb 6. doi: 10.1111/1756-185X.13479. [Epub ahead of print]

95.	Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
	Ferenci P¹, Bourgeois S², Buggisch P³, Norris S⁴, Curescu M⁵, Larrey D⁶, Marra F⁷, Kleine H⁸, Dorr P⁹, Charafeddine M⁹, Crown E⁹, Bondin M⁹, Back D⁷, Flisiak R¹⁰. J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080. [Epub ahead of print]

96.	Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival
	Robbins JR^1,2, Schmid RK², Hammad AY³, Gamblin TC³, Erickson BA². Cancer Med. 2019 Jan 31. doi: 10.1002/cam4.1948. [Epub ahead of print]

97.	Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project
	Kempf MC¹, Ott C², Wise JM², Footman AP³, Araya BY³, Hardy CM⁴, Walker C⁴, Latham C⁵, Stockett R⁵, Daniels G⁵, Alexander M⁵, Lanzi RG³. Am J Prev Med. 2018 Nov;55(5S1):S112-S121. doi: 10.1016/j.amepre.2018.05.015.

98.	Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
	Lawitz E¹, Poordad F¹, Anderson LJ², Vesay M², Kelly MM², Liu H², Gao W², Fernsler D², Asante-Appiah E², Robertson MN², Hanna GJ², Barr E², Butterton J², Kowdley KV³, Hassanein T⁴, Sahota A⁵, Gordon SC⁶, Yeh WW². J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]

99.	Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
	Grebely J¹, Dore GJ², Alami NN³, Conway B⁴, Dillon JF⁵, Gschwantler M⁶, Felizarta F⁷, Hézode C⁸, Tomasiewicz K⁹, Fredrick LM³, Dumas EO³, Mensa FJ³. Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print]

100.	Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection
	Nguyen J¹, Barritt Iv AS², Jhaveri R³. J Pediatr. 2019 Feb 6. pii: S0022-3476(18)31729-3. doi: 10.1016/j.jpeds.2018.12.012. [Epub ahead of print]

101.	Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States
	Chaillon A¹, Rand EB², Reau N³, Martin NK¹,⁴. Clin Infect Dis. 2019 Jan 28. doi: 10.1093/cid/ciz063. [Epub ahead of print]

102.	A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C
	Powell D¹, Alpert A², Pacula RL³. Health Aff (Millwood). 2019 Feb;38(2):287-294. doi: 10.1377/hlthaff.2018.05232.

103.	Hepatitis C Virus: No Longer a Barrier to Oncology Care
	Laique SN¹, Vargas HE¹. Am J Gastroenterol. 2019 Feb;114(2):207-208. doi: 10.14309/ajg.0000000000000095.

104.

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1

Shah ND¹, Ventura-Cots M², Abraldes JG³, Alboraie M⁴, Alfadhli A⁵, Argemi J⁶, Badia-Aranda E⁷, Soler EA⁸, Barritt AS 4th¹, Bessone F⁹, Biryukova M¹⁰, Carrilho FJ¹¹, Fernández MC⁸, Guiridi ZD¹⁰, El Kassas M¹², Eng-Kiong T¹³, Farias A¹¹, George J¹⁴, Gui W¹⁵, Thurairajah PH¹³, Hsiang JC¹³, Husic-Selimovic A¹⁶, Isakov V¹⁰, Karoney M¹⁷, Kim W¹⁸, Kluwe J¹⁹, Kochhar R²⁰, Dhaka N²⁰, Costa PM²¹, Nabeshima MA¹¹, Ono SK¹¹, Reis D²¹, Rodil A¹¹, Domech CR⁸, Sáez-Royuela F⁷, Scheurich C¹⁹, Siow W¹⁴, Sivac-Burina N¹⁶, Dos Santos Traquino ES⁸, Some F¹⁷, Spreckic S¹⁶, Tan S²², Vorobioff J⁹, Wandera A¹⁷, Wu P²², Yakoub M¹², Yang L¹⁵, Yu Y²², Zahiragic N¹⁶, Zhang C²², Cortez-Pinto H²¹, Bataller R²³. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30073-4. doi: 10.1016/j.cgh.2019.01.026. [Epub ahead of print]

105.	Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
	Shaheen AA¹, Nguyen HH¹, Congly SE¹, Kaplan GG¹, Swain MG¹. Liver Int. 2019 Jan 28. doi: 10.1111/liv.14054. [Epub ahead of print]

106.	Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals
	Ottman AA¹, Townsend ML¹, Hashem MG¹, Britt RB¹. Ann Pharmacother. 2019 Jan 17:1060028018824988. doi: 10.1177/1060028018824988. [Epub ahead of print]

107.	The successful scale-up of direct-acting antiviral hepatitis C treatments will benefit from concerted investments in implementation science
	Knight R¹, Ti M². Can J Public Health. 2019 Jan 8. doi: 10.17269/s41997-018-0164-0. [Epub ahead of print]

108.	Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care
	Tasillo A¹, Eftekhari Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R, Randall L, Salomon JA, Linas BP. Obstet Gynecol. 2019 Feb;133(2):289-300. doi: 10.1097/AOG.0000000000003062.

109.	Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care
	Kushner T¹, Terrault NA². Hepatol Commun. 2018 Nov 30;3(1):20-28. doi: 10.1002/hep4.1282. eCollection 2019 Jan.

110.	The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA
	Coyle C¹,², Moorman AC³, Bartholomew T², Klein G⁴, Kwakwa H⁵, Mehta SH¹, Holtzman D³. Hepatology. 2019 Jan 11. doi: 10.1002/hep.30501. [Epub ahead of print]

111.	Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
	Rosenberg ES¹, Rosenthal EM¹, Hall EW², Barker L³, Hofmeister MG³, Sullivan PS², Dietz P⁴, Mermin J⁴, Ryerson AB³. JAMA Netw Open. 2018 Dec 7;1(8):e186371. doi: 10.1001/jamanetworkopen.2018.6371.

112.	Treating HCV Infection: It Doesn't Get Much Better Than This
	Naggie S¹. Top Antivir Med. 2019 Jan;26(4):104-108.

113.	Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program
	Burton MJ¹, Voluse AC², Anthony V³. J Subst Abuse Treat. 2019 Mar;98:9-14. doi: 10.1016/j.jsat.2018.11.008. Epub 2018 Nov 20.

114.	Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients
	Shoreibah M¹, Romano J², Sims OT³,⁴,⁵, Guo Y⁶, Jones D⁷, Venkata K², Kommineni V², Orr J⁸, Fitzmorris P¹, Massoud OI¹. J Clin Transl Hepatol. 2018 Dec 28;6(4):391-395. doi: 10.14218/JCTH.2018.00026. Epub 2018 Jul 11.

115.	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
	Mathur P¹, Kottilil S¹, Wilson E¹. J Clin Transl Hepatol. 2018 Dec 28;6(4):431-437. doi: 10.14218/JCTH.2018.00007. Epub 2018 Sep 27.

116.	Machine learning models to predict disease progression among veterans with hepatitis C virus
	Konerman MA¹, Beste LA², Van T³, Liu B⁴, Zhang X⁴, Zhu J⁴, Saini SD¹,³, Su GL¹,³, Nallamothu BK⁵,⁶, Ioannou GN⁷,⁸, Waljee AK¹,³,⁶. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019.

117.	HCV therapy: no one to let behind
	Bourlière M¹, Pietri O². Int J Antimicrob Agents. 2018 Dec 31. pii: S0924-8579(18)30380-7. doi: 10.1016/j.ijantimicag.2018.12.010. [Epub ahead of print]

118.	Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review
	Murdock RM¹, Brizzi MB¹, Perez O¹, Badowski ME². Infect Dis Ther. 2019 Jan 3. doi: 10.1007/s40121-018-0228-8. [Epub ahead of print]

119.	High resolution evolutionary analysis of within-host hepatitis C virus infection
	Raghwani J¹, Wu CH², Ho CKY³, De Jong M³, Molenkamp R³, Schinkel J³, Pybus OG⁴, Lythgoe KA¹. J Infect Dis. 2019 Jan 2. doi: 10.1093/infdis/jiy747. [Epub ahead of print]

120.	Heavy Drinking and Treatment among HIV/HCV Co-Infected Patients
	Elliott JC¹,², Shalev N³, Hasin DS¹,²,⁴. J Subst Abus Alcohol. 2018;6(2). pii: 1079. Epub 2018 Jul 26.

121.	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus
	Li DK¹, Chung RT². Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1.

122.	Hepatitis C and pregnancy outcomes: a systematic review protocol
	Parent S¹, Salters K¹,², Awendila L¹, Ti L³,⁴. BMJ Open. 2018 Dec 22;8(12):e024288. doi: 10.1136/bmjopen-2018-024288.

123.	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure
	Lim TR¹,², Hazlehurst JM³, Oprescu AI¹, Armstrong MJ¹,², Abdullah SF⁴, Davies NP⁵, Flintham R⁵, Balfe P¹, Mutimer DJ¹,², McKeating JA⁶, Tomlinson JW⁷. Clin Endocrinol (Oxf). 2018 Dec 26. doi: 10.1111/cen.13924. [Epub ahead of print]

124.	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
	Foster GR¹, Asselah T², Kopecky-Bromberg S³, Lei Y³, Asatryan A³, Trinh R³, Zadeikis N³, Mensa FJ³. PLoS One. 2019 Jan 2;14(1):e0208506. doi: 10.1371/journal.pone.0208506. eCollection 2019.

125.	Use of Hepatitis C AB-Positive Donor Liver in Hepatitis C Nonviremic Liver Transplant Recipients
	Luckett K¹, Kaiser T¹, Bari K¹, Safdar K¹, Schoech MR¹, Apewokin S¹, Diwan T¹, Cuffy MC¹, Anwar N¹, Shah SA². J Am Coll Surg. 2018 Dec 23. pii: S1072-7515(18)32228-2. doi: 10.1016/j.jamcollsurg.2018.12.004. [Epub ahead of print]

126.	Sustained virological response does not improve long-term glycemic control in patients with type 2 diabetes and chronic hepatitis C
	Li J¹, Gordon SC², Rupp LB³, Zhang T¹, Trudeau S¹, Holmberg SD⁴, Moorman AC⁴, Spradling PR⁴, Teshale EH⁴, Boscarino JA⁵, Schmidt MA⁶, Daida YG⁷, Lu M¹; CHeCS Investigators. Liver Int. 2018 Dec 20. doi: 10.1111/liv.14031. [Epub ahead of print]

127.	Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
	Cardona-Gonzalez MG¹, Goldman JD¹,², Narayan L¹, Brainard DM³, Kowdley KV¹. Hepatol Commun. 2018 Nov 14;2(12):1446-1450. doi: 10.1002/hep4.1280. eCollection 2018 Dec.

128.	A Bitter Pill to Swallow: Why Medication Safety Is Critical in Hepatitis C Treatment
	Sullivan KM, Spooner LM, Harris E, Lowe K, Abraham GM. P T. 2018 Dec;43(12):764-768.

129.	Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients
	Shetty A¹, Buch A², Saab S³,⁴,⁵. Dig Dis Sci. 2018 Dec 17. doi: 10.1007/s10620-018-5404-x. [Epub ahead of print]

130.	Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals
	Trivedi HD¹, Patwardhan VR², Malik R³. Dig Liver Dis. 2018 Nov 28. pii: S1590-8658(18)31235-0. doi: 10.1016/j.dld.2018.11.016. [Epub ahead of print]

131.	Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective
	Crowley D¹,²,³, Van Hout MC⁴,⁵, Lambert JS⁶,⁷, Kelly E⁸, Murphy C⁵,⁸, Cullen W⁶. Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z.

132.	Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes
	Zuckerman A¹, Carver A¹, Chastain CA². Curr Treat Options Infect Dis. 2018;10(4):431-446. doi: 10.1007/s40506-018-0177-5. Epub 2018 Oct 18.

133.	Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago
	Couri T¹, Cotter TG², Chen D³, Hammes M⁴, Reddy B⁴, Josephson M⁴, Yeh H⁵, Chung RT⁶, Paul S². Am J Nephrol. 2018 Dec 14;49(1):32-40. doi: 10.1159/000495263. [Epub ahead of print]

134.	Management and treatment of the HCV-infected kidney transplant patient
	Wong T¹, Bloom RD¹. Semin Dial. 2018 Dec 9. doi: 10.1111/sdi.12766. [Epub ahead of print]

135.	Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy
	Cohen E¹, Liapakis A². Semin Dial. 2018 Dec 17. doi: 10.1111/sdi.12763. [Epub ahead of print]

136.	Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis Cvirus-infected donors into hepatitis C virus-negative patients
	Goldberg D¹,², Reese PP²,³. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12767. [Epub ahead of print]

137.

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

D'Ambrosio R¹, Pasulo L², Puoti M³, Vinci M⁴, Schiavini M⁵, Lazzaroni S², Soria A⁶, Gatti F⁷, Menzaghi B⁸, Aghemo A⁹, Capelli F¹⁰, Rumi MG¹¹, Morini L¹², Giorgini A¹³, Pigozzi MG¹⁴, Rossini A¹⁴, Maggiolo F², Pan A¹⁵, Memoli M¹⁶, Spinelli O¹⁷, Del Poggio P², Saladino V¹⁸, Spinetti A¹⁴, De Bona A¹³, Capretti A¹³, Uberti-Foppa C¹⁹, Bonfanti P²⁰, Terreni N²¹, Menozzi F²², Colombo AE¹⁷, Giglio O¹⁷, Centenaro R²³, Borghi M²⁴, Baiguera C³, Picciotto V⁴, Landonio S⁵, Gori A²⁵, Magnani C²⁶, Noventa F²⁷, Paolucci S²⁸, Lampertico P²⁴, Fagiuoli S²; NAVIGATORE-Lombardia Study Group. J Hepatol. 2018 Nov 23. pii: S0168-8278(18)32543-1. doi: 10.1016/j.jhep.2018.11.011. [Epub ahead of print]

138.	Hepatitis C: is eradication possible?
	Lombardi A¹,², Mondelli MU¹,²; ESCMID Study Group for Viral Hepatitis (ESGVH). Liver Int. 2018 Nov 25. doi: 10.1111/liv.14011. [Epub ahead of print]

139.	Treating hepatitis C virus in dialysis patients: How, when, and why?
	Pagan J¹, Ladino M¹,², Roth D¹. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12764. [Epub ahead of print]

140.	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease
	Bruchfeld A¹, Lindahl K². Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12762. [Epub ahead of print]

141.	Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV
	Frost MC¹, Matson TE², Tsui JI³, Williams EC⁴. Drug Alcohol Depend. 2018 Oct 30;194:288-295. doi: 10.1016/j.drugalcdep.2018.10.008. [Epub ahead of print]

142.	The Revolution in Treatment of Hepatitis C
	Mayberry J¹, Lee WM². Med Clin North Am. 2019 Jan;103(1):43-55. doi: 10.1016/j.mcna.2018.08.007.

143.	Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016
	Assoumou SA¹, Wang J², Tasillo A², Eftekhari Yazdi G², Tsui JI³, Strick L⁴, Linas BP⁵. Am J Prev Med. 2018 Nov 12. pii: S0749-3797(18)32221-9. doi: 10.1016/j.amepre.2018.08.016. [Epub ahead of print]

144.	Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV
	Price JC¹, McKinney JE¹, Crouch PC², Dillon SM³, Radix A⁴, Stivala A⁴, Carollo JR⁵, Fierer DS⁵. J Infect Dis. 2018 Nov 20. doi: 10.1093/infdis/jiy670. [Epub ahead of print]

145.	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients
	Lybeck C¹, Brenndörfer ED², Sällberg M², Montgomery SM³,⁴,⁵, Aleman S⁶,⁷, Duberg AS¹. Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316. [Epub ahead of print]

146.	Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings
	Burrell CN¹, Sharon MJ¹, Davis SM¹, Wojcik EM¹, Martin IBK¹. West J Emerg Med. 2018 Nov;19(6):1057-1064. doi: 10.5811/westjem.2018.9.39512. Epub 2018 Oct 9.

147.

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

Stone J¹, Fraser H², Lim AG², Walker JG², Ward Z², MacGregor L², Trickey A², Abbott S², Strathdee SA³, Abramovitz D³, Maher L⁴, Iversen J⁴, Bruneau J⁵, Zang G⁶, Garfein RS³, Yen YF⁷, Azim T⁸, Mehta SH⁹, Milloy MJ¹⁰, Hellard ME¹¹, Sacks-Davis R¹², Dietze PM¹³, Aitken C¹³, Aladashvili M¹⁴, Tsertsvadze T¹⁵, Mrav?ík V¹⁶, Alary M¹⁷, Roy E¹⁸, Smyrnov P¹⁹, Sazonova Y¹⁹, Young AM²⁰, Havens JR²¹, Hope VD²², Desai M²³, Heinsbroek E²³, Hutchinson SJ²⁴, Palmateer NE²⁴, McAuley A²⁵, Platt L²⁶, Martin NK²⁷, Altice FL²⁸, Hickman M², Vickerman P². Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29.

148.	Identifying barriers to treatment of HCV in the primary care setting
	Johnson S¹,², Aluzaite K³, Taar A³, Schultz M³,⁴. Hepatol Int. 2018 Oct 30. doi: 10.1007/s12072-018-9902-x. [Epub ahead of print]

149.	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
	Grebely J¹, Puoti M², Wedemeyer H³, Cooper C⁴, Sulkowski MS⁵, Foster GR⁶, Berg T⁷, Villa E⁸, Rodriguez-Perez F⁹, Wyles DL¹⁰, Schnell G¹¹, Alami NN¹¹, Zhang Z¹¹, Dumas E¹¹, Dore GJ¹. Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248. doi: 10.1093/ofid/ofy248. eCollection 2018 Nov.

150.	Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)
	Poordad F¹, Shiffman ML², Ghesquiere W³, Wong A⁴, Huhn GD⁵, Wong F⁶, Ramji A⁷, Shafran SD⁸, McPhee F⁹, Yang R⁹, Noviello S¹⁰, Linaberry M¹⁰; ALLY-3C study team. Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print]

151.	Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program
	Talal AH¹,², McLeod A², Andrews P², Nieves-McGrath H¹, Chen Y³, Reynolds A⁴, Sylvester C², Dickerson SS⁵, Markatou M³, Brown LS². Telemed J E Health. 2018 Oct 16. doi: 10.1089/tmj.2018.0161. [Epub ahead of print]

152.	Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges
	Baumert TF¹, Berg T², Lim JK³, Nelson DR⁴. Gastroenterology. 2018 Oct 17. pii: S0016-5085(18)35155-2. doi: 10.1053/j.gastro.2018.10.024. [Epub ahead of print]

153.	Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
	Tran TT¹, Mehta D²,³, Mensa F³, Park C³, Bao Y³, Sanchez Gonzalez Y⁴. Infect Dis Ther. 2018 Dec;7(4):473-484. doi: 10.1007/s40121-018-0218-x. Epub 2018 Oct 27.

154.	Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
	Palaniswami PM¹, El Sayed A¹, Asriel B¹, Carollo JR¹, Fierer DS¹; New York Acute Hepatitis C Surveillance Network.Collaborators (61) Open Forum Infect Dis. 2018 Sep 21;5(10):ofy238. doi: 10.1093/ofid/ofy238. eCollection 2018 Oct.

155.	Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?
	Ruggieri A¹, Gagliardi MC¹, Anticoli S¹. Front Immunol. 2018 Oct 8;9:2302. doi: 10.3389/fimmu.2018.02302. eCollection 2018

156.	Telementoring for hepatitis C treatment in correctional facilities
	Neuhaus M¹, Langbecker D¹, Caffery LJ¹, Taylor M¹, Garner L¹, Williams G², Smith AC¹, Macdonald GA³. J Telemed Telecare. 2018 Dec;24(10):690-696. doi: 10.1177/1357633X18795361.

157.	Care of Incarcerated Patients
	Davis DM¹, Bello JK¹, Rottnek F¹. Am Fam Physician. 2018 Nov 15;98(10):577-583.

158.	Hepatitis C Virus in Women of Childbearing Age, Pregnant Women, and Children
	Schillie SF¹, Canary L², Koneru A², Nelson NP², Tanico W³, Kaufman HW⁴, Hariri S², Vellozzi CJ². Am J Prev Med. 2018 Nov;55(5):633-641. doi: 10.1016/j.amepre.2018.05.029.

159.	The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease
	Younossi Z¹,², Papatheodoridis G³, Cacoub P⁴,⁵, Negro F⁶, Wedemeyer H⁷, Henry L⁸, Hatzakis A⁹,¹⁰. J Viral Hepat. 2018 Nov;25 Suppl 3:6-14. doi: 10.1111/jvh.13005.

160.	Sex hormone levels by presence and severity of cirrhosis in women with chronic hepatitis Cvirus infection
	Sarkar M¹, Lai JC¹, Sawinski D², Zeigler TE³, Cedars M⁴, Forde KA⁵,⁶. J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027. [Epub ahead of print]

161.	Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States
	Young K¹, Liu B², Bhuket T², Gish RG³,⁴, Wong RJ². J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039. [Epub ahead of print]

162.	Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management in Opioid Use Disorder Patients on Methadone
	Talal AH¹,², Andrews P², Mcleod A², Chen Y³, Sylvester C², Markatou M³, Brown LS². Clin Infect Dis. 2018 Oct 17. doi: 10.1093/cid/ciy899. [Epub ahead of print]

163.	National Trends in Liver Transplantation in Older Adults
	Haugen CE¹, Holscher CM¹, Garonzik-Wang J¹, Pozo M¹, Warsame F¹, McAdams-DeMarco M¹,², Segev DL¹,². J Am Geriatr Soc. 2018 Oct 16. doi: 10.1111/jgs.15583. [Epub ahead of print]

164.	Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis
	Flamm S¹, Mutimer D², Asatryan A³, Wang S³, Rockstroh J⁴, Horsmans Y⁵, Kwo PY⁶, Weiland O⁷, Villa E⁸, Heo J⁹, Gane E¹⁰, Ryder SD¹¹, Welzel TM¹², Ruane PJ¹³, Agarwal K¹⁴, Ng TI³, Xue Z³, Lovell SS³, Krishnan P³, Kopecky-Bromberg S³, Trinh R³, Mensa FJ³, Wyles DL¹⁵. J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038. [Epub ahead of print]

165.	The actual management of Hepatitis B and Hepatitis C in children
	Batsis ID¹, Wasuwanich P², Karnsakul WW³. Minerva Pediatr. 2018 Oct 18. doi: 10.23736/S0026-4946.18.05410-5. [Epub ahead of print]

166.	Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir
	Pearlman BL¹,²,³, Hinds AE¹. Aliment Pharmacol Ther. 2018 Nov;48(9):914-923. doi: 10.1111/apt.14977. Epub 2018 Oct 4.

167.	Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism
	Spaulding AC¹,², Chhatwal J³,⁴, Adee MG¹, Lawrence RT⁵, Beckwith CG⁶,⁷, Oehsen WV⁸. J Correct Health Care. 2018 Oct 15:1078345818805770. doi: 10.1177/1078345818805770. [Epub ahead of print]

168.	Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine
	Morey S¹,², Hamoodi A³, Jones D⁴, Young T¹, Thompson C⁴, Dhuny J⁵, Buchanan E¹, Miller C¹, Hewett M¹, Valappil M¹, Hunter E⁶, McPherson S¹,⁷. J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017. [Epub ahead of print]

169.	Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus
	Saab S¹,²,³,⁴, Ahn T¹,²,³,⁴, McDaniel T¹,²,³,⁴, Yanny B¹,²,³,⁴, Tong MJ¹,²,³,⁴. Gastroenterol Hepatol (N Y). 2018 Aug;14(8):459-462.

170.	Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S
	Park H¹, Wang W¹, Henry L¹, Nelson DR². Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303. [Epub ahead of print]

171.	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development
	Bailey JR¹, Barnes E², Cox AL¹. Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35035-2. doi: 10.1053/j.gastro.2018.08.060. [Epub ahead of print]

172.	Differences in Referral Access to Care Between Gastrointestinal Subspecialty Patients: Barriers and Opportunities
	Reddy K¹, Patrick C¹, Liaquat H¹, Rodriquez E¹, Stocker A¹, Cave B², Cave MC¹, Smart L¹, Cutts T³, Abell T¹. Health Equity. 2018 Jun 1;2(1):103-108. doi: 10.1089/heq.2018.0001. eCollection 2018.

173.	Elimination of Hepatitis C in Liver Transplant Recipients
	Saab S¹,², Challita Y¹, Chen PH², Jimenez MA², Lee AD², Saab EG², Ahn T², Choi G¹,², Durazo FA¹,², El-Kabany MM¹,², Han SB¹,², Grotts J¹, Agopian VG², Busuttil RW². J Clin Transl Hepatol. 2018 Sep 28;6(3):247-250. doi: 10.14218/JCTH.2017.00079. Epub 2018 Jun 8.

174.	Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
	Brown PR¹, Sadiq O¹, Weick A², Lenhart A¹, Elbatta M², Fernandez C², Kutait A², Pompa R², Jafri SM². Hepatol Commun. 2018 Sep 24;2(10):1172-1178. doi: 10.1002/hep4.1243. eCollection 2018 Oct.

175.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

Minutolo R¹, Aghemo A²,³, Chirianni A⁴, Fabrizi F⁵, Gesualdo L⁶, Giannini EG⁷, Maggi P⁸, Montinaro V⁶, Paoletti E⁹, Persico M¹⁰, Perticone F¹¹, Petta S¹², Puoti M¹³, Raimondo G¹⁴, Rendina M¹⁵, Zignego AL¹⁶; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Infection. 2018 Sep 25. doi: 10.1007/s15010-018-1209-2. [Epub ahead of print]

176.	Increased HCV Screening Yields Discordant Gains in Diagnoses Among Urban and Rural Veteran Populations in Texas: Results of a Statewide Quality Improvement Initiative
	Wray D, Coppin JD, Scott D, Jacob DA, Jinadatha C. Jt Comm J Qual Patient Saf. 2018 Sep 25. pii: S1553-7250(18)30089-8. doi: 10.1016/j.jcjq.2018.06.005. [Epub ahead of print]

177.	Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use
	Des Jarlais DC¹, Arasteh K², Feelemyer J², McKnight C², Barnes DM², Perlman DC², Uuskula A³, Cooper HLF⁴, Tross S⁵. Drug Alcohol Depend. 2018 Sep 12;192:74-79. doi: 10.1016/j.drugalcdep.2018.07.034. [Epub ahead of print]

178.	Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
	Knight LL¹, Wagner K¹, Leyva Y¹, Bruce VR¹, White KAM¹, Talamantes YS¹, Price B¹, Page K¹, Carvour ML¹. Health Promot Pract. 2018 Nov;19(6):815-822. doi: 10.1177/1524839918799455. Epub 2018 Sep 18.

179.	Evolution of Pretreatment Assessment and Direct Acting Antiviral Regimens in Accordance with Upgrading Guidelines: A Retrospective Study in HIV/HCV Coinfected Patients
	Henry Z¹, Gonzales Zamora JA². Med Sci (Basel). 2018 Sep 20;6(4). pii: E81. doi: 10.3390/medsci6040081.

180.	Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection
	Tartof SY¹, Hsu JW², Wei R², Rubenstein KB³, Hu H³, Arduino JM⁴, Horberg M³, Derose SF², Qian L², Rodriguez CV³. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1471-1478. doi: 10.2215/CJN.01530218. Epub 2018 Sep 21.

181.	Race and Hepatitis C Care Continuum in an Underserved Birth Cohort
	Kim NJ¹,², Locke CJ¹,², Park H¹,², Magee C², Bacchetti P³, Khalili M⁴,⁵,⁶. J Gen Intern Med. 2018 Sep 20. doi: 10.1007/s11606-018-4649-6. [Epub ahead of print]

182.	Hepatitis C care cascade among persons born 1945-1965: 3 medical centers
	Brady JE¹, Vellozzi C, Hariri S, Kruger DL, Nerenz DR, Brown KA, Federman AD, Krauskopf K, Kil N, Massoud OI, Wise JM, Seay TA, Smith BD, Yartel AK, Rein DB. Am J Manag Care. 2018 Sep;24(9):421-427.

183.	Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population
	Kim NJ¹,², Magee C², Cummings C¹,², Park H¹,², Khalili M¹,²,³. Hepatol Commun. 2018 Sep 24;2(10):1274-1283. doi: 10.1002/hep4.1246. eCollection 2018 Oct.

184.	Limited Coverage of Hepatitis C Virus Testing in the United States, 2013-2017
	Patel EU¹, Mehta SH², Boon D², Quinn TC³, Thomas DL⁴, Tobian AAR¹. Clin Infect Dis. 2018 Sep 15. doi: 10.1093/cid/ciy803. [Epub ahead of print]

185.	Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance
	Rosenberg BR¹,², Depla M³, Freije CA², Gaucher D³, Mazouz S³,⁴, Boisvert M³, Bédard N³, Bruneau J³,⁵, Rice CM⁶,⁷, Shoukry NH³,⁸. PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep.

186.	Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C
	Lynch SM¹, Wilson SM²,³, DeRycke EC⁴, Driscoll MA⁴,⁵, Becker WC⁴,⁶, Goulet JL⁴,⁷, Kerns RD⁶, Mattocks KM⁸,⁹, Brandt CA⁴,⁷, Bathulapalli H⁴, Skanderson M⁴, Haskell SG⁴,⁶, Bastian LA⁴,⁶. Pain Med. 2018 Sep 1;19(suppl_1):S5-S11. doi: 10.1093/pm/pny146.

187.	New York State announces initiative to eliminate hepatitis C
	Nelson R. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):666. doi: 10.1016/S2468-1253(18)30275-9.

188.	Why Me? Understanding the HCV Care Continuum Among People With Serious Mental Illness
	Arnold RM¹, Machover H¹, Wall ME¹, Ahmadizadeh I¹, Potts W¹, Himelhoch S¹. Psychiatr Serv. 2018 Sep 17:appips201700542. doi: 10.1176/appi.ps.201700542. [Epub ahead of print]

189.

The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial

Lawitz E¹, Bidair M², Marbury T³, Jones CT⁴, Barve A⁵, Magnusson B⁶, Barkan DT⁴, Bodendorf U⁶, Bracken K⁷, Canino E⁴, Chen D⁴, Dabovic K⁵, Heimbach T⁵, Ison M⁴, Jones CL⁴, Kovacs SJ⁷, Lakshman JP⁵, Li B⁷, Raman P⁵, Steiner-Swiat R⁵, Thohan S⁷, Wong KA⁴, Zhong W⁴, Colvin RA⁸. Clin Ther. 2018 Sep;40(9):1567-1581.e4. doi: 10.1016/j.clinthera.2018.07.019. Epub 2018 Sep 2.

190.

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Fontana RJ, Gordon SC, Heller T, Holmberg SD, Jhaveri R, Jonas MM, Kiser JJ, Linas BP, Lo Re V 3rd, Morgan TR, Nahass RG, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Swan T, Terrault NA, Trooskin SB, Wong JB, Workowski KA. Clin Infect Dis. 2018 Sep 12. doi: 10.1093/cid/ciy585. [Epub ahead of print]

191.	Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure
	Jones H¹, Patel P¹, Sears D¹. J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988. [Epub ahead of print]

192.	Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA
	Smith MK¹, Graham M¹, Latkin CA¹, Mehta SH¹, Cummings DAT². Epidemiol Infect. 2018 Oct;146(14):1845-1853. doi: 10.1017/S0950268818002042. Epub 2018 Aug 2.

193.	'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs
	Skeer MR¹, Ladin K², Wilkins LE³, Landy DM⁴, Stopka TJ⁵. Drug Alcohol Depend. 2018 Sep 1;190:246-254. doi: 10.1016/j.drugalcdep.2018.06.013. Epub 2018 Jul 20.

194.	Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
	Rossi C¹, Butt ZA², Wong S³, Buxton JA², Islam N⁴, Yu A³, Darvishian M², Gilbert M², Wong J², Chapinal N³, Binka M¹, Alvarez M³, Tyndall MW², Krajden M¹, Janjua NZ⁵; BC Hepatitis Testers Cohort Team. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32288-8. doi: 10.1016/j.jhep.2018.07.025. [Epub ahead of print]

195.	Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care
	Epstein RL¹, Sabharwal V², Wachman EM³, Saia KA⁴, Vellozzi C⁵, Hariri S⁵, Linas BP⁶. J Pediatr. 2018 Aug 28. pii: S0022-3476(18)30899-0. doi: 10.1016/j.jpeds.2018.07.006. [Epub ahead of print]

196.	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
	Evon DM¹, Stewart PW², Amador J², Serper M³, Lok AS⁴, Sterling RK⁵, Sarkar S⁶, Golin CE⁷,⁸, Reeve BB⁹, Nelson DR¹⁰, Reau N¹¹, Lim JK¹², Reddy KR³, Di Bisceglie AM¹³, Fried MW¹. PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018.

197.	Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation
	Shelton BA¹, Sawinski D², Linas BP³, Reese PP², Mustian M¹, Hungerpiller M¹, Reed RD¹, MacLennan PA¹, Locke JE¹. Am J Transplant. 2018 Jul 30. doi: 10.1111/ajt.15040. [Epub ahead of print]

198.	Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers
	Adams LM¹, Balderson B², Packett BJ 2nd³. AIDS Patient Care STDS. 2018 Aug;32(8):314-320. doi: 10.1089/apc.2018.0006.

199.	A Head CT is Unnecessary in the Initial Evaluation of A Cirrhotic Patient with Recurrent Hepatic Encephalopathy
	Kumar S¹, Modi R², Bhandari BM², Sass DA¹, Rothstein KD. Ann Hepatol. 2018 Aug 24;17(5):810-814. doi: 10.5604/01.3001.0012.3141.

200.	Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis Cin Children Ages 6-11
	Murray KF¹, Balistreri WF², Bansal S³, Whitworth S⁴, Evans HM⁵, Gonzalez-Peralta RP⁶, Wen J⁷, Massetto B⁸, Kersey K⁸, Shao J⁸, Garrison KL⁸, Parhy B⁸, Brainard DM⁸, Arnon R⁹, Gillis LA¹⁰, Jonas MM¹¹, Chuan-Hao L¹², Narkewicz MR¹³, Schwarz K¹⁴, Rosenthal P¹⁵. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123. [Epub ahead of print]

201.	Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center
	Hodges J¹, Reyes J², Campbell J³, Klein W³, Wurcel A²,⁴. J Community Health. 2018 Aug 21. doi: 10.1007/s10900-018-0568-z. [Epub ahead of print]

202.	Cost-effectiveness of Transplanting HCV-Infected Livers into Uninfected Recipients with Preemptive Antiviral Therapy
	Bethea ED¹, Samur S², Kanwal F³, Ayer T⁴, Hur C¹, Roberts MS⁵, Terrault N⁶, Chung RT⁷, Chhatwal J⁸. Clin Gastroenterol Hepatol. 2018 Aug 20. pii: S1542-3565(18)30880-2. doi: 10.1016/j.cgh.2018.08.042. [Epub ahead of print]

203.	Evaluating HCV screening, linkage to care, and treatment across insurers
	Mulligan K¹, Sullivan J, Yoon L, Chou J, Van Nuys K. Am J Manag Care. 2018 Aug 1;24(8):e257-e264.

204.	Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective
	Saab S¹,², Kardashian A¹, Saggi S², Choi G¹,², Agopian V², Tong MJ². Clin Transplant. 2018 Aug 21:e13383. doi: 10.1111/ctr.13383. [Epub ahead of print]

205.	Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C
	Marshall MC¹,², Herrera JL³. Dig Dis Sci. 2018 Aug 20. doi: 10.1007/s10620-018-5247-5. [Epub ahead of print]

206.	Using HIV Surveillance Data for Targeted, Community-based Hepatitis C Virus Testing among Baby Boomers in Washington, D.C
	Deerin JF, Mikre M, Castel AD, Young AT, Kuo I. J Health Care Poor Underserved. 2018;29(3):964-974. doi: 10.1353/hpu.2018.0072.

207.	Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer
	Dandachi D¹,², Hassan M³, Kaseb A⁴, Angelidakis G², Torres HA²,⁴. J Hepatocell Carcinoma. 2018 Aug 2;5:81-86. doi: 10.2147/JHC.S164568. eCollection 2018.

208.	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse
	Bonsall D¹, Black S², Howe AY², Chase R², Ingravallo P², Pak I², Brown A¹, Smith DA¹, Bowden R¹, Barnes E¹. Infect Drug Resist. 2018 Aug 8;11:1119-1135. doi: 10.2147/IDR.S156581. eCollection 2018.

209.	Danoprevir: First Global Approval
	Markham A¹, Keam SJ². Drugs. 2018 Aug;78(12):1271-1276. doi: 10.1007/s40265-018-0960-0.

210.	Hepatitis C infection substantially reduces survival of alcohol-dependent patients
	Muga R¹, Sanvisens A¹, Jarrin I², Fuster D¹, Bolao F³, Tor J¹, Muñoz A⁴. Clin Epidemiol. 2018 Aug 1;10:897-905. doi: 10.2147/CLEP.S162308. eCollection 2018.

211.	Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients
	Saab S¹, Barnard A, Challita Y, Adeniyi A, Aziz A, Choi G, Durazo FA, El-Kabany MM, Han SB, Busuttil RW. Exp Clin Transplant. 2018 Aug;16(4):419-424.

212.	Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings
	Scott N¹,², Sacks-Davis R¹,², Pedrana A¹,², Doyle J¹,³, Thompson A⁴,⁵, Hellard M¹,²,³. J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975. [Epub ahead of print]

213.	A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study
	Ochalek TA¹, Heil SH², Higgins ST², Badger GJ³, Sigmon SC². Drug Alcohol Depend. 2018 Sep 1;190:224-228. doi: 10.1016/j.drugalcdep.2018.05.032. Epub 2018 Jul 19.

214.	Take Charge, Get Cured: The development and user testing of a culturally targeted mHealth decision tool on HCV treatment initiation for methadone patients
	Bauerle Bass S¹, Jessop A², Gashat M², Maurer L³, Alhajji M³, Forry J³. Patient Educ Couns. 2018 Jul 20. pii: S0738-3991(18)30350-1. doi: 10.1016/j.pec.2018.07.007. [Epub ahead of print]

215.	An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department
	Evans H¹,², Balasegaram S¹,², Douthwaite S³, Hunter L⁴, Kulasegaram R⁵, Wong T⁶, Querol-Rubiera A³, Nebbia G³. PLoS One. 2018 Jul 25;13(7):e0198520. doi: 10.1371/journal.pone.0198520. eCollection 2018.

216.	Changes in Practice and Perception of Hepatitis C and Liver Transplantation: Results of a National Survey
	Shaffer AA¹,², Thomas AG¹, Bowring MG¹, Van Pilsum Rasmussen SE¹, Cash A¹, Kucirka L¹,², Alqahtani S³, Gurakar A³, Sulkowski M³,⁴, Cameron AM¹, Segev DL¹,², Durand CM⁴. Transpl Infect Dis. 2018 Aug 24:e12982. doi: 10.1111/tid.12982. [Epub ahead of print]

217.	Hepatitis C Virus (HCV) RNA Level in Plasma and Kidney Tissue in HCV Antibody Positive Donors: Quantitative Comparison
	Shike H¹, Kadry Z², Imamura-Kawasawa Y³, Greene W¹, Riley T⁴, Nathan HM⁵, Hasz RD⁵, Jain A². Clin Transplant. 2018 Jul 25:e13358. doi: 10.1111/ctr.13358. [Epub ahead of print]

218.	Development and Validation of an Electronic Medical Record-Based Algorithm to Identify Patient Milestones in the Hepatitis C Virus Care Cascade
	Zucker J¹,², Aaron JG¹, Feller DJ³, Slowikowski J⁴, Evans H⁵, Scherer ML¹, Yin MT¹, Gordon P¹. Open Forum Infect Dis. 2018 Jul 3;5(7):ofy153. doi: 10.1093/ofid/ofy153. eCollection 2018 Jul.

219.	Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study
	Gentile I, Fusco F, Buonomo AR, Scotto R, Zappulo E, Pinchera B, Persico F, Califano G, Borgia G, Longo N. Sex Health. 2018 Jul 26. doi: 10.1071/SH17168. [Epub ahead of print]

220.	FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals
	Herink MC¹, Irwin AN¹, Zumach GM¹. Pharmacotherapy. 2018 Jul 24. doi: 10.1002/phar.2167. [Epub ahead of print]

221.	Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study
	Gayam V¹, Mandal AK¹, Khalid M¹, Mukhtar O¹, Gill A¹, Garlapati P¹, Tiongson B¹, Sherigar J², Mansour M¹, Mohanty S². Gastroenterology Res. 2018 Aug;11(4):309-316. doi: 10.14740/gr1072w. Epub 2018 Feb 8.

222.	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs
	Grebely J¹, Larney S², Peacock A¹, Colledge S¹, Leung J³, Hickman M⁴, Vickerman P⁴, Blach S⁵, Cunningham E¹, Dumchev K⁶, Lynskey M⁷, Stone J⁴, Trickey A⁴, Razavi H⁵, Mattick RP², Farrell M², Dore GJ¹, Degenhardt L². Addiction. 2018 Jul 23. doi: 10.1111/add.14393. [Epub ahead of print]

223.	Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment
	Redman JS¹, Sterling RK².Author informationAm J Gastroenterol. 2018 Jul 24. doi: 10.1038/s41395-018-0201-x. [Epub ahead of print]

224.

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

Suda G¹, Kurosaki M², Itakura J², Izumi N², Uchida Y³, Mochida S³, Hasebe C⁴, Abe M⁴, Haga H⁵, Ueno Y⁵, Masakane I⁶, Abe K⁷, Takahashi A⁷, Ohira H⁷, Furuya K⁸, Baba M⁸, Yamamoto Y⁹, Kobayashi T¹⁰, Kawakami A¹¹, Kumagai K¹², Terasita K¹, Ohara M¹, Kawagishi N¹, Umemura M¹, Nakai M¹, Sho T¹, Natsuizaka M¹, Morikawa K¹, Ogawa K¹, Sakamoto N¹³; NORTE Study Group. J Gastroenterol. 2018 Jul 17. doi: 10.1007/s00535-018-1495-6. [Epub ahead of print]

225.	Disparities in Access to Direct Acting Antiviral Regimens for Hepatitis C Virus (HCV): The Impact of Race and Insurance Status
	Younossi ZM¹,². Am J Gastroenterol. 2018 Jul 18. doi: 10.1038/s41395-018-0200-y. [Epub ahead of print]

226.	Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients
	Rice DP¹, Ordoveza MA¹, Palmer AM¹, Wu GY², Chirch LM². AIDS Care. 2018 Jul 18:1-5. doi: 10.1080/09540121.2018.1499857. [Epub ahead of print]

227.	Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
	Jain MK¹,², Thamer M³, Therapondos G⁴, Shiffman ML⁵, Kshirsagar O³, Clark C², Wong RJ⁶. Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171. [Epub ahead of print]

228.	Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City
	Tieu HV¹,², Laeyendecker O³,⁴, Nandi V⁵, Rose R⁶, Fernandez R⁴, Lynch B³, Hoover DR⁷, Frye V⁸, Koblin BA¹. PLoS One. 2018 Jul 18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018.

229.	The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis
	Wurcel AG¹,², Burke DJ³, Wang JJ⁴, Engle B⁵, Noonan K⁶, Knox TA⁵, Kim AY⁷, Linas BP⁴. J Urban Health. 2018 Jul 19. doi: 10.1007/s11524-018-0277-z. [Epub ahead of print]

230.	Disparities in hepatitis C virus infection screening among Baby Boomers in the United States
	Nili M¹, Luo L¹, Feng X¹, Chang J², Tan X³. Am J Infect Control. 2018 Jul 13. pii: S0196-6553(18)30699-0. doi: 10.1016/j.ajic.2018.06.008. [Epub ahead of print]

231.	Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy
	Brewer A, Hanna C, Eckmann L, Schadler A, Divine H. J Am Pharm Assoc (2003). 2018 Jul - Aug;58(4S):S69-S72.e1. doi: 10.1016/j.japh.2018.04.031.

232.	Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
	Stewart RA¹, MacDonald BR², Chu TC², Moore JD³, Fasanmi EO⁴, Ojha RP⁵,⁶. Dig Dis Sci. 2018 Jul 16. doi: 10.1007/s10620-018-5205-2. [Epub ahead of print]

233.	Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
	Flamm S¹, Reddy KR², Zadeikis N³, Hassanein T⁴, Bacon BR⁵, Maieron A⁶, Zeuzem S⁷, Bourliere M⁸, Calleja JL⁹, Kosloski MP³, Oberoi RK³, Lin CW³, Yu Y³, Lovell S³, Semizarov D³, Mensa FJ³. Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30702-X. doi: 10.1016/j.cgh.2018.07.003. [Epub ahead of print]

234.	Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
	Vermehren J¹, Park JS², Jacobson I², Zeuzem S³. J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32181-0. doi: 10.1016/j.jhep.2018.07.002. [Epub ahead of print]

235.	Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system
	Sessa M¹,², Bernardi FF¹, Vitale A³, Schiavone B³, Gritti G¹, Mascolo A¹, Bertini M¹, Scavone C¹, Sportiello L¹, Rossi F¹, Capuano A¹. J Clin Pharm Ther. 2018 Jul 16. doi: 10.1111/jcpt.12744. [Epub ahead of print]

236.	Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users
	Major M¹, Gutfraind A²,³, Shekhtman L²,⁴, Cui Q⁵, Kachko A⁵, Cotler SJ², Hajarizadeh B⁶, Sacks-Davis R⁷,⁸, Page K⁹, Boodram B³, Dahari H¹⁰. Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

237.	Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert
	Yeboah-Korang A¹, Beig MI¹, Khan MQ¹, Goldstein JL¹, Macapinlac DM¹, Maurer D¹, Sonnenberg A², Fimmel CJ¹. J Transl Int Med. 2018 Jun 26;6(2):82-89. doi: 10.2478/jtim-2018-0012. eCollection 2018 Jun.

238.	Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients
	Corson M¹, Moch A¹, Saab S¹. Gastroenterol Hepatol (N Y). 2018 May;14(5):280-285.

239.	Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis
	Eckman MH¹, Woodle ES¹, Thakar CV¹, Paterno F¹, Sherman KE¹. Ann Intern Med. 2018 Jul 10. doi: 10.7326/M17-3088. [Epub ahead of print]

240.	Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C
	Evon DM¹, Golin CE²,³, Ruffin R⁴, Ayres S³, Fried MW¹. Pilot Feasibility Stud. 2018 Jun 27;4:92. doi: 10.1186/s40814-018-0285-5. eCollection 2018.

241.	Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers
	Kapadia SN¹, Marks KM². Clin Ther. 2018 Jul 5. pii: S0149-2918(18)30237-6. doi: 10.1016/j.clinthera.2018.05.010. [Epub ahead of print]

242.	Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
	Gonzales Zamora JA¹. Diseases. 2018 Jun 19;6(2). pii: E51. doi: 10.3390/diseases6020051.

243.	Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials
	Fan H¹, Huang P², Tian T¹, Wu J¹, Xia X³, Feng Y³, Wang J⁴, Yu R¹, Zhang Y⁵, Yue M⁶. J Gastrointestin Liver Dis. 2018 Jun;27(2):159-168. doi: 10.15403/jgld.2014.1121.272.sof.

244.	Incidence and prevalence of antibody to hepatitis C virus in FDNY first responders before and after work at the World Trade Center disaster site
	Webber MP¹,², Liu Y², Cohen HW¹, Schwartz T², Weiden MD², Kelly K², Ortiz V², Zeig-Owens R¹,², Jaber N², Colbeth HL², Prezant DJ²,³. Am J Ind Med. 2018 Jun 20. doi: 10.1002/ajim.22871. [Epub ahead of print]

245.	Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be
	Potluri VS¹, Bloom RD². Kidney Int. 2018 Jul;94(1):18-21. doi: 10.1016/j.kint.2018.03.018.

246.	Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C
	Younossi ZM¹,², Stepanova M³, Reddy R⁴, Manns MP⁵, Bourliere M⁶, Gordon SC⁷, Schiff E⁸, Tran T⁹, Younossi I³, Racila A³. Liver Int. 2018 Jun 12. doi: 10.1111/liv.13900. [Epub ahead of print]

247.	State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015
	Lu CY¹, Zhang F², Golonski N², Lupton C², Jeffrey P³, Wagner AK². Value Health. 2018 Jun;21(6):692-697. doi: 10.1016/j.jval.2017.09.011. Epub 2017 Nov 7.

248.	SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient
	Lo Menzo S¹, Biagi E¹, Di Nuzzo M¹, Grilli A¹, Contini C¹. Ann Hepatol. 2018 July - August ,;17(4):661-664. doi: 10.5604/01.3001.0012.0950.

249.	A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017
	Moore MS¹, Bocour A¹, Laraque F¹, Winters A¹. Public Health Rep. 2018 Jul/Aug;133(4):497-501. doi: 10.1177/0033354918776641. Epub 2018 Jun 14.

250.	Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era
	Zuckerman A¹, Douglas A², Nwosu S³, Choi L³, Chastain C⁴. PLoS One. 2018 Jun 18;13(6):e0199174. doi: 10.1371/journal.pone.0199174. eCollection 2018.

251.	Hepatitis C antibody reactivity among high-risk rural women: opportunities for services and treatment in the criminal justice system
	Strickland JC¹, Staton M²,³, Leukefeld CG²,³, Oser CB³,⁴, Webster JM²,³. Int J Prison Health. 2018 Jun 11;14(2):89-100. doi: 10.1108/IJPH-03-2017-0012.

252.

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

Bourlière M¹, Gordon SC², Schiff ER³, Tran TT⁴, Ravendhran N⁵, Landis CS⁶, Hyland RH⁷, Stamm LM⁷, Zhang J⁷, Dvory-Sobol H⁷, Subramanian GM⁷, Brainard DM⁷, McHutchison JG⁷, Serfaty L⁸, Thompson AJ⁹, Sepe TE¹⁰, Curry MP¹¹, Reddy KR¹², Manns MP¹³. Lancet Gastroenterol Hepatol. 2018 May 30. pii: S2468-1253(18)30118-3. doi: 10.1016/S2468-1253(18)30118-3. [Epub ahead of print]

253.	Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment
	Goel A¹, Chen Q²,³,⁴, Chhatwal J³,⁴, Aggarwal R¹. J Gastroenterol Hepatol. 2018 Jun 4. doi: 10.1111/jgh.14301. [Epub ahead of print]

254.	Intelligent Network DisRuption Analysis (INDRA): A targeted strategy for efficient interruption of hepatitis C transmissions
	Campo DS¹, Khudyakov Y². Infect Genet Evol. 2018 May 31;63:204-215. doi: 10.1016/j.meegid.2018.05.028. [Epub ahead of print]

255.	Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection
	Wandrer F¹, Han B², Liebig S¹, Schlue J³, Manns MP¹,⁴, Schulze-Osthoff K⁵,⁶, Bantel H¹,⁴. Aliment Pharmacol Ther. 2018 Aug;48(3):270-280. doi: 10.1111/apt.14802. Epub 2018 Jun 4.

256.	Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
	Sundberg I¹, Lannergård A², Ramklint M³, Cunningham JL³. BMC Psychiatry. 2018 May 29;18(1):157. doi: 10.1186/s12888-018-1735-6.

257.	Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005-2015
	Reilley B¹, Leston J², Doshani M³, Haberling DL⁴, Persvon M⁴, Weiser T⁵, Collier M³, Iralu J⁶, Mera J⁷, Haverkate R⁸. J Community Health. 2018 May 28. doi: 10.1007/s10900-018-0528-7. [Epub ahead of print]

258.	Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community
	Tierney AR¹, Huepfel W², Shaukat AP³, Lake JR², Boldt M⁴, Wang Q², Hassan MA². J Immigr Minor Health. 2018 May 25. doi: 10.1007/s10903-018-0758-x. [Epub ahead of print]

259.	Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy
	Abutaleb A¹,², Kottilil S¹, Wilson E³. Hepatol Int. 2018 May;12(3):214-222. doi: 10.1007/s12072-018-9873-y. Epub 2018 May 29.

260.	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
	Ascione A¹, De Luca M², Melazzini M³, Montilla S³, Trotta MP³, Petta S⁴, Puoti M⁵, Sangiovanni V⁶, Messina V⁷, Bruno S⁸, Izzi A⁹, Villa E¹⁰, Aghemo A¹¹, Zignego AL¹², Orlandini A¹³, Fontvanella L¹⁴, Gasbarrini A¹⁵, Marzioni M¹⁶, Giannini EG¹⁷, Craxì A⁴; ABACUS Study Group. Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x. [Epub ahead of print]

261.	Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults
	Mazzarelli C¹,², Considine A¹, Childs K¹, Carey I¹, Manini MA¹, Suddle A¹, Dusheiko G¹, Agarwal K¹, Cannon MD¹. J Am Geriatr Soc. 2018 May 25. doi: 10.1111/jgs.15392. [Epub ahead of print]

262.	Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study
	Butt AA¹,²,³,⁴, Ren Y¹, Puenpatom A⁵, Arduino JM⁵, Kumar R⁵, Abou-Samra AB²,³,⁴. Aliment Pharmacol Ther. 2018 Jul;48(1):35-43. doi: 10.1111/apt.14799. Epub 2018 May 24.

263.	Hepatitis C genotype change after transplantation utilizing hepatitis C positive donor organs
	Adekunle R¹, Jonchhe S², Ravichandran B², Wilson E³, Husson J³. Transpl Infect Dis. 2018 May 24:e12925. doi: 10.1111/tid.12925. [Epub ahead of print]

264.	The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective
	Jonas MC¹, Loftus B², Horberg MA³. Infect Dis Clin North Am. 2018 Jun;32(2):481-493. doi: 10.1016/j.idc.2018.02.007.

265.	Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling
	Chhatwal J¹, Chen Q², Aggarwal R³. Infect Dis Clin North Am. 2018 Jun;32(2):461-480. doi: 10.1016/j.idc.2018.02.008.

266.	Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination
	Spaulding AC¹, Adee MG², Lawrence RT³, Chhatwal J⁴, von Oehsen W⁵. Infect Dis Clin North Am. 2018 Jun;32(2):323-345. doi: 10.1016/j.idc.2018.02.014.

267.	Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice
	Norton BL¹, Akiyama MJ², Zamor PJ³, Litwin AH². Infect Dis Clin North Am. 2018 Jun;32(2):347-370. doi: 10.1016/j.idc.2018.02.001.

268.	Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure
	Clement ME¹, Collins LF², Wilder JM³, Mugavero M⁴, Barker T⁵, Naggie S⁶. Infect Dis Clin North Am. 2018 Jun;32(2):407-423. doi: 10.1016/j.idc.2018.02.005.

269.	A Guide to the Economics of Hepatitis C Virus Cure in 2017
	Linas BP¹, Nolen S². Infect Dis Clin North Am. 2018 Jun;32(2):447-459. doi: 10.1016/j.idc.2018.02.013.

270.	Hepatitis C Virus Diagnosis and the Holy Grail
	Applegate TL¹, Fajardo E², Sacks JA³. Infect Dis Clin North Am. 2018 Jun;32(2):425-445. doi: 10.1016/j.idc.2018.02.010.

271.	Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success
	Belperio PS¹, Chartier M², Gonzalez RI³, Park AM⁴, Ross DB², Morgan TR⁵, Backus LI⁶. Infect Dis Clin North Am. 2018 Jun;32(2):281-292. doi: 10.1016/j.idc.2018.02.011.

272.	New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care
	Facente SN¹, Burk K², Eagen K³, Mara ES⁴, Smith AA², Lynch CS⁵. Infect Dis Clin North Am. 2018 Jun;32(2):313-322. doi: 10.1016/j.idc.2018.02.012.

273.	Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings
	Moorman AC¹, Rupp LB², Gordon SC², Zhong Y³, Xing J³, Lu M⁴, Boscarino JA⁵, Schmidt MA⁶, Daida YG⁷, Teshale EH³, Spradling PR³, Holmberg SD³; CHeCS Investigators. Infect Dis Clin North Am. 2018 Jun;32(2):253-268. doi: 10.1016/j.idc.2018.02.002.

274.	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?
	Ward Z¹, Platt L², Sweeney S², Hope VD³,⁴, Maher L⁵, Hutchinson S⁶,⁷, Palmateer N⁶,⁷, Smith J⁸, Craine N⁸, Taylor A⁹, Martin N¹⁰, Ayres R¹¹, Dillon J¹², Hickman M¹, Vickerman P¹. Addiction. 2018 May 17. doi: 10.1111/add.14217. [Epub ahead of print]

275.	Localized US Efforts to Eliminate Hepatitis C
	Gaudino A¹, Gay B¹, Garmon C², Selick M³, Vreeland R⁴, Burk K⁵, Huriaux E⁶, Facente SN⁷, Luetkemeyer A⁸, Waters P⁹, Graham CS¹⁰. Infect Dis Clin North Am. 2018 Jun;32(2):293-311. doi: 10.1016/j.idc.2018.02.009.

276.	The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients
	Gottlieb RL¹,²,³, Hall SA¹,²,³. Curr Transplant Rep. 2018;5(2):145-152. doi: 10.1007/s40472-018-0192-y. Epub 2018 Apr 10.

277.	Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010
	Hall EW¹, Rosenberg ES², Sullivan PS³. BMC Infect Dis. 2018 May 16;18(1):224. doi: 10.1186/s12879-018-3133-6.

278.	Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician
	Alroy-Preis S¹, Daly ER¹, Adamski C¹, Dionne-Odom J¹,², Talbot EA¹,², Gao F¹, Cavallo SJ¹, Hansen K¹, Mahoney JC¹, Metcalf E¹, Loring C¹, Bean C¹, Drobeniuc J³, Xia GL³, Kamili S³, Montero JT¹; New Hampshire and Centers for Disease Control and Prevention Investigation Teams. Clin Infect Dis. 2018 May 14. doi: 10.1093/cid/ciy193. [Epub ahead of print]

279.	Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?
	Rich KM¹, Bia J², Altice FL¹,³, Feinberg J⁴. Curr HIV/AIDS Rep. 2018 May 17. doi: 10.1007/s11904-018-0396-x. [Epub ahead of print]

280.	Incidence of acute kidney injury in patients co-infected with HIV and hepatitis Cvirus receiving tenofovir disoproxil fumarate and ledipasvir/sofosbuvir in a real-world, urban, Ryan White clinic
	Michal JL¹, Rab S², Patel M³, Kyle A⁴, Miller L⁵, Easley KA⁶, Kalapila A⁷. AIDS Res Hum Retroviruses. 2018 May 16. doi: 10.1089/AID.2017.0271. [Epub ahead of print]

281.	Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach
	Deming R¹, Ford MM¹, Moore MS¹, Lim S¹, Perumalswami P², Weiss J³, Wyatt B², Shukla S⁴, Litwin A⁴, Reynoso S⁴, Laraque F¹. J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929. [Epub ahead of print]

282.	Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis
	McDermott CL, Lockhart CM¹, Devine B². J Virus Erad. 2018 Apr 1;4(2):118-122.

283.	Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?
	Bunchorntavakul C¹, Mitrani R², Reddy KR². J Clin Exp Hepatol. 2018 Mar;8(1):81-94. doi: 10.1016/j.jceh.2017.11.012. Epub 2017 Dec 7.

284.	Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
	Gilman AJ¹, Le AK², Zhao C³, Hoang J², Yasukawa LA⁴, Weber SC⁴, Vierling JM⁵, Nguyen MH². BMJ Open Gastroenterol. 2018 May 5;5(1):e000203. doi: 10.1136/bmjgast-2018-000203. eCollection 2018.

285.	Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use
	Owens MD¹, Ioannou GN², Tsui JL², Edelman EJ³, Greene PA⁴, Williams EC⁵. Drug Alcohol Depend. 2018 May 8;188:79-85. doi: 10.1016/j.drugalcdep.2018.03.047. [Epub ahead of print]

286.	The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study
	Durand CM¹, Bowring MG¹, Thomas AG¹, Kucirka LM¹, Massie AB², Cameron A¹, Desai NM¹, Sulkowski M¹, Segev DL³. Ann Intern Med. 2018 Apr 17. doi: 10.7326/M17-2451. [Epub ahead of print]

287.	Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis
	Fabrizi F¹, Donato FM², Messa P³. Ann Hepatol. 2018 Apr 9;17(3):364-391. doi: 10.5604/01.3001.0011.7382.

288.	Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis Ccirrhosis and metabolic risk factors
	Wong A¹,², Le A³, Lee MH⁴, Lin YJ⁴, Nguyen P³, Trinh S³, Dang H³, Nguyen MH⁵. Sci Rep. 2018 May 8;8(1):7164. doi: 10.1038/s41598-018-25533-2.

289.	Treatment for hepatitis C virus-associated mixed cryoglobulinaemia
	Montero N¹, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ. Cochrane Database Syst Rev. 2018 May 7;5:CD011403. doi: 10.1002/14651858.CD011403.pub2. [Epub ahead of print]

290.	Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans
	Beck KR¹, Kim NJ¹, Khalili M². Ann Hepatol. 2018 Apr 9;17(3):413-418. doi: 10.5604/01.3001.0011.7385.

291.	Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care
	Martin SA¹,²,³, Bosse J⁴, Wilson A⁵, Losikoff P⁶,⁷, Chiodo L⁵,⁴. Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7.

292.	Hepatitis C in Pregnancy
	Dibba P¹, Cholankeril R², Li AA³, Patel M⁴, Fayek M⁵, Dibble C⁶, Okpara N⁷, Hines A⁸, Ahmed A⁹. Diseases. 2018 Apr 27;6(2). pii: E31. doi: 10.3390/diseases6020031.

293.	Timing of hepatitis C virus infection treatment in kidney transplant candidates
	Cohen-Bucay A¹,², Francis JM¹, Gordon CE¹. Hemodial Int. 2018 Apr;22 Suppl 1:S61-S70. doi: 10.1111/hdi.12643.

294.	Mental and physical health-related quality of life in patients with hepatitis C is related to baseline comorbidities and improves only marginally with hepatitis Ccure
	Thuluvath PJ¹,², Savva Y³. Clin Transl Gastroenterol. 2018 Apr 25;9(4):149. doi: 10.1038/s41424-018-0016-5.

295.	Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
	Hill A¹, Tahat L², Mohammed MK³, Tayyem RF³, Khwairakpam G⁴, Nath S⁵, Freeman J⁶, Benbitour I⁷, Helmy S⁸. J Virus Erad. 2018 Apr 1;4(2):128-131.

296.	Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network
	Flamm SL¹, Bacon B², Curry MP³, Milligan S⁴, Nwankwo CU⁵, Tsai N⁶, Younossi Z⁷, Afdhal N³. Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14635. [Epub ahead of print]

297.	Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection
	Cory TJ¹, Mu Y¹, Gong Y², Kodidela S², Kumar S². Expert Opin Pharmacother. 2018 May;19(7):749-757. doi: 10.1080/14656566.2018.1459567. Epub 2018 Apr 10.

298.	Results of a Hepatitis C Virus Screening Program of the 1945-1965 Birth Cohort in a Large Emergency Department in New Jersey
	Cornett JK¹, Bodiwala V¹, Razuk V¹, Shukla D¹, Narayanan N¹,². Open Forum Infect Dis. 2018 Mar 26;5(4):ofy065. doi: 10.1093/ofid/ofy065. eCollection 2018 Apr.

299.	Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France
	Cousien A¹, Tran VC², Deuffic-Burban S¹,², Jauffret-Roustide M³,⁴, Mabileau G¹, Dhersin JS⁵, Yazdanpanah Y¹,⁶. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919. [Epub ahead of print]

300.	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
	Reau N¹, Kwo PY², Rhee S³, Brown RS Jr.⁴, Agarwal K⁵, Angus P⁶, Gane E⁷, Kao JH⁸, Mantry PS⁹, Mutimer D¹⁰, Reddy KR¹¹, Tran TT¹², Hu YB³, Gulati A³, Krishnan P³, Dumas EO³, Porcalla A³, Shulman NS³, Liu W³, Samanta S³, Trinh R³, Forns X¹³. Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046. [Epub ahead of print]

301.	Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C
	Wade AJ¹,²,³, McCormack A⁴, Roder C⁴, McDonald K⁵, Davies M⁵,⁶, Scott N², Wardrop M¹, Athan E¹,⁴, Hellard ME²,³. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910. [Epub ahead of print]

302.	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
	Martinello M¹,², Bhagani S³, Gane E⁴, Orkin C⁵, Cooke G⁶, Dore GJ¹,², Petoumenos K¹, Applegate TL¹, Tu E¹, Marks P¹, Pagani N⁷, Grebely J¹, Nelson M⁷, Matthews GV¹,². J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917. [Epub ahead of print]

303.	Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination
	Facente SN¹,², Grebe E³, Burk K⁴, Morris MD², Murphy EL²,⁵, Mirzazadeh A², Smith AA⁴, Sanchez MA⁴, Evans JL², Nishimura A⁴, Raymond HF²,⁶; End Hep C SF. PLoS One. 2018 Apr 11;13(4):e0195575. doi: 10.1371/journal.pone.0195575. eCollection 2018.

304.	Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir
	German P¹, Mathias A², Brainard DM², Kearney BP². Clin Pharmacokinet. 2018 Apr 11. doi: 10.1007/s40262-018-0654-5. [Epub ahead of print]

305.	Alcohol Consumption and Chronic Liver Disease Mortality in New Mexico and the United States, 1999-2013
	Tomedi LE¹, Roeber J¹, Landen M¹. Public Health Rep. 2018 Jan 1:33354918766890. doi: 10.1177/0033354918766890. [Epub ahead of print]

306.	Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era
	Sacks-Davis R¹,², Doyle JS¹,³, Rauch A⁴, Beguelin C⁴, Pedrana AE¹,⁵, Matthews GV⁶, Prins M⁷, van der Valk M⁸, Klein MB⁹, Saeed S¹⁰, Lacombe K¹¹, Chkhartishvili N¹², Altice FL¹³,¹⁴,¹⁵, Hellard ME¹,⁵. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.

307.	Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
	Martin NK¹,², Boerekamps A³, Hill AM⁴, Rijnders BJA³,⁵. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25062. doi: 10.1002/jia2.25062.

308.

HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities

Bosh KA¹, Coyle JR², Hansen V³, Kim EM³, Speers S⁴, Comer M⁵, Maddox LM⁵, Khuwaja S⁶, Zhou W⁶, Jatta A⁷, Mayer R⁷, Brantley AD⁸, Muriithi NW⁸, Bhattacharjee R⁹, Flynn C⁹, Bouton L¹⁰, John B¹⁰, Keusch J², Barber CA¹¹, Sweet K¹¹, Ramaswamy C¹², Westheimer EF¹², VanderBusch L¹³, Nishimura A¹⁴, Vu A¹⁴, Hoffman-Arriaga L¹⁵, Rowlinson E¹⁵, Carter AO¹⁶, Yerkes LE¹⁶, Li W¹⁷, Reuer JR¹⁷, Stockman LJ¹⁸, Tang T¹⁹, Brooks JT¹, Teshale EH²⁰, Hall HI¹. Epidemiol Infect. 2018 Apr 11:1-11. doi: 10.1017/S0950268818000766. [Epub ahead of print]

309.	How far are we from viral hepatitis elimination service coverage targets?
	Hutin YJ¹, Bulterys M¹, Hirnschall GO¹. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25050. doi: 10.1002/jia2.25050.

310.	Systematic Review of the Economic Burden of Overt Hepatic Encephalopathyand Pharmacoeconomic Impact of Rifaximin
	Neff G¹, Iii WZ². Pharmacoeconomics. 2018 Apr 12. doi: 10.1007/s40273-018-0641-6. [Epub ahead of print]

311.	Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review
	Tamborini Permunian E¹, Gervaso L², Gerdes V³, Moja L⁴, Guasti L⁵,⁶, Squizzato A¹. Intern Emerg Med. 2018 Apr 2. doi: 10.1007/s11739-018-1828-8. [Epub ahead of print]

312.	Mother-to-child transmission of hepatitis C virus
	Pott H Junior¹, Theodoro M², de Almeida Vespoli J², Senise JF³, Castelo A³. Eur J Obstet Gynecol Reprod Biol. 2018 Mar 20;224:125-130. doi: 10.1016/j.ejogrb.2018.03.034. [Epub ahead of print]

313.	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort
	Kwo P¹, Fried MW², Reddy KR³, Soldevila-Pico C⁴, Khemichian S⁵, Darling J², Zamor PJ⁶, Napoli AA⁷, Anduze-Faris B⁷, Brown RS Jr.⁸. Hepatol Commun. 2018 Feb 27;2(4):354-363. doi: 10.1002/hep4.1156. eCollection 2018 Apr.

314.	Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US
	Des Jarlais DC¹, Cooper HLF², Arasteh K¹, Feelemyer J¹, McKnight C¹, Ross Z³. PLoS One. 2018 Mar 29;13(3):e0194799. doi: 10.1371/journal.pone.0194799. eCollection 2018.

315.	Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
	Weiss L¹,², Wustmann K³, Semmo M⁴, Schwerzmann M³, Semmo N¹. Case Rep Gastroenterol. 2018 Feb 21;12(1):92-98. doi: 10.1159/000486951. eCollection 2018 Jan-Apr.

316.	Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015
	Kasting ML¹,², Giuliano AR²,³, Reich RR⁴, Roetzheim RG¹,⁵, Nelson DR⁶, Shenkman E⁷,⁸, Vadaparampil ST⁹,². Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):503-513. doi: 10.1158/1055-9965.EPI-17-0855. Epub 2018 Mar 27.

317.	Increasing Hepatitis C Virus Knowledge Through an Evidence-Based Educational Intervention
	Koman D¹. Gastroenterol Nurs. 2018 Mar/Apr;41(2):95-102. doi: 10.1097/SGA.0000000000000310.

318.	Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis
	Wang H¹, Swann R², Thomas E³, Innes HA⁴,⁵, Valerio H⁴,⁵, Hayes PC⁶, Allen S⁷, Barclay ST⁸, Wilks D⁹, Fox R¹⁰, Bhattacharyya D¹¹, Kennedy N¹², Morris J¹³, Fraser A¹⁴, Stanley AJ⁸, Gunson R¹⁵, Mclntyre PG¹⁶, Hunt A¹⁷, Hutchinson SJ⁴,⁵, Mills PR², Dillon JF¹⁸. J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897. [Epub ahead of print]

319.	HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens
	Boyd SD¹, Harrington P¹, Komatsu TE¹, Naeger LK¹, Chan-Tack K¹, Murray J¹, Birnkrant D¹, Struble K¹. J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896. [Epub ahead of print]

320.	Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment
	Dobler CC¹, Morgan RL², Falck-Ytter Y³, Montori VM⁴, Murad MH¹. BMJ Evid Based Med. 2018 Apr;23(2):50-53. doi: 10.1136/bmjebm-2017-110852. Epub 2018 Feb 26.

321.	Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C
	Heo YA¹, Deeks ED². Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.

322.	It's Not Much of a Life: The Benefits and Ethics of Using Life History Methods With People Who Inject Drugs in Qualitative Harm Reduction Research
	Harris M¹, Rhodes T¹. Qual Health Res. 2018 Mar 1:1049732318764393. doi: 10.1177/1049732318764393. [Epub ahead of print]

323.	Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis
	McLinden T¹, Moodie EEM¹, Hamelin AM¹, Harper S¹, Rossi C¹, Walmsley SL², Rourke SB³, Cooper C⁴, Klein MB⁵, Cox J⁶. Drug Alcohol Depend. 2018 Feb 20;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031. [Epub ahead of print]

324.	HCV viraemia in anti-HCV-negative haemodialysis patients: Do we need HCV RNA detection test?
	Papadopoulos N¹, Griveas I², Sveroni E¹, Argiana V¹, Kalliaropoulos A³, Martinez-Gonzalez B³, Deutsch M⁴. Int J Artif Organs. 2018 Mar;41(3):168-170. doi: 10.1177/0391398817752326. Epub 2018 Feb 13.

325.	The Role of Aging, Drug Dependence, and Hepatitis C Comorbidity in Alcoholism Cortical Compromise
	Sullivan EV¹, Zahr NM¹,², Sassoon SA², Thompson WK³, Kwon D¹,², Pohl KM², Pfefferbaum A¹,². JAMA Psychiatry. 2018 Mar 14. doi: 10.1001/jamapsychiatry.2018.0021. [Epub ahead of print]

326.	Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment
	Wong RJ¹, Jain MK²,³, Therapondos G⁴, Shiffman ML⁵, Kshirsagar O⁶, Clark C³, Thamer M⁶. Am J Gastroenterol. 2018 Mar 9. doi: 10.1038/s41395-018-0033-8. [Epub ahead of print]

327.	Hepatitis C in Injection-Drug Users ? A Hidden Danger of the Opioid Epidemic
	Lang, TJ, Ward, JW. N Engl J Med 2018 Mar 29; 378:1169-1171.

328.	Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial
	Kleinstein SE¹,², Shea PR¹, Stamm LM³, Sulkowski M⁴, Goldstein DB¹, Naggie S⁵,⁶. Clin Infect Dis. 2018 Mar 7. doi: 10.1093/cid/cix1051. [Epub ahead of print]

329.	Direct-acting antiviral treatment for patients with hepatocellular carcinoma
	Kushner T¹, Dieterich D, Saberi B. Curr Opin Gastroenterol. 2018 Mar 6. doi: 10.1097/MOG.0000000000000431. [Epub ahead of print]

330.	Diagnosis and monitoring of HCV infection using the cobas® HCV test for use on the cobas® 6800/8800 systems
	Yao JD¹, Young S², Heilek GM³, Marino E³, Paxinos EE³, Marins EG³, Valsamakis A⁴. J Clin Virol. 2018 Feb 24;102:63-69. doi: 10.1016/j.jcv.2018.02.017. [Epub ahead of print]

331.	A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients
	Sims OT¹,²,³,⁴, Melton PA⁵, Ji S⁶. J Community Health. 2018 Mar 6. doi: 10.1007/s10900-018-0476-2. [Epub ahead of print]

332.	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis CVirus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial
	Durand CM¹, Bowring MG¹, Brown DM¹, Chattergoon MA¹, Massaccesi G¹, Bair N¹, Wesson R¹, Reyad A¹, Naqvi FF¹, Ostrander D¹, Sugarman J², Segev DL¹, Sulkowski M¹, Desai NM¹. Ann Intern Med. 2018 Mar 6. doi: 10.7326/M17-2871. [Epub ahead of print]

333.	Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents
	Gade AR¹, Patel M¹, West DR¹, Abrams GA¹. South Med J. 2018 Mar;111(3):137-141. doi: 10.14423/SMJ.0000000000000774.

334.	Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study
	Singer AW¹, Reddy KR², Telep LE¹, Osinusi AO¹, Brainard DM¹, Buti M³, Chokkalingam AP¹,⁴. Aliment Pharmacol Ther. 2018 Mar 7. doi: 10.1111/apt.14593. [Epub ahead of print]

335.	Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis
	Petta S¹, Adinolfi LE², Fracanzani AL³, Rini F⁴, Caldarella R⁵, Calvaruso V⁴, Cammà C⁴, Ciaccio M⁵, Di Marco V⁴, Grimaudo S⁴, Licata A⁴, Marrone A², Nevola R², Pipitone RM⁴, Pinto A⁶, Rinaldi L², Torres D⁶, Tuttolomondo A⁶, Valenti L³, Fargion S³, Craxì A⁴. J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132-6. doi: 10.1016/j.jhep.2018.02.015. [Epub ahead of print]

336.	Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
	Valerio H¹, McAuley A², Innes H³, Palmateer N³, Goldberg DJ², Munro A⁴, Taylor A⁵, Hutchinson SJ³. Int J Drug Policy. 2018 Feb;52:115-122. doi: 10.1016/j.drugpo.2017.12.014.

337.	The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions
	Perlman DC¹,², Jordan AE³,⁴. Curr HIV/AIDS Rep. 2018 Feb 19. doi: 10.1007/s11904-018-0390-3. [Epub ahead of print]

338.	Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups
	Falla AM¹,², Hofstraat SHI³, Duffell E⁴, Hahné SJM³, Tavoschi L⁴, Veldhuijzen IK⁵,³. BMC Infect Dis. 2018 Feb 12;18(1):79. doi: 10.1186/s12879-018-2988-x.

339.	Regulation of insulin resistance and type II diabetes by hepatitis C virus infection: A driver function of circulating miRNAs
	Singhal A¹, Agrawal A², Ling J¹. J Cell Mol Med. 2018 Feb 7. doi: 10.1111/jcmm.13553. [Epub ahead of print]

340.	A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection
	Sims OT: ¹,: ²,: ³,: ⁴, Hong BA: ⁵, Ji S: ⁶, Pollio DE: ⁷,: ⁸,: ⁹, North CS: ¹⁰,: ¹¹. J Relig Health. 2018 Feb 6. doi: 10.1007/s10943-018-0565-7. [Epub ahead of print]

341.	Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV
	Barritt AS 4th¹, Jhaveri R². Curr HIV/AIDS Rep. 2018 Feb 22. doi: 10.1007/s11904-018-0386-z. [Epub ahead of print]

342.	Glecaprevir + pibrentasvir for treatment of hepatitis C
	Carrion AF¹, Martin P². Expert Opin Pharmacother. 2018 Mar 7:1-7. doi: 10.1080/14656566.2018.1444030. [Epub ahead of print]

343.	Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial
	Foster GR¹, Agarwal K², Cramp ME³, Moreea S⁴, Barclay S⁵, Collier J⁶, Brown AS⁷, Ryder SD⁸, Ustianowski A⁹, Forton DM¹⁰, Fox R¹¹, Gordon F¹², Rosenberg WM¹³, Mutimer DJ¹⁴, Du J¹⁵, Gilbert CL¹⁵, Asante-Appiah E¹⁵, Wahl J¹⁵, Robertson MN¹⁵, Barr E¹⁵, Haber B¹⁵. Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852. [Epub ahead of print]

344.	Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis
	Asselah T¹, Reesink H², Gerstoft J³, de Ledinghen V⁴, Pockros PJ⁵, Robertson M⁶, Hwang P⁶, Asante-Appiah E⁶, Wahl J⁶, Nguyen BY⁶, Barr E⁶, Talwani R⁶, Serfaty L⁷. Liver Int. 2018 Feb 20. doi: 10.1111/liv.13727. [Epub ahead of print]

345.	Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia: a multicentre open-label study
	Mazzaro C¹, Dal Maso L², Quartuccio L³, Ghersetti M⁴, Lenzi M⁵, Mauro E⁴, Bond M³, Casarin P⁴, Gattei V⁶, Crosato IM⁷, De Vita S³, Pozzato G⁸. Clin Exp Rheumatol. 2018 Feb 13. [Epub ahead of print]

346.	Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort
	Maier MM¹,², Zhou XH³,⁴, Chapko M⁴,⁵, Leipertz SL⁶, Wang X⁷, Beste LA⁸,⁹. Dig Dis Sci. 2018 Feb 16. doi: 10.1007/s10620-018-4956-0. [Epub ahead of print]

347.	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies
	Grebely J¹, Feld JJ², Wyles D³, Sulkowski M⁴, Ni L⁵, Llewellyn J⁵, Mir HM⁵, Sajed N⁵, Stamm LM⁵, Hyland RH⁵, McNally J⁵, Brainard DM⁵, Jacobson I⁶, Zeuzem S⁷, Bourlière M⁸, Foster G⁹, Afdhal N¹⁰, Dore GJ¹. Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001. eCollection 2018 Feb.

348.	Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population
	Fill MA¹, Sizemore LA², Rickles M², Cooper KC³, Buecker CM⁴, Mullins HL⁵, Hofmeister MG¹, Abara WE¹, Foster MA⁶, Asher AK⁶, Schaffner W⁷, Dunn JR², Jones TF², Wester C². Epidemiol Infect. 2018 Feb 12:1-7. doi: 10.1017/S0950268818000080. [Epub ahead of print]

349.	Is global elimination of HCV realistic?
	Calvaruso V¹, Petta S¹, Craxì A¹. Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668.

350.	Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study
	Kelly ML¹,²,³, Riordan SM⁴,⁵, Bopage R², Lloyd AR¹,³,⁶, Post JJ¹,²,³,⁴. PLoS One. 2018 Feb 13;13(2):e0192763. doi: 10.1371/journal.pone.0192763. eCollection 2018.

351.	Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in
	Pol S¹,², Parlati L¹. Liver Int. 2018 Feb;38 Suppl 1:28-33. doi: 10.1111/liv.13626.

352.	The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities
	Cortesi PA¹, Belli LS²,³, Facchetti R¹, Mazzarelli C², Perricone G², De Nicola S², Cesana G¹, Duvoux C⁴, Mantovani LG¹,³, Strazzabosco M³,⁵; European Liver and Intestine Transplant Association (ELITA). J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877. [Epub ahead of print]

353.	The next wave of hepatitis C virus: The epidemic of intravenous drug use
	Shiffman ML¹. Liver Int. 2018 Feb;38 Suppl 1:34-39. doi: 10.1111/liv.13647.

354.	Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
	Asselah T¹, Marcellin P¹, Schinazi RF². Liver Int. 2018 Feb;38 Suppl 1:7-13. doi: 10.1111/liv.13673.

355.	Managing hepatitis C in patients with the complications of cirrhosis
	Mücke MM¹, Mücke VT¹, Lange CM¹, Zeuzem S¹. Liver Int. 2018 Feb;38 Suppl 1:14-20. doi: 10.1111/liv.13636.

356.	Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA
	Chhatwal J¹,²,³, Chen Q¹,², Ayer T⁴, Bethea ED¹,²,³, Kanwal F⁵,⁶, Kowdley KV⁷, Wang X⁸, Roberts MS⁹, Gordon SC¹⁰. Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14527. [Epub ahead of print]

357.	Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction
	Cox-North P¹, Hawkins KL², Rossiter ST², Hawley MN², Bhattacharya R², Landis CS¹,². Hepatol Commun. 2017 Apr 18;1(3):248-255. doi: 10.1002/hep4.1035. eCollection 2017 May.

358.	Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis Cinfection
	Reau N¹, Robertson MN², Feng HP², Caro L², Yeh WW², Nguyen BT², Wahl J², Barr E², Hwang P², Klopfer SO². Hepatol Commun. 2017 Aug 22;1(8):757-764. doi: 10.1002/hep4.1081. eCollection 2017 Oct.

359.	Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations
	Wittenborn J¹, Brady J¹, Dougherty M¹, Rein D¹. Hepatol Commun. 2017 Mar 30;1(2):99-109. doi: 10.1002/hep4.1031. eCollection 2017 Apr.

360.	Prevalence and economic burden of extrahepatic manifestations of hepatitis Cvirus are underestimated but can be improved with therapy
	Reau N¹, Vekeman F², Wu E², Bao Y³, Gonzalez YS³. Hepatol Commun. 2017 May 23;1(5):439-452. doi: 10.1002/hep4.1049. eCollection 2017 Jul.

361.	Vertical transmission of hepatitis C: Testing and health-care engagement
	Reid S¹,², Day CA³, Bowen DG⁴, Minnis J², Ludlow J⁵,⁶, Jacobs S⁵,⁶, Gordon A⁵,⁶, Haber PS²,³. J Paediatr Child Health. 2018 Jan 2. doi: 10.1111/jpc.13832. [Epub ahead of print]

362.	Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol
	Swan D¹, Cullen W¹, Macias J², Oprea C³,⁴, Story A⁵, Surey J⁶, Vickerman P⁷, Lambert JS¹,⁸. Expert Rev Gastroenterol Hepatol. 2018 Jan 16:1-12. doi: 10.1080/17474124.2018.1424541. [Epub ahead of print]

363.	Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection
	Collins LF¹, Chan A², Zheng J³, Chow SC³,⁴, Wilder JM⁴,⁵, Muir AJ⁴,⁵, Naggie S²,⁴. Open Forum Infect Dis. 2017 Dec 9;5(1):ofx264. doi: 10.1093/ofid/ofx264. eCollection 2018 Jan.

364.	Multimethod assessment of baseline depression and relationship to hepatitis Ctreatment discontinuation
	Weiss JJ¹, Prieto S¹, Bräu N²,³, Dieterich DT³, Marcus SM⁴, Stivala A⁵, Gorman JM⁶. Int J Psychiatry Med. 2018 Jan 1:91217417749796. doi: 10.1177/0091217417749796. [Epub ahead of print]

365.	Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic
	Burton MJ¹, Voluse AC¹, Patel AB¹, Konkle-Parker D¹. South Med J. 2018 Jan;111(1):45-50. doi: 10.14423/SMJ.0000000000000750.

366.	Mapping the Barriers and Facilitators of HCV Treatment Initiation in Methadone Maintenance Therapy Patients: Implications for Intervention Development
	Bass SB¹, Jessop A², Maurer L¹, Gashat M², Al Hajji M¹, Gutierrez M¹. J Health Commun. 2018;23(1):117-127. doi: 10.1080/10810730.2017.1414902. Epub 2017 Dec 18.

367.	Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition
	Indolfi G¹, Hierro L², Dezsofi A³, Jahnel J⁴, Debray D⁵, Hadzic N⁶, Czubowski P⁷, Gupte G⁸, Mozer-Glassberg Y⁹, van der Woerd W¹⁰, Smets F¹¹, Verkade HJ¹², Fischler B¹²,¹³. J Pediatr Gastroenterol Nutr. 2017 Dec 28. doi: 10.1097/MPG.0000000000001872. [Epub ahead of print]

368.	Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis
	McDonald SA¹,², Innes HA¹,², Aspinall EJ¹,², Hayes PC³, Alavi M², Valerio H¹,², Goldberg DJ¹,², Hutchinson SJ¹,². Liver Int. 2017 Dec 30. doi: 10.1111/liv.13681. [Epub ahead of print]

369.	Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants
	Gottwein JM¹, Pham LV², Mikkelsen LS², Ghanem L², Ramirez S², Scheel TKH², Carlsen THR², Bukh J¹. Gastroenterology. 2017 Dec 21. pii: S0016-5085(17)36720-3. doi: 10.1053/j.gastro.2017.12.015. [Epub ahead of print]

370.

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group N Engl J Med 2014; 370:211-221January 16, 2014DOI: 10.1056/NEJMoa1306218

371.	Diagnosis and Management of Hepatitis C Infection in Primary Care Settings
	Guss D¹, Sherigar J², Rosen P³, Mohanty SR². J Gen Intern Med. 2018 Jan 19. doi: 10.1007/s11606-017-4280-y. [Epub ahead of print]

372.	What's hot, what's new: Report from the American Transplant Congress 2017
	Cooper M¹, Li XC², Adams AB³. Am J Transplant. 2017 Dec 19. doi: 10.1111/ajt.14628. [Epub ahead of print]

373.	Comorbidities Among US Patients With Prevalent HIV Infection-A Trend Analysis
	Gallant J¹, Hsue PY², Shreay S³, Meyer N⁴. J Infect Dis. 2017 Dec 19;216(12):1525-1533. doi: 10.1093/infdis/jix518.

374.	Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes
	Younossi ZM¹,², Stepanova M³, Asselah T⁴, Foster G⁵, Patel K⁶, Brau N⁷, Swain M⁸, Tran T⁹, Esteban R¹⁰, Colombo M¹¹, Pianko S¹², Henry L³, Bourliere M¹³. Clin Infect Dis. 2017 Dec 20. doi: 10.1093/cid/cix1106. [Epub ahead of print]

375.	Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population
	Rose R¹, Lamers SL¹, Massaccesi G², Osburn W², Ray SC², Thomas DL², Cox AL², Laeyendecker O³. Infect Genet Evol. 2017 Dec 16;58:77-82. doi: 10.1016/j.meegid.2017.12.015. [Epub ahead of print]

376.	Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic
	Rickles M1, Rebeiro PF2, Sizemore L1, Juarez P3, Mutter M1, Wester C1, McPheeters M1. Clin Infect Dis. 2017 Dec 7. doi: 10.1093/cid/cix1079. [Epub ahead of print]

377.	Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature
	Fabiani S1, Fallahi P1, Ferrari SM1, Miccoli M1, Antonelli A2. Rev Endocr Metab Disord. 2018 Jan 11. doi: 10.1007/s11154-017-9440-1. [Epub ahead of print]

378.	HCV clearance by direct-acting antiviral treatments reverses insulin resistance in chronic hepatitis C patients
	Adinolfi LE1, Nevola R1,2, Guerrera B1,2, D'Alterio G1, Marrone A1, Giordano M1,2, Rinaldi L1. J Gastroenterol Hepatol. 2017 Dec 11. doi: 10.1111/jgh.14067. [Epub ahead of print]

379.	GHOST: global hepatitis outbreak and surveillance technology
	Longmire AG1,2, Sims S1,3,2, Rytsareva I1, Campo DS4, Skums P1,3, Dimitrova Z1, Ramachandran S1, Medrzycki M1, Thai H1, Ganova-Raeva L1, Lin Y1, Punkova LT1, Sue A1, Mirabito M5,2, Wang S5,2, Tracy R5,2, Bolet V6, Sukalac T5, Lynberg C7, Khudyakov Y1. BMC Genomics. 2017 Dec 6;18(Suppl 10):916. doi: 10.1186/s12864-017-4268-3.

380.	Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment
	Marshall WL1, Feng HP2, Wenning L1, Garrett G1, Huang X1, Liu F1, Panebianco D1, Caro L1, Fandozzi C1, Lasseter KC3, Preston RA4, Marbury T5, Butterton JR1, Iwamoto M1, Yeh WW1. Eur J Drug Metab Pharmacokinet. 2017 Dec 15. doi: 10.1007/s13318-017-0451-9. [Epub ahead of print]

381.	Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York City
	Moore MS1, Bocour A, Jordan L, McGibbon E, Varma JK, Winters A, Laraque F. J Public Health Manag Pract. 2017 Dec 7. doi: 10.1097/PHH.0000000000000688. [Epub ahead of print]

382.	National Health Care Spending In 2016: Spending And Enrollment Growth Slow After Initial Coverage Expansions
	Hartman M1, Martin AB2, Espinosa N3, Catlin A4, The National Health Expenditure Accounts Team5. Health Aff (Millwood). 2018 Jan;37(1):150-160. doi: 10.1377/hlthaff.2017.1299. Epub 2017 Dec 6.

383.	Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review
	Babiker A1, Jeudy J2, Kligerman S2, Khambaty M3,4, Shah A5, Bagchi S3,4. J Clin Transl Hepatol. 2017 Dec 28;5(4):343-362. doi: 10.14218/JCTH.2017.00021. Epub 2017 Aug 31.

384.	Update on hepatitis C and implications for pregnancy
	Post JJ1. Obstet Med. 2017 Dec;10(4):157-160. doi: 10.1177/1753495X17708093. Epub 2017 Jun 14.

385.	Hepatitis C virus genotyping of organ donor samples to aid in transplantation of HCV-positive organs
	Gentile C1, Van Deerlin VM1, Goldberg DS2,3,4, Reese PP3,4,5, Hasz RD6, Abt P7, Blumberg E8, Farooqi MS9. Clin Transplant. 2017 Dec 8. doi: 10.1111/ctr.13172. [Epub ahead of print]

386.

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

Rosenthal E1, Fougerou-Leurent C2,3, Renault A3,4, Carrieri MP5,6, Marcellin F5,6, Garraffo R7, Teicher E8, Aumaitre H9, Lacombe K10, Bailly F11, Billaud E12, Chevaliez S13, Dominguez S14, Valantin MA15, Reynes J16, Naqvi A17, Cotte L18, Metivier S19, Leroy V20, Dupon M21, Allegre T22, De Truchis P23, Jeantils V24, Chas J25, Salmon-Ceron D26, Morlat P27, Neau D28, Perré P29, Piroth L30, Pol S31, Bourlière M32, Pageaux GP33, Alric L34, Zucman D35, Girard PM10, Poizot-Martin I36,37, Yazdanpanah Y38, Raffi F12, Pabic EL2,3, Tual C2,3, Pailhé A39, Amri I39, Bellissant E2,3,4, Molina JM40; ANRS HC31 SOFTRIH Study Group. Collaborators (17) HIV Med. 2017 Dec 7. doi: 10.1111/hiv.12571. [Epub ahead of print]

387.	Validation of an Algorithm to Identify Infective Endocarditis in People Who Inject Drugs
	Ball LJ1, Sherazi A, Laczko D, Gupta K, Koivu S, A Weir M, Mele T, Tirona R, McCormick JK, Silverman M. Med Care. 2017 Dec 1. doi: 10.1097/MLR.0000000000000838. [Epub ahead of print]

388.	Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives
	Harrington PR1, Komatsu TE1, Deming DJ1, Donaldson EF1, O'Rear JJ1, Naeger LK1. Hepatology. 2017 Dec 1. doi: 10.1002/hep.29693. [Epub ahead of print]

389.	Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ? 15)
	McCaughan GW1, Thwaites PA2, Roberts SK3, Strasser SI1, Mitchell J3, Morales B2, Mason S1, Gow P2, Wigg A4, Tallis C5, Jeffrey G6, George J7, Thompson AJ8, Parker FC2, Angus PW2; Australian Liver Association Clinical Research Network. Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14404. [Epub ahead of print]

390.	The Effect of Interferon-Free Regimens on Health-Related Quality of Life in East Asian Patients with Chronic Hepatitis C
	Younossi ZM1,2, Stepanova M3, Henry L3, Han KH4, Ahn SH4, Lim YS5, Chuang WL6, Kao JH7, Kinh N8, Lai CL9, Yuen MF9, Chan HL10, Lai W11. Liver Int. 2017 Dec 2. doi: 10.1111/liv.13650. [Epub ahead of print]

391.	Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers
	Carlucci JG1,2, Farooq SA1, Sizemore L2, Rickles M2, Cosley B3, McCormack L3, Wester C2. PLoS One. 2017 Nov 30;12(11):e0188624. doi: 10.1371/journal.pone.0188624. eCollection 2017.

392.	Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin
	Younossi ZM1,2, Stepanova M3, Schwarz KB4, Wirth S5, Rosenthal P6, Gonzalez-Peralta R7, Murray K8, Henry L3, Hunt S3. J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830. [Epub ahead of print]

393.	Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3
	Younossi ZM1, Stepanova M2, Jacobson IM3, Asselah T4, Gane EJ5, Lawitz E6, Foster GR7, Roberts SK8, Thompson AJ8, Willems BE9, Welzel TM10, Pearlman B11, Younossi I2, Racila A1, Henry L2. Aliment Pharmacol Ther. 2018 Jan;47(2):259-267. doi: 10.1111/apt.14423. Epub 2017 Nov 27.

394.	Hepatitis C virus infection and risk of gallstones: A meta-analysis
	Wijarnpreecha K1, Thongprayoon C1, Panjawatanan P2, Lekuthai N3, Ungprasert P3,4. J Evid Based Med. 2017 Nov;10(4):263-270. doi: 10.1111/jebm.12277.

395.	Towards the Elimination of Hepatitis C in the United States
	Saab S1, Le L2, Saggi S1, Sundaram V3, Tong M1. Hepatology. 2017 Nov 27. doi: 10.1002/hep.29685. [Epub ahead of print]

396.	Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals
	Zhu J, Hazen RJ, Joyce C, Delpino A, Kirkham HS, Strickland CD, Markes-Wilson S, Kim T, Kang M, Rubin RA, Stein LL.AbstractJ Am Pharm Assoc (2003). 2017 Nov 16. pii: S1544-3191(17)30967-6. doi: 10.1016/j.japh.2017.10.011. [Epub ahead of print]

397.	Using peer advocates to improve access to services among hard-to-reach populations with hepatitis C: a qualitative study of client and provider relationships
	MacLellan J1, Surey J2, Abubakar I2, Stagg HR2, Mannell J3. Harm Reduct J. 2017 Nov 28;14(1):76. doi: 10.1186/s12954-017-0202-x.

398.	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir
	Younossi ZM1, Stepanova M2, Gordon S3, Zeuzem S4, Mann MP5, Jacobson I6, Bourliere M7, Cooper C8, Flamm S9, Reddy KR10, Kowdley K11, Younossi I2, Hunt S2. Clin Gastroenterol Hepatol. 2017 Nov 16. pii: S1542-3565(17)31360-5. doi: 10.1016/j.cgh.2017.11.023. [Epub ahead of print]

399.	Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention
	Abara WE1, Qaseem A1, Schillie S1, McMahon BJ1, Harris AM1; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804. doi: 10.7326/M17-1106. Epub 2017 Nov 21.

400.	Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in post-mortem blood specimens using infectious disease assays licensed for cadaveric donor screening
	Greenwald MA1, Kerby S2, Francis K2, Noller AC3, Gormley WT3, Biswas R2, Forshee RA4. Transpl Infect Dis. 2017 Nov 27. doi: 10.1111/tid.12825. [Epub ahead of print]

401.	Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital
	Assoumou SA, Huang W, Young K, Horsburgh CR, Linas BP. J Health Care Poor Underserved. 2017;28(4):1333-1344. doi: 10.1353/hpu.2017.0118.

402.	Use of organs from hepatitis C virus positive donors for uninfected recipients: a potential cost-effective approach to save lives?
	Trotter PB1,2, Summers DM1,2, Ushiro-Lumb I2, Robb M2, Bradley JA1, Powell J3, Watson CJE1, Neuberger J4. Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002033. [Epub ahead of print]

403.	Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems
	Camus G1, Xu S2, Han B2, Lu J2, Dvory-Sobol H2, Yu M2, Cheng G2, Miller MD2, Doehle BP2, Mo H2. Virology. 2017 Nov 22;514:134-141. doi: 10.1016/j.virol.2017.11.003. [Epub ahead of print]

404.	Improving patient access to hepatitis C virus treatment
	McLaughlin MM, Marx KT, Terriff C; American Academy of HIV Medicine Pharmacists Committee. AbstractJ Am Pharm Assoc (2003). 2017 Nov 16. pii: S1544-3191(17)30969-X. doi: 10.1016/j.japh.2017.10.013. [Epub ahead of print]

405.	No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV
	Chaudhury CS1, Sheehan J1, Chairez C1, Akoth E2, Gross C2, Silk R2, Kattakuzhy S2, Rosenthal E2, Kottilil S2, Masur H3, Hadigan C1. J Infect Dis. 2017 Nov 17. doi: 10.1093/infdis/jix517. [Epub ahead of print]

406.	Hepatitis C Virus Recurrence Occurs Earlier in Patients Receiving Donation After Circulatory Death Liver Transplant Grafts Compared With Those Receiving Donation After Brainstem Death Grafts
	Townsend SA1, Monga MA2, Nightingale P3, Mutimer D3, Elsharkawy AM3, Holt A3. Transplant Proc. 2017 Nov;49(9):2129-2134. doi: 10.1016/j.transproceed.2017.07.016.

407.	Effectiveness of current and future regimens for treating genotype 3 hepatitis Cvirus infection: a large-scale systematic review
	Fathi H1, Clark A2, Hill NR2, Dusheiko G3. BMC Infect Dis. 2017 Nov 16;17(1):722. doi: 10.1186/s12879-017-2820-z.

408.	Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure
	Poordad F1, Pol S2, Asatryan A3, Buti M4, Shaw D5, Hézode C6, Felizarta F7, Reindollar RW8, Gordon SC9, Pianko S10, Fried MW11, Bernstein DE12, Gallant J13, Lin CW3, Lei Y3, Ng TI3, Krishnan P3, Kopecky-Bromberg S3, Kort J3, Mensa F3. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print]

409.	The future of viral hepatitis testing: innovations in testing technologies and approaches
	Peeling RW1, Boeras DI2, Marinucci F3, Easterbrook P4. BMC Infect Dis. 2017 Nov 1;17(Suppl 1):699. doi: 10.1186/s12879-017-2775-0.

410.	Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study
	Brown A1, Hézode C2, Zuckerman E3, Foster GR4, Zekry A5, Roberts SK6, Lahser F7, Durkan C7, Badshah C7, Zhang B7, Robertson M7, Wahl J7, Barr E7, Haber B7; C-SCAPE Study Investigators. J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801. [Epub ahead of print]

411.	Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C
	Konerman MA1, Lu D1, Zhang Y1, Thomson M1, Zhu J1, Verma A2, Liu B1, Talaat N1, Balis U3, Higgins PDR1, Lok ASF1, Waljee AK1,4. PLoS One. 2017 Nov 6;12(11):e0187344. doi: 10.1371/journal.pone.0187344. eCollection 2017.

412.	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world
	Tempestilli M1, Fabbri G2, Mastrorosa I2, Timelli L2, Notari S1, Bellagamba R2, Libertone R2, Lupi F2, Zaccarelli M2, Antinori A2, Agrati C1, Ammassari A2. J Antimicrob Chemother. 2017 Nov 2. doi: 10.1093/jac/dkx348. [Epub ahead of print]

413.	Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population
	Sikavi C1, Chen PH2, Lee AD2, Saab EG2, Choi G2,3, Saab S2,3. Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642. [Epub ahead of print]

414.	The influence of immunosuppressants on direct-acting antiviral therapy is dependent on hepatitis C virus genotype
	Frey A1, Piras-Straub K1,2, Walker A3, Timm J3, Gerken G2, Herzer K1,2. Transpl Infect Dis. 2017 Nov 7. doi: 10.1111/tid.12803. [Epub ahead of print]

415.	Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse
	Barritt AS 4th1, Lee B2, Runge T1, Schmidt M3, Jhaveri R4. J Pediatr. 2017 Oct 26. pii: S0022-3476(17)31189-7. doi: 10.1016/j.jpeds.2017.09.016. [Epub ahead of print]

416.

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

Fraser H1, Martin NK2, Brummer-Korvenkontio H3, Carrieri P4, Dalgard O5, Dillon J6, Goldberg D7, Hutchinson S8, Jauffret-Roustide M9, Kåberg M10, Matser AA11, Mati?i? M12, Midgard H13, Mravcik V14, Øvrehus A15, Prins M16, Reimer J17, Robaeys G18, Schulte B19, van Santen DK20, Zimmermann R21, Vickerman P22, Hickman M22. J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387-5. doi: 10.1016/j.jhep.2017.10.010. [Epub ahead of print]

417.	Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C
	Evon DM1, Golin CE2,3, Ruffin R4, Fried MW1. Contemp Clin Trials Commun. 2017 Jun;6:85-96. doi: 10.1016/j.conctc.2017.03.008. Epub 2017 Apr 2.

418.	Hepatitis C Virus Infection in the Older Patient
	Reid M1, Price JC1, Tien PC2. Infect Dis Clin North Am. 2017 Dec;31(4):827-838. doi: 10.1016/j.idc.2017.07.014.

419.	Estimating HCV disease burden-volume 4 (editorial)
	Dore GJ1, Hatzakis A2, Negro F3, Waked I4. J Viral Hepat. 2017 Oct;24 Suppl 2:4-7. doi: 10.1111/jvh.12763.

420.	Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis
	Jordan AE1, Perlman DC2, Smith DJ3, Reed JR3, Hagan H4. J Clin Epidemiol. 2017 Nov 1. pii: S0895-4356(17)30469-9. doi: 10.1016/j.jclinepi.2017.10.015. [Epub ahead of print]

421.	Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)
	Brown AN1, Liu L2, Rodriquez JL3, Zhao L2, Schuster L2, Li E2, Wang GP2,4, Neely MN5, Yamada W5, Drusano GL3. Sci Rep. 2017 Oct 31;7(1):14421. doi: 10.1038/s41598-017-15007-2.

422.	Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers
	Rattay T1, Dumont IP2, Heinzow HS3, Hutton DW4. Gastroenterology. 2017 Oct 23. pii: S0016-5085(17)36275-3. doi: 10.1053/j.gastro.2017.10.016. [Epub ahead of print]

423.	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review
	Larney S1, Peacock A2, Leung J3, Colledge S2, Hickman M4, Vickerman P4, Grebely J5, Dumchev KV6, Griffiths P7, Hines L8, Cunningham EB5, Mattick RP2, Lynskey M8, Marsden J8, Strang J8, Degenhardt L2. Lancet Glob Health. 2017 Dec;5(12):e1208-e1220. doi: 10.1016/S2214-109X(17)30373-X. Epub 2017 Oct 23.

424.	Increased Risk for Mother-to-Infant Transmission of Hepatitis C Virus Among Medicaid Recipients - Wisconsin, 2011-2015
	Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. MMWR Morb Mortal Wkly Rep. 2017 Oct 27;66(42):1136-1139. doi: 10.15585/mmwr.mm6642a3.

425.	Epidemiology of Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis
	Smith DJ1, Neurer J1, Jordan AE1,2, Hagan H1,2. JMIR Res Protoc. 2017 Oct 20;6(10):e201. doi: 10.2196/resprot.7936.

426.	Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor
	Lawitz E1, Yang JC2, Stamm LM2, Taylor JG2, Cheng G2, Brainard DM2, Miller MD2, Mo H2, Dvory-Sobol H2. Antivir Ther. 2017 Oct 24. doi: 10.3851/IMP3202. [Epub ahead of print]

427.	Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia
	Younossi ZM1,2, Chan HLY3, Dan YY4, Lee MH5, Lim YS6, Kruger E7, Tan SC7. J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808. [Epub ahead of print]

428.	Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis CTelemedicine Patient
	Cooper CL1, Hatashita H2, Corsi DJ3, Parmar P2, Corrin R2, Garber G4. Ann Hepatol. 2017 Oct 16;16(6):874-880. doi: 10.5604/01.3001.0010.5277.

429.	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis
	Bethea E1,2,3, Chen Q1,2, Hur C1,2,3, Chung RT2,3, Chhatwal J1,2,3. Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611. [Epub ahead of print]

430.	Comparison of the Hepatitis C Continua of Care between HCV/HIV Co-Infected and HCV Mono-Infected Patients in Two Treatment Eras during 2008-2015
	Roberson JL1, Lagasca AM2,3, Kan VL2,4. AIDS Res Hum Retroviruses. 2017 Oct 3. doi: 10.1089/AID.2017.0092. [Epub ahead of print]

431.	Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women
	Sarkar M1, Dodge JL2, Greenblatt RM3, Kuniholm MH4, DeHovitz J5, Plankey M6, Kovacs A7, French AL8, Seaberg EC9, Ofotokun I10, Fischl M11, Overton E12, Kelly E13, Bacchetti P14, Peters MG1; Women?s Interagency HIV Study. Clin Infect Dis. 2017 Jul 26. doi: 10.1093/cid/cix643. [Epub ahead of print]

432.	Hepatitis C Genotype 3 Infection: Pathogenesis and Treatment Horizons
	Maddur H1, Flamm SL2. Clin Liver Dis. 2017 Nov;21(4):645-657. doi: 10.1016/j.cld.2017.06.009. Epub 2017 Aug 5.

433.	Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician
	Weisberg IS1, Jacobson IM2. Clin Liver Dis. 2017 Nov;21(4):659-672. doi: 10.1016/j.cld.2017.06.007. Epub 2017 Aug 19.

434.	Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider
	Weil C1, Mehta D2,3, Koren G1, Pinsky B2, Samp JC2, Chodick G1,4, Shalev V1,4. J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800. [Epub ahead of print]

435.	Evaluation of the Impact of Mandating Health Care Providers to Offer Hepatitis CVirus Screening to All Persons Born During 1945-1965 - New York, 2014
	Flanigan CA, Leung SJ, Rowe KA, Levey WK, King A, Sommer JN, Morne JE, Zucker HA. MMWR Morb Mortal Wkly Rep. 2017 Sep 29;66(38):1023-1026. doi: 10.15585/mmwr.mm6638a3.

436.	Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-naïve Hepatitis C virus Genotype 1-infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen
	Bourgeois S1, Horsmans Y2, Nevens F3, van Vlierberghe H4, Moreno C5, Beumont M6, Vijgen L6, van Eygen V6, Luo D7, Hillewaert V6, Van Remoortere P7, van de Logt J8, Ouwerkerk-Mahadevan S6. Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01217-17. doi: 10.1128/AAC.01217-17. [Epub ahead of print]

437.	Health-Related Quality of Life in Adolescent Patients with Hepatitis C Genotype 1 Treated with Sofosbuvir and Ledipasvir
	Younossi ZM1, Stepanova M, Balistreri W, Schwarz K, Murray KF, Rosenthal P, Bansal S, Hunt S. J Pediatr Gastroenterol Nutr. 2017 Sep 27. doi: 10.1097/MPG.0000000000001754. [Epub ahead of print]

438.	Hepatitis C in a new therapeutic era: Recontextualising the lived experience
	Whiteley D1,2,3, Whittaker A2,3, Elliott L4, Cunningham-Burley S5.

439.	Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs
	Belperio PS1, Chartier M1, Ross DB1, Alaigh P1, Shulkin D1. Ann Intern Med. 2017 Oct 3;167(7):499-504. doi: 10.7326/M17-1073. Epub 2017 Sep 26.

440.

Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies

Origa R1, Ponti ML2, Filosa A3, Galeota Lanza A3, Piga A4, Saracco GM4, Pinto V5, Picciotto A6, Rigano P7, Madonia S7, Rosso R8, D'Ascola D9, Cappellini MD10, D'Ambrosio R10, Tartaglione I11, De Franceschi L12, Gianesin B5, Di Marco V13, Forni GL5; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24911. [Epub ahead of print]

441.	'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment
	Henderson C1, Madden A2, Kelsall J3. Int J Drug Policy. 2017 Sep 15. pii: S0955-3959(17)30263-3. doi: 10.1016/j.drugpo.2017.08.004. [Epub ahead of print]

442.	Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube
	Jindracek L1, Stark J1. J Pharm Pract. 2017 Jan 1:897190017731245. doi: 10.1177/0897190017731245. [Epub ahead of print]

443.	Glecaprevir/Pibrentasvir: First Global Approval
	Lamb YN1. Drugs. 2017 Sep 19. doi: 10.1007/s40265-017-0817-y. [Epub ahead of print]

444.	Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials
	Mehta DA1,2, Cohen E3, Charafeddine M3, Cohen DE3, Bao Y4, Sanchez Gonzalez Y4, Tran TT5. Infect Dis Ther. 2017 Sep 22. doi: 10.1007/s40121-017-0171-0. [Epub ahead of print]

445.	Neighborhood Inequalities in Hepatitis C Mortality: Spatial and Temporal Patterns and Associated Factors
	Ford MM1, Desai PS2, Maduro G3, Laraque F4. J Urban Health. 2017 Jun 16. doi: 10.1007/s11524-017-0174-x. [Epub ahead of print]

446.	Use and acceptability of salivary hepatitis C virus testing in an English Young Offender Institution
	Candfield S1, Samuel MI2, Ritchie D3,4, McDonald C2, Brady M2,3, Taylor C2. Int J STD AIDS. 2017 Jan 1:956462417696214. doi: 10.1177/0956462417696214. [Epub ahead of print]

447.	Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact
	MacGregor L1, Martin NK1,2, Mukandavire C1, Hickson F3, Weatherburn P3, Hickman M1, Vickerman P1. Int J Epidemiol. 2017 Jun 12. doi: 10.1093/ije/dyx075. [Epub ahead of print]

448.	Racial Disparities in Hepatitis C Treatment Eligibility
	Sims OT1, Pollio DE1, Hong BA2, North CS3. Ann Hepatol. 2017 Aug 1;16(4):530-537. doi: 10.5604/01.3001.0010.0282.

449.	Hepatitis C Virus Prevalence in Egyptian Americans in Southern California
	Saab S1, Viramontes MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG, Saab EG, Saab CE, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M. J Clin Gastroenterol. 2017 Jun 14. doi: 10.1097/MCG.0000000000000858. [Epub ahead of print]

450.	Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics
	Hossain N1, Puchakayala B1, Kanwar P1, Verma S1,2, Abraham G1, Ivanov Z1, Niaz MO1, Mohanty SR3. Dig Dis Sci. 2017 Sep 14. doi: 10.1007/s10620-017-4754-0. [Epub ahead of print]

451.	The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience
	Martini S1, Donato MF2, Mazzarelli C3, Rendina M4, Visco-Comandini U5, Filì D6, Gianstefani A7, Fagiuoli S8, Melazzini M9, Montilla S9, Pani L9, Petraglia S9, Russo P9, Trotta MP9, Carrai P10, Caraceni P7; ITACOPS study group. Liver Int. 2017 Sep 16. doi: 10.1111/liv.13588. [Epub ahead of print]

452.	Editorial: Direct Antiviral Agents Eliminate the Age Barrier to Treatment of Chronic Hepatitis C
	Koff RS1. Am J Gastroenterol. 2017 Sep;112(9):1410-1411. doi: 10.1038/ajg.2017.205.

453.	Association between infection burden and adult height
	Hedges DW1, Berrett AN2, Erickson LD3, Brown BL2, Gale SD4. Econ Hum Biol. 2017 Sep 2;27(Pt A):275-280. doi: 10.1016/j.ehb.2017.08.002. [Epub ahead of print]

454.	Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
	Kiser JJ1, Lu D2, Rosenkranz SL2, Morse GD3, DiFrancesco R3, Sherman KE4, Butt AA5,6; ACTG A5309s study team. Drugs R D. 2017 Sep 5. doi: 10.1007/s40268-017-0205-9. [Epub ahead of print]

455.	Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment
	Tumber MB. J Leg Med. 2017 Jan-Jun;37(1-2):21-64. doi: 10.1080/01947648.2017.1284700.

456.	Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
	Wright N1, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B. Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962. [Epub ahead of print]

457.	Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial
	Wyles D1, Poordad F2, Wang S3, Alric L4, Felizarta F5, Kwo PY6, Maliakkal B7, Agarwal K8, Hassanein T9, Weilert F10, Lee SS11, Kort J3, Lovell SS3, Liu R3, Lin CW3, Pilot-Matias T3, Krishnan P3, Mensa FJ3. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print]

458.	Hepatic immunopathology during occult hepacivirus re-infection
	Manickam C1, Martinot AJ1, Jones RA1, Varner V1, Reeves RK2. Virology. 2017 Sep 12;512:48-55. doi: 10.1016/j.virol.2017.08.037. [Epub ahead of print]

459.	When and how can nephrologists treat hepatitis C virus infection in dialysis patients?
	Davis MI1, Chute DF2, Chung RT2, Sise ME1. Semin Dial. 2017 Sep 18. doi: 10.1111/sdi.12650. [Epub ahead of print]

460.	The furthest left behind: the urgent need to scale up harm reduction in prisons
	Sander G1, Murphy F1. Int J Prison Health. 2017 Sep 11;13(3-4):185-191. doi: 10.1108/IJPH-08-2016-0044.

461.	Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis
	Platt L1, Minozzi S2, Reed J3, Vickerman P4, Hagan H3, French C4, Jordan A3, Degenhardt L5, Hope V6, Hutchinson S7, Maher L8, Palmateer N7, Taylor A9, Bruneau J10, Hickman M4. Addiction. 2017 Sep 11. doi: 10.1111/add.14012. [Epub ahead of print]

462.	Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health
	Morris MD1, Brown B2, Allen SA3. Int J Prison Health. 2017 Sep 11;13(3-4):192-199. doi: 10.1108/IJPH-07-2016-0028.

463.	High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members
	Boodram B1, Hotton AL2, Shekhtman L3,4, Gutfraind A3, Dahari H3. J Urban Health. 2017 Sep 5. doi: 10.1007/s11524-017-0185-7. [Epub ahead of print]

464.	A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus
	Kanwal F1, Pyne JM2,3, Tavakoli-Tabasi S4, Nicholson S5, Dieckgraefe B6, Storay E7, Goetz MB8, Kramer JR9, Smith D10, Sansgiry S11, Tansel A12, Gifford AL13,14, Asch SM15. Health Serv Res. 2017 Sep 11. doi: 10.1111/1475-6773.12758. [Epub ahead of print]

465.	The Effect of Psychosocial Factors on Success Rates of Hepatitis C Treatment
	Janda M1, Mergenhagen KA2. Psychosomatics. 2017 Jul 15. pii: S0033-3182(17)30156-1. doi: 10.1016/j.psym.2017.07.003. [Epub ahead of print]

466.	Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
	Stevenson HL1, Utay NS2. Trop Dis Travel Med Vaccines. 2016 Sep 27;2:21. doi: 10.1186/s40794-016-0038-5. eCollection 2016.

467.	Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort
	Serper M1,2,3, Forde KA3,4, Kaplan DE1,3. J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784. [Epub ahead of print]

468.	Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s
	Garvey P1, Murphy N2, Flanagan P2, Brennan A2, Courtney G3, Crosbie O4, Crowe J5, Hegarty J6, Lee J7, McIver M2, McNulty C6, Murray F8, Nolan N6, O'Farrelly C9, Stewart S5, Tait M10, Norris S11, Thornton L2. J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249-3. doi: 10.1016/j.jhep.2017.07.034. [Epub ahead of print]

469.	Chronic Hepatitis C Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD
	Park H1, Chen C1, Wang W1, Henry L1, Cook RL2, Nelson DR2. Hepatology. 2017 Sep 5. doi: 10.1002/hep.29505. [Epub ahead of print]

470.	Imaging for the Diagnosis of Hepatocellular Carcinoma: a Systematic Review and Meta-analysis
	Roberts LR1, Sirlin CB2, Zaiem F3, Almasri J3, Prokop LJ3, Heimbach J1, Murad MH3, Mohammed K3. Hepatology. 2017 Aug 31. doi: 10.1002/hep.29487. [Epub ahead of print]

471.	Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes
	Cohen JB1, Eddinger KC2, Shelton B3, Locke JE3, Forde KA4,5, Sawinski D1. Clin Kidney J. 2017 Aug;10(4):564-572. doi: 10.1093/ckj/sfx048. Epub 2017 Jul 11.

472.	Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series
	Millman AJ1, Ntiri-Reid B2, Irvin R3, Kaufmann MH4, Aronsohn A5, Duchin JS6, Scott JD7, Vellozzi C1. Top Antivir Med. 2017 Jul/Aug;25(3):110-113.

473.	Feasibility of Treating Hepatitis C in a Transient Jail Population
	MacDonald R1, Akiyama MJ1,2, Kopolow A1, Rosner Z1, McGahee W1, Joseph R1, Jaffer M1, Venters H1. Open Forum Infect Dis. 2017 Jul 7;4(3):ofx142. doi: 10.1093/ofid/ofx142. eCollection 2017 Summer.

474.	Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection
	Allyn PR1, O'Malley SM2, Ferguson J3, Tseng CH4, Chew KW1,2, Bhattacharya D1,2. Int J STD AIDS. 2017 Jan 1:956462417725462. doi: 10.1177/0956462417725462. [Epub ahead of print]

475.	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
	Waziry R1, Hajarizadeh B2, Grebely J2, Amin J3, Law M2, Danta M4, George J5, Dore GJ2. J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199-2. doi: 10.1016/j.jhep.2017.07.025. [Epub ahead of print]

476.	Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis Cgenotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety
	Latt NL1, Yanny BT1, Gharibian D1, Gevorkyan R1, Sahota AK1. World J Gastroenterol. 2017 Jul 14;23(26):4759-4766. doi: 10.3748/wjg.v23.i26.4759.

477.	Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome
	Jeffrey AW1, Huang Y1, de Boer WB1, Adams LA1, MacQuillan G1, Speers D1, Joseph J1, Jeffrey GP1. World J Hepatol. 2017 Jul 8;9(19):850-856. doi: 10.4254/wjh.v9.i19.850.

478.	The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries
	Hill AM1, Nath S2, Simmons B2. J Virus Erad. 2017 Jul 1;3(3):117-123.

479.	HCV Viremic Donors With Hepatic Bridging Fibrosis: Are We Ready To Use Their Livers in The Era of Direct-Acting Antivirals?
	Martini S1, David E2, Tandoi F3, Dell Olio D4, Salizzoni M3, Saracco GM1, Romagnoli R3. Am J Transplant. 2017 Jul 25. doi: 10.1111/ajt.14447. [Epub ahead of print]

480.	Chronic hepatitis C virus infection and neurocognitive function in adult survivors of childhood cancer
	Studaway A1, Ojha RP2, Brinkman TM1,3, Zhang N4, Baassiri M5, Banerjee P1, Ehrhardt MJ1,5, Srivastava D4, Robison LL1, Hudson MM1,5, Krull KR1,3. Cancer. 2017 Jul 25. doi: 10.1002/cncr.30913. [Epub ahead of print]

481.

Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study

Wiessing L1, Ferri M2, B?lá?ková V3,4,5, Carrieri P6,7, Friedman SR8, Folch C9,10, Dolan K11, Galvin B12, Vickerman P13, Lazarus JV14,15, Mrav?ík V3,4,16, Kretzschmar M17,18, Sypsa V19, Sarasa-Renedo A10,20, Uusküla A21, Paraskevis D19, Mendão L22, Rossi D23, van Gelder N2, Mitcheson L24, Paoli L25,26, Gomez CD27, Milhet M27, Dascalu N28, Knight J29, Hay G30, Kalamara E2, Simon R2; EUBEST working group, Comiskey C31, Rossi C32, Griffiths P2. Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6.

482.	Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010
	Rosenberg ES1, Hall EW1, Sullivan PS1, Sanchez TH1, Workowski KA2, Ward JW3, Holtzman D3. Clin Infect Dis. 2017 Jun 1;64(11):1573-1581. doi: 10.1093/cid/cix202.

483.	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C
	Tapper EB1, Afdhal NH, Curry MP. Transplantation. 2017 May;101(5):933-937. doi: 10.1097/TP.0000000000001611.

484.	Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy
	Langness JA1, Tabano D2, Wieland A3, Tise S3, Pratt L3, Harrington LA4, Lin S1, Ghuschcyan V2, Nair KV2, Everson GT4. Ann Hepatol. 2017 May - Jun;16(3):366-374. doi: 10.5604/16652681.1235479.

485.	Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'
	Harris M1. Int J Drug Policy. 2017 Apr 25. pii: S0955-3959(17)30089-0. doi: 10.1016/j.drugpo.2017.03.015. [Epub ahead of print]

486.	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
	Young J1, Weis N2, Hofer H3, Irving W4, Weiland O5, Giostra E6, Pascasio JM7, Castells L8, Prieto M9, Postema R10, Lefevre C11, Evans D11, Bucher HC12, Calleja JL13. BMC Infect Dis. 2017 Jan 7;17(1):45. doi: 10.1186/s12879-016-2106-x.

487.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

van der Ree MH1, de Vree JM2, Stelma F1, Willemse S3, van der Valk M4, Rietdijk S5, Molenkamp R6, Schinkel J6, van Nuenen AC7, Beuers U3, Hadi S8, Harbers M8, van der Veer E9, Liu K10, Grundy J10, Patick AK10, Pavlicek A10, Blem J10, Huang M10, Grint P10, Neben S10, Gibson NW10, Kootstra NA7, Reesink HW11. Lancet. 2017 Jan 10. pii: S0140-6736(16)31715-9. doi: 10.1016/S0140-6736(16)31715-9. [Epub ahead of print]

488.	Genotype specific peripheral lipid profile changes with hepatitis C therapy
	Pedersen MR1, Patel A1, Backstedt D1, Choi M1, Seetharam AB1. World J Gastroenterol. 2016 Dec 14;22(46):10226-10231. doi: 10.3748/wjg.v22.i46.10226.

489.	Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy
	Lynch SM1, Wu GY1. J Clin Transl Hepatol. 2016 Dec 28;4(4):310-319. doi: 10.14218/JCTH.2016.00027. Epub 2016 Nov 3.

490.	Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study
	Foster MA1, Xing J2, Moorman AC2, Boscarino J3, Gordon SC4, Lu M4, Rupp L4, Schmidt MA5, Trinacty CM6, Xu F2, Holmberg SD2, Spradling PR2. Dig Dis Sci. 2016 Aug 10. [Epub ahead of print]

491.

Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras

Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R; North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Clin Infect Dis. 2016 Aug 9. pii: ciw531. [Epub ahead of print]

492.	Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening
	Irvin R1, McAdams-Mahmoud A1, Hickman D2, Wilson J2, Fenwick W2, Chen I3, Irvin N4, Falade-Nwulia O1, Sulkowski M1, Chaisson R1, Thomas DL1, Mehta SH5. J Community Med Health Educ. 2016 Jun;6(3). pii: 431. Epub 2016 May 30.

493.	Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis
	Saab S1, A Jimenez M, N Bau S, Choi G, Durazo FA, M El-Kabany M, Han SB, Busuttil RW. J Clin Gastroenterol. 2016 Aug 19. [Epub ahead of print]

494.	Generic medications for hepatitis C
	Jensen DM1, Sebhatu P1, Reau NS1. Liver Int. 2016 Jul;36(7):925-8. doi: 10.1111/liv.13120.

495.	Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice
	Backus LI1, Belperio PS1, Shahoumian TA1, Loomis TP1, Mole LA1. Aliment Pharmacol Ther. 2016 Jun 13. doi: 10.1111/apt.13696. [Epub ahead of print]

496.	The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis
	Loy M1, Serra G2, Chessa L2. J Ultrasound. 2014 Jul 5;19(2):91-8. doi: 10.1007/s40477-014-0114-5. eCollection 2016.

497.	Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus
	Younossi ZM1,2, Stepanova M3, Sulkowski M4, Naggie S5, Henry L3, Hunt S3. J Viral Hepat. 2016 Jun 13. doi: 10.1111/jvh.12554. [Epub ahead of print]

498.	Behavioral Interventions to Reduce Alcohol Use Among Patients with Hepatitis C: A Systematic Review
	Sims OT1,2,3,4, Maynard QR5, Melton PA5,6. Soc Work Public Health. 2016 Jun 13:1-9. [Epub ahead of print]

499.	The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
	Stone J1, Martin NK2,1, Hickman M1, Hellard M3, Scott N3, McBryde E3, Drummer H4, Vickerman P1. PLoS One. 2016 May 25;11(5):e0156213. doi: 10.1371/journal.pone.0156213. eCollection 2016.

500.	Changes in Liver Volume in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy
	Fitzpatrick JA1, Kim JU2, Cobbold JF2, McPhail MJ2, Crossey MM2, Bak-Bol AA2, Zaky A2, Taylor-Robinson SD2. J Clin Exp Hepatol. 2016 Mar;6(1):15-20. doi: 10.1016/j.jceh.2015.11.004. Epub 2015 Dec 6.

501.	Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients
	Tseng A1, Wong DK1. J Hepatol. 2016 May 19. pii: S0168-8278(16)30201-X. doi: 10.1016/j.jhep.2016.05.015. [Epub ahead of print]

502.	A systematic review of community based hepatitis C treatment
	Wade AJ1,2, Veronese V3,4, Hellard ME3,4,5, Doyle JS3,5,6. BMC Infect Dis. 2016 May 16;16(1):202. doi: 10.1186/s12879-016-1548-5.

503.	Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010
	Taylor AL1, Denniston MM2, Klevens RM2, McKnight-Eily LR3, Jiles RB2. Am J Prev Med. 2016 May 2. pii: S0749-3797(16)30065-4. doi: 10.1016/j.amepre.2016.02.033. [Epub ahead of print]

504.	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort
	Foster GR1, Coppola C2, Derbala M3, Ferenci P4, Orlandini A5, Reddy KR6, Tallarico L7, Shiffman ML8, Ahlers S9, Bakalos G10, Hassanein T11; GUARD-C Study Group. PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016.

505.	Sofosbuvir and Simeprevir without Ribavirin Effectively Treat Hepatitis C Virus Genotype 1 Infection after Liver Transplantation in a Two-Center Experience
	Jackson WE1, Hanouneh M2, Apfel T2, Alkhouri N1, John BV1, Zervos X3, Zein NN1, Hanouneh IA1. Clin Transplant. 2016 Mar 28. doi: 10.1111/ctr.12738. [Epub ahead of print]

506.	GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study
	Rodriguez-Torres M1, Glass S2, Hill J3, Freilich B4, Hassman D5, Di Bisceglie AM6, Taylor JG7, Kirby BJ7, Dvory-Sobol H7, Yang JC7, An D7, Stamm LM7, Brainard DM7, Kim S8, Krefetz D9, Smith W10, Marbury T11, Lawitz E12. J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527. [Epub ahead of print]

507.	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
	Younossi ZM1, Stepanova M, Chan HL, Lee MH, Yu ML, Dan YY, Choi MS, Henry L. Medicine (Baltimore). 2016 Mar;95(9):e2702. doi: 10.1097/MD.0000000000002702.

508.	Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals
	Chhatwal J1,2,3, Wang X4,5, Ayer T4, Kabiri M6, Chung RT2,3, Hur C1,2,3, Donohue JM6, Roberts MS6, Kanwal F7,8. Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571. [Epub ahead of print]

509.	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
	Younossi ZM1, Stepanova M, Chan HL, Lee MH, Yu ML, Dan YY, Choi MS, Henry L. Medicine (Baltimore). 2016 Mar;95(9):e2702. doi: 10.1097/MD.0000000000002702.

510.	Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders
	Carey KJ1, Huang W2, Linas BP3, Tsui JI4. J Subst Abuse Treat. 2016 Feb 13. pii: S0740-5472(16)00041-6. doi: 10.1016/j.jsat.2016.01.009. [Epub ahead of print]

511.	Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge
	De Monte A1, Courjon J2, Anty R3, Cua E2, Naqvi A2, Mondain V2, Cottalorda J1, Ollier L4, Giordanengo V5. J Clin Virol. 2016 Mar 3;78:27-30. doi: 10.1016/j.jcv.2016.02.026. [Epub ahead of print]

512.	Perspectives on treating hepatitis C infection in the liver transplantation setting
	Chen T1, Terrault NA. Curr Opin Organ Transplant. 2016 Apr;21(2):111-9. doi: 10.1097/MOT.0000000000000288.

513.	Elbasvir/Grazoprevir: First Global Approval
	Keating GM1. Drugs. 2016 Apr;76(5):617-24. doi: 10.1007/s40265-016-0558-3.

514.	Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies
	Martinello M1, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV. Antivir Ther. 2016 Feb 11. doi: 10.3851/IMP3035. [Epub ahead of print]

515.	Challenging hepatitis C-infected liver transplant patients
	Oliver M1, Ortiz CC2, Ortiz J3. Hepat Med. 2016 Jan 18;8:1-8. doi: 10.2147/HMER.S96110. eCollection 2016.

516.	Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis
	Martin NK1,2, Vickerman P2, Brew IF3, Williamson J3, Miners A4, Irving WL5, Saksena S6, Hutchinson SJ7, Mandal S8, O'Moore E8, Hickman M2. Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497. [Epub ahead of print]

517.	Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
	Issa D1, Eghtesad B2, Zein NN1, Yerian L3, Cruise M3, Alkhouri N1, Adams R2, Hanouneh IA1. Int J Organ Transplant Med. 2016;7(1):38-45. Epub 2016 Feb 1.

518.	Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C
	Valcour VG1, Rubin LH, Obasi MU, Maki PM, Peters MG, Levin S, Crystal HA, Young MA, Mack WJ, Cohen MH, Pierce CB, Adimora AA, Tien PC; Women?s Interagency HIV Study protocol team. J Acquir Immune Defic Syndr. 2016 Feb 16. [Epub ahead of print]

519.	Direct-Acting Antiviral Agents for the Hepatitis C Virus-Infected Chronic Kidney Disease Population: The Dawn of a New Era
	Kusnir J1, Roth D1. Semin Dial. 2016 Jan;29(1):5-6. doi: 10.1111/sdi.12456.

520.	The expanding toolbox for hepatitis C virus research
	Ortega-Prieto AM1, Dorner M1. J Viral Hepat. 2016 Jan 13. doi: 10.1111/jvh.12500. [Epub ahead of print]

521.	Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison
	Andersohn F1,2, Claes AK3, Kulp W4, Mahlich J5,6, Rockstroh JK7. BMC Infect Dis. 2016 Jan 11;16(1):10. doi: 10.1186/s12879-015-1311-3.

522.	Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents
	Granot E, Sokal EM. Isr Med Assoc J. 2015 Nov;17(11):707-11.

523.	Chronic hepatitis C virus infection, a new cardiovascular risk factor?
	Domont F1,2, Cacoub P1,3,4,2. Liver Int. 2016 Jan 13. doi: 10.1111/liv.13064. [Epub ahead of print]

524.	Hepatitis C genotype 4: The past, present, and future
	Abdel-Ghaffar TY1, Sira MM1, El Naghi S1. World J Hepatol. 2015 Dec 8;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792.

525.	Synergistic activity of combined NS5A inhibitors
	O'Boyle DR 2nd1, Nower PT2, Gao M2, Fridell R2, Wang C2, Hewawasam P2, Lopez O2, Tu Y2, Meanwell NA2, Belema M2, Roberts SB2, Cockett M2, Sun JH2. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02639-15. [Epub ahead of print]

526.	Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution
	Eslam M1, George J1. Semin Liver Dis. 2015 Nov;35(4):402-20. doi: 10.1055/s-0035-1567830. Epub 2015 Dec 16.

527.	The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care
	Cachay ER1, Wyles D1, Hill L2, Ballard C3, Torriani F1, Colwell B3, Kuo A4, Schooley R5, Mathews CW6. Open Forum Infect Dis. 2015 Nov 12;2(4):ofv168. doi: 10.1093/ofid/ofv168. eCollection 2015.

528.	Potent Antiviral Activity of Direct-Acting Antivirals, ABT-493 and ABT-530, With 3-day Monotherapy for Hepatitis C Genotype 1 Infection
	Lawitz EJ1, O'Riordan WD2, Asatryan A3, Freilich BL4, Box TD5, Overcash JS2, Lovell S3, Ng TI3, Liu W3, Campbell A3, Lin CW3, Yao B3, Kort J3. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02264-15. [Epub ahead of print]

529.	Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States
	Weber NC1, Klepser ME1, Akers JM2, Klepser DG3, Adams AJ4. Expert Rev Mol Diagn. 2015 Nov 27:1-12. [Epub ahead of print]

530.	Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial
	Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK. Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10.

531.	IFN-lambda therapy: current status and future perspectives
	Lasfar A1, Zloza A2, Cohen-Solal KA3. Drug Discov Today. 2015 Nov 10. pii: S1359-6446(15)00419-5. doi: 10.1016/j.drudis.2015.10.021. [Epub ahead of print]

532.	Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance
	Nakatsuka K1, Atsukawa M1, Shimizu M1, Takahashi H1, Kawamoto C1. World J Hepatol. 2015 Nov 8;7(25):2590-6. doi: 10.4254/wjh.v7.i25.2590.

533.	Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers
	Patel K1,2,3, Tillmann HL1,2, Matta B2, Sheridan MJ4, Gardner SD5, Shackel NA3, McHutchison JG6, Goodman ZD7. Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13471. [Epub ahead of print]

534.	Towards a more accurate estimate of the prevalence of hepatitis C in the United States
	Edlin BR1,2, Eckhardt BJ1, Shu MA3, Holmberg SD4, Swan T5. Hepatology. 2015 Jul 14. doi: 10.1002/hep.27978. [Epub ahead of print]

535.	Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET
	Brown RS Jr1, O'Leary JG2, Reddy KR3, Kuo A4, Morelli GJ5, Burton JR Jr6, Stravitz RT7, Durand C8, Di Bisceglie AM9, Kwo P10, Frenette CT11, Stewart TG12, Nelson DR5, Fried MW12, Terrault NA13; HCV-TARGET Study Group. Liver Transpl. 2015 Oct 31. doi: 10.1002/lt.24366. [Epub ahead of print]

536.	Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease
	Padam P1, Clark S1, Irving W2, Gellissen R3, Thomson E4, Main J5, Cooke GS1. J Viral Hepat. 2015 Oct 29. doi: 10.1111/jvh.12484. [Epub ahead of print]

537.	Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study
	Jensen DM1, Brunda M2, Elston R3, Gane EJ4, George J5, Glavini K6, Hammond JM6, Le Pogam S7, Nájera I6, Passe S2, Piekarska A8, Rodriguez I2, Zeuzem S9, Chu T2; ANNAPURNA study investigators. Liver Int. 2015 Oct 31. doi: 10.1111/liv.12997. [Epub ahead of print]

538.	Show Me Echo - Hepatitis C: A telemedicine mentoring program for patients with hepatitis C in underserved and rural areas in Missouri as a model in developing countries
	Tahan V1, Almashhrawi A, Mutrux R, Ibdah JA. Turk J Gastroenterol. 2015 Oct 26. doi: 10.5152/tjg.2015.159000. [Epub ahead of print]

539.	Next-Generation Regimens: The Future of Hepatitis C Virus Therapy
	Vizuete J1, Hubbard H2, Lawitz E2. Clin Liver Dis. 2015 Nov;19(4):707-16. doi: 10.1016/j.cld.2015.06.009. Epub 2015 Jul 26.

540.	Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment
	Costilla V1, Mathur N1, Gutierrez JA2. Clin Liver Dis. 2015 Nov;19(4):641-56. doi: 10.1016/j.cld.2015.06.005. Epub 2015 Jul 29.

541.	Regimens for Patients Coinfected with Human Immunodeficiency Virus
	Wyles DL1. Clin Liver Dis. 2015 Nov;19(4):689-706. doi: 10.1016/j.cld.2015.06.008. Epub 2015 Aug 29.

542.	Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients
	Saxena V1, Terrault N2. Clin Liver Dis. 2015 Nov;19(4):669-88. doi: 10.1016/j.cld.2015.06.007. Epub 2015 Jul 26.

543.	Regimens for Cirrhotic Patients
	Kwo PY1. Clin Liver Dis. 2015 Nov;19(4):657-67. doi: 10.1016/j.cld.2015.06.006. Epub 2015 Jul 26.

544.	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
	Buti M1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Forns X8. Clin Infect Dis. 2015 Sep 14. pii: civ722. [Epub ahead of print]

545.	Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients
	ANRS CO13 HEPAVIH Cohort. AIDS. 2015 Sep 10;29(14):1821-30. doi: 10.1097/QAD.0000000000000787.

546.	Pros and Cons: Usage of organs from donors infected with hepatitis C virus - revision in the direct acting antiviral era
	Coilly A1, Samuel D2. J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00617-0. doi: 10.1016/j.jhep.2015.09.002. [Epub ahead of print]

547.	The prevalence of hepatitis C among healthcare workers: a systematic review and meta-analysis
	Westermann C1, Peters C1, Lisiak B2, Lamberti M3, Nienhaus A4. Occup Environ Med. 2015 Oct 5. pii: oemed-2015-102879. doi: 10.1136/oemed-2015-102879. [Epub ahead of print]

548.	Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies
	Petta S1, Maida M2, Macaluso FS2, Barbara M2, Licata A2, Craxì A2, Cammà C2. Gastroenterology. 2015 Sep 16. pii: S0016-5085(15)01322-0. doi: 10.1053/j.gastro.2015.09.007. [Epub ahead of print]

549.	Hepatitis C Virus in the US Military Retiree Population: To Screen, or Not to Screen?
	Laufer CB1, Carroll MB2. J Clin Med Res. 2015 Oct;7(10):757-61. doi: 10.14740/jocmr2233w. Epub 2015 Aug 23.

550.	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
	Lam BP1, Jeffers T1, Younoszai Z1, Fazel Y1, Younossi ZM2. Therap Adv Gastroenterol. 2015 Sep;8(5):298-312. doi: 10.1177/1756283X15587481.

551.	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial)
	Poordad F1, Rustgi V2, Brown RS Jr3, Patel V4, Kugelmas M5, Regenstein F6, Balart L7, LaBrecque D8, Brown K9, Avila M10, Biederman M11, Freed G12, Smith R13, Bernstein M14, Arnold H15, Cahan J16, Fink S17, Katkov W18, Massoumi H19, Harrison S20. Therap Adv Gastroenterol. 2015 Sep;8(5):263-9. doi: 10.1177/1756283X15588876.

552.	Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review
	Mitchell O1, Gurakar A1. J Clin Transl Hepatol. 2015 Jun 28;3(2):140-8. doi: 10.14218/JCTH.2015.00005. Epub 2015 Jun 15.

553.	Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature
	Kwo PY1, Badshah MB. Curr Gastroenterol Rep. 2015 Oct;17(10):462. doi: 10.1007/s11894-015-0462-0.

554.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV

Susanna Naggie, M.D., M.H.S., Curtis Cooper, M.D., Michael Saag, M.D., Kimberly Workowski, M.D., Peter Ruane, M.D., William J. Towner, M.D., Kristen Marks, M.D., Anne Luetkemeyer, M.D., Rachel P. Baden, M.D., Paul E. Sax, M.D., Edward Gane, M.D., Jorge Santana-Bagur, M.D., Luisa M. Stamm, M.D., Ph.D., Jenny C. Yang, Pharm.D., Polina German, Pharm.D., Hadas Dvory-Sobol, Ph.D., Liyun Ni, M.A., Phillip S. Pang, M.D., Ph.D., John G. McHutchison, M.D., Catherine A.M. Stedman, M.B., Ch.B., Ph.D., Javier O. Morales-Ramirez, M.D., Norbert Bräu, M.D., Dushyantha Jayaweera, M.D., Amy E. Colson, M.D., Pablo Tebas, M.D., David K. Wong, M.D., Douglas Dieterich, M.D., and Mark Sulkowski, M.D. for the ION-4 Investigators

555.	Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?
	Walker CM1, Grakoui A2. Curr Opin Immunol. 2015 Aug;35:137-43. doi: 10.1016/j.coi.2015.06.010. Epub 2015 Aug 1.

556.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

David L. Wyles, M.D., Peter J. Ruane, M.D., Mark S. Sulkowski, M.D., Douglas Dieterich, M.D., Anne Luetkemeyer, M.D., Timothy R. Morgan, M.D., Kenneth E. Sherman, M.D., Ph.D., Robin Dretler, M.D., Dawn Fishbein, M.D., Joseph C. Gathe, Jr., M.D., Sarah Henn, M.D., Federico Hinestrosa, M.D., Charles Huynh, D.O., Cheryl McDonald, M.D., Anthony Mills, M.D., Edgar Turner Overton, M.D., Moti Ramgopal, M.D., Bruce Rashbaum, M.D., Graham Ray, M.S.N., A.N.P., Anthony Scarsella, M.D., Joseph Yozviak, D.O., Fiona McPhee, Ph.D., Zhaohui Liu, Ph.D., Eric Hughes, M.D., Ph.D., Philip D. Yin, M.D., Ph.D., Stephanie Noviello, M.D., and Peter Ackerman, M.D. for the ALLY-2 Investigators

557.	Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin
	Shiffman ML1, James AM1, Long AG1, Alexander PC1. Am J Gastroenterol. 2015 Aug;110(8):1179-85. doi: 10.1038/ajg.2015.218. Epub 2015 Jul 28.

558.	Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study
	Gordon SC1, Lamerato LE2, Rupp LB3, Holmberg SD4, Moorman AC4, Spradling PR4, Teshale E4, Xu F4, Boscarino JA5, Vijayadeva V6, Schmidt MA7, Oja-Tebbe N2, Lu M2. Am J Gastroenterol. 2015 Aug;110(8):1169-77. doi: 10.1038/ajg.2015.203. Epub 2015 Jul 28.

559.	Human rights and access to hepatitis C treatment for people who inject drugs
	Wolfe D1, Luhmann N2, Harris M3, Momenghalibaf A4, Albers E5, Byrne J6, Swan T7. Int J Drug Policy. 2015 Jun 23. pii: S0955-3959(15)00140-1. doi: 10.1016/j.drugpo.2015.05.007. [Epub ahead of print]

560.	Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM
	Sherman AC1, Sherman KE. Curr HIV/AIDS Rep. 2015 Sep;12(3):353-61. doi: 10.1007/s11904-015-0274-8.

561.	Development of sofosbuvir for the treatment of hepatitis C virus infection
	Lawitz E1, Jacobson IM2, Nelson DR3, Zeuzem S4, Sulkowski MS5, Esteban R6, Brainard D7, McNally J7, Symonds WT7, McHutchison JG7, Dieterich D8, Gane E9. Ann N Y Acad Sci. 2015 Jul 31. doi: 10.1111/nyas.12832. [Epub ahead of print]

562.	Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System
	Cheetham TC1, Niu F, Chiang K, Yuan Y, Kalsekar A, Hechter R, Hay JW, Nyberg L. J Manag Care Spec Pharm. 2015 Aug;21(8):641-7.

563.	Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
	Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4.

564.	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial
	Shiffman ML1, Cheinquer H2, Berg CP3, Berg T4, de Figueiredo-Mendes C5, Dore GJ6, Ferraz ML7, Mendes-Corrêa MC8, Lima MP9, Parise ER10, Rios AM11, Reuter T12, Sanyal AJ13, Shafran SD14, Hohmann M15, Tatsch F16,17, Bakalos G18, Zeuzem S1 Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24.

565.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Naggie S1, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.

566.	HCV Infection is Associated with Lower Survival in Simultaneous Liver Kidney Transplant Recipients in the U.S.
	Perumpail RB1, Wong RJ2, Scandling JD3, Ha LD1, Todo T4, Bonham CA4, Saab S5, Younossi ZM6,7, Ahmed A1. Clin Transplant. 2015 Jul 23. doi: 10.1111/ctr.12598. [Epub ahead of print]

567.	HCV treatment: is it possible to cure all HCV patients?
	Muir AJ1, Naggie S2. Clin Gastroenterol Hepatol. 2015 Jul 17. pii: S1542-3565(15)00973-8. doi: 10.1016/j.cgh.2015.07.015. [Epub ahead of print]

568.	Hepatitis C in children in times of change
	Baker RD1, Baker SS. Curr Opin Pediatr. 2015 Jul 18. [Epub ahead of print]

569.	Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations-diagnosis and management
	Shah M1, Younossi ZM. Am J Manag Care. 2015 Mar;21(5 Suppl):s86-96.

570.	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis
	Lawitz E1, Makara M2, Akarca US3, Thuluvath PJ4, Preotescu LL5, Varunok P6, Morillas RM7, Hall C8, Mobashery N8, Redman R8, Pilot-Matias T8, Vilchez RA8, Hézode C9. Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936-1. doi: 10.1053/j.gastro.2015.07.001. [Epub ahead of print]

571.	Revolutionizing treatment outcomes in hepatitis c: managed care implications and considerations-the new and evolving standards of care
	Owens GM1. Am J Manag Care. 2015 Mar;21(5 Suppl):s97-s105.

572.	Revolutionizing treatment outcomes in hepatitis c: managed care implications and considerations-a clinical overview
	Shah M1, Younossi ZM, Opsha Y. Am J Manag Care. 2015 Mar;21(5 Suppl):s76-85.

573.	Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011
	Tong X1, Spradling PR. J Viral Hepat. 2015 Apr 20. doi: 10.1111/jvh.12414. [Epub ahead of print]

574.	Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin: A Matched Analysis
	Saab S1,2, Jimenez M3, Bau S2, Goo T1, Zhao D3, Durazo F1,2, Han S1,2, El Kabany M1,2, Kaldas F2, Tong MJ2,4, Busuttil RW2. Clin Transplant. 2015 Jul 4. doi: 10.1111/ctr.12584. [Epub ahead of print]

575.	Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection
	Signorovitch JE1, Betts KA1, Song Y1, Sorg RA2, Li J1, Behl AS3, Kalsekar A3. J Comp Eff Res. 2015 Jul 10:1-13. [Epub ahead of print]

576.	Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis
	Bailly F1, Pradat P, Virlogeux V, Zoulim F. Dig Dis. 2015;33(4):613-23. doi: 10.1159/000375359. Epub 2015 Jul 6.

577.	Modelling hepatitis C therapy-predicting effects of treatment
	Perelson AS1, Guedj J2. Nat Rev Gastroenterol Hepatol. 2015 Jun 30. doi: 10.1038/nrgastro.2015.97. [Epub ahead of print]

578.	The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
	Harris M1, Albers E2, Swan T3. Int J Drug Policy. 2015 Jun 4. pii: S0955-3959(15)00138-3. doi: 10.1016/j.drugpo.2015.05.005. [Epub ahead of print]

579.	Cost-effectiveness of strategies for testing current hepatitis C virus infection
	Chapko MK1, Dufour DR2, Hatia R3, Drobeniuc J3, Ward JW3, Teo CG3. Hepatology. 2015 Jun 30. doi: 10.1002/hep.27966. [Epub ahead of print]

580.	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study
	Fortier E1, Alavi M2, Micallef M2, Dunlop AJ3, Balcomb AC4, Day CA5, Treloar C6, Bath N7, Haber PS8, Dore GJ2, Bruneau J9, Grebely J10; ETHOS Study Group. Int J Drug Policy. 2015 Jun 11. pii: S0955-3959(15)00181-4. doi: 10.1016/j.drugpo.2015.06.001. [Epub ahead of print]

581.	A phase II, randomized, controlled trial of S-adenosylmethionine in reducing serum alpha-fetoprotein (AFP) in patients with hepatitis C cirrhosis and elevated AFP
	Morgan TR1, Osann K2, Bottiglieri T3, Pimstone N4, Hoefs JC5, Hu KQ6, Hassanein T7, Boyer T8, Kong L9, Chen WP10, Richmond E11, Gonzalez R12, Rodriguez LM13, Meyskens FL14. Cancer Prev Res (Phila). 2015 Jun 30. pii: canprevres.0029.2015. [Epub ahead of print]

582.	Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
	Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M15-0406. [Epub ahead of print]

583.	Assessment of Drug-Drug Interactions Between Daclatasvir and Methadone or Buprenorphine/Naloxone
	Garimella T1, Wang R2, Luo WL2, Wastall P2, Kandoussi H2, DeMicco M3, Bruce RD4, Hwang C2, Bertz R2, Bifano M2. Antimicrob Agents Chemother. 2015 Jun 29. pii: AAC.00478-15. [Epub ahead of print]

584.	Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans
	Backus LI1,2, Belperio PS1, Shahoumian TA1, Loomis TP1, Mole LA1. Aliment Pharmacol Ther. 2015 Jun 26. doi: 10.1111/apt.13300. [Epub ahead of print]

585.	Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review
	Onofrey S, Aneja J, Haney GA, Nagami EH, Jr AD, Lauer GM, Hills-Evans K, Barton K, Kulaga S, Bowen MJ, Cocoros N, McGovern BH, Church DR, Kim AY. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M14-2939. [Epub ahead of print]

586.	Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir
	(Paritaprevir), Ombitasvir, and Dasabuvir in Hepatic Impairment.

587.	The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception
	Safo SA1, Batchelder A2,3, Peyser D4,5, Litwin AH6.

588.	Interferon-free, direct-acting antiviral therapy for chronic hepatitis C
	Gutierrez JA1, Lawitz EJ1, Poordad F1. J Viral Hepat. 2015 Jun 17. doi: 10.1111/jvh.12422. [Epub ahead of print]

589.	HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users
	Elliott JC1, Hasin DS, Stohl M, Des Jarlais DC. AIDS Behav. 2015 Jun 17. [Epub ahead of print]

590.	Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum
	Meyer JP1, Moghimi Y2, Marcus R3, Lim JK4, Litwin AH5, Altice FL6. Int J Drug Policy. 2015 May 17. pii: S0955-3959(15)00135-8. doi: 10.1016/j.drugpo.2015.05.002. [Epub ahead of print]

591.	Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013
	Jordan AE1, Des Jarlais DC2, Arasteh K2, McKnight C2, Nash D3, Perlman DC4. Drug Alcohol Depend. 2015 Apr 13. pii: S0376-8716(15)00195-7. doi: 10.1016/j.drugalcdep.2015.03.039. [Epub ahead of print]

592.	Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent
	Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print]

593.	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-?-induced protein 10 levels in HBV/HCV-coinfected patients
	Wiegand SB1, Jaroszewicz J2, Potthoff A3, Höner Zu Siederdissen C3, Maasoumy B3, Deterding K3, Manns MP1, Wedemeyer H1, Cornberg M4. Clin Microbiol Infect. 2015 Apr 13. pii: S1198-743X(15)00367-5. doi: 10.1016/j.cmi.2015.03.003. [Epub ahead of print]

594.	Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study
	Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print]

595.	Treatment of hepatitis C in difficult-to-treat patients
	Ferenci P1. Nat Rev Gastroenterol Hepatol. 2015 Apr 21. doi: 10.1038/nrgastro.2015.53. [Epub ahead of print]

596.	Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease
	Weinstein AA1, Escheik C2, Oe B2, Price JK2, Gerber L3, Younossi Z2. PM R. 2015 Jun 11. pii: S1934-1482(15)00287-7. doi: 10.1016/j.pmrj.2015.06.001. [Epub ahead of print]

597.	The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life
	Younossi ZM1,2, Stepanova M1,2, Nader F1,2, Lam B1,2, Hunt S1,2. Aliment Pharmacol Ther. 2015 Jun 9. doi: 10.1111/apt.13269. [Epub ahead of print]

598.	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study
	Younossi ZM1,2, Stepanova M1,2, Pol S3, Bronowicki JP4, Carrieri MP5,6,7, Bourlière M8. Liver Int. 2015 Jun 9. doi: 10.1111/liv.12886. [Epub ahead of print]

599.	Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes
	Watt GP1, Vatcheva KP1, Beretta L2, Pan JJ3, Fallon MB3, McCORMICK JB1, Fisher-Hoch SP1. Epidemiol Infect. 2015 Jun 19:1-9. [Epub ahead of print]

600.	The corrected donor age for hepatitis C virus infected liver transplant recipients
	Dirchwolf M1, Dodge JL2, Gralla J3, Bambha KM3, Nydam T3, Hung KW3, Rosen HR3, Feng S2, Terrault NA2, Biggins SW3. Liver Transpl. 2015 Jun 13. doi: 10.1002/lt.24194. [Epub ahead of print]

601.	Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C
	Fazel Y1, Lam B, Golabi P, Younossi Z. Expert Opin Drug Saf. 2015 Jun 4:1-10. [Epub ahead of print]

602.	Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients: Implications for Future HIV/HCV Screening Interventions
	Merchant RC1, DeLong AK, Liu T, Baird JR. AIDS Behav. 2015 Jun 3. [Epub ahead of print]

603.

Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013

Wandeler G1, Schlauri M2, Jaquier ME2, Rohrbach J2, Metzner KJ3, Fehr J3, Ambrosioni J4, Cavassini M5, Stöckle M6, Schmid P7, Bernasconi E8, Keiser O9, Salazar-Vizcaya L9, Furrer H2, Rauch A2; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. Open Forum Infect Dis. 2015 Mar 25;2(1):ofv026. doi: 10.1093/ofid/ofv026. eCollection

604.	Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens
	Chen TY1, Jain MK1. AIDS Patient Care STDS. 2015 Jun;29(6):329-37. doi: 10.1089/apc.2014.0247.

605.	Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens
	Harrington PR1, Fleischer R1, Connelly SM1, Lewis LL1, Murray J1. Clin Infect Dis. 2015 May 28. pii: civ419. [Epub ahead of print]

606.	A Clinician's Guide to Drug-Drug Interactions with Direct Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection
	Dick TB1, Lindberg LS1, Ramirez DD1, Charlton MR2. Hepatology. 2015 May 29. doi: 10.1002/hep.27920. [Epub ahead of print]

607.	Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis
	Combellick J1, Smith DJ, Jordan AE, Hagan H. JMIR Res Protoc. 2015 Jun 8;4(2):e68. doi: 10.2196/resprot.4518.

608.	Is antenatal screening for hepatitis C virus cost effective? A decade's experience at a London centre
	Selvapatt N1, Ward T2, Bailey H3, Bennett H2, Thorne C3, See LM4, Tudor-Williams G5, Thursz M6, McEwan P7, Brown A8. J Hepatol. 2015 May 26. pii: S0168-8278(15)00342-6. doi: 10.1016/j.jhep.2015.05.015. [Epub ahead of print]

609.	Hepatitis C Infection in the Elderly
	Saab S1, Rheem J, Sundaram V. Dig Dis Sci. 2015 May 26. [Epub ahead of print]

610.	Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection
	Yang HJ1, Ryoo JY, Yoo BK. Int J Clin Pharm. 2015 Jun 6. [Epub ahead of print]

611.	Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
	Bunchorntavakul C1,2, Reddy KR2. Aliment Pharmacol Ther. 2015 May 27. doi: 10.1111/apt.13264. [Epub ahead of print]

612.	Beyond viral response: A prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support
	Mason K1, Dodd Z1, Sockalingam S2, Altenberg J1, Meaney C3, Millson P4, Powis J5. Int J Drug Policy. 2015 Apr 29. pii: S0955-3959(15)00123-1. doi: 10.1016/j.drugpo.2015.04.012. [Epub ahead of print]

613.	Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant
	Herzer K1, Papadopoulos-Köhn A, Walker A, Achterfeld A, Paul A, Canbay A, Timm J, Gerken G. Digestion. 2015 May 19;91(4):326-333. [Epub ahead of print]

614.	Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype
	Peltenburg NC, Bakker JA, Vroemen WH, de Knegt RJ, Leers MP, Bierau J, Verbon A. Clin Chem Lab Med. 2015 May 13. pii: /j/cclm.ahead-of-print/cclm-2015-0057/cclm-2015-0057.xml. doi: 10.1515/cclm-2015-0057. [Epub ahead of print]

615.	Therapy for hepatitis C genotype 3: moving forward
	Buti M1,2, Llaneras J1, Riveiro-Barciela M1, Esteban R1,2. J Viral Hepat. 2015 May 13. doi: 10.1111/jvh.12419. [Epub ahead of print]

616.	Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin
	Rower JE1, Meissner EG2, Jimmerson LC1, Osinusi A3, Sims Z2, Petersen T2, Bushman LR1, Wolfe P4, McHutchison JG5, Kottilil S2, Kiser JJ6. J Antimicrob Chemother. 2015 May 13. pii: dkv122. [Epub ahead of print]

617.	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study
	Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill J, Hull M, Walmsley S, Klein MB. HIV Clin Trials. 2015 May-Jun;16(3):100-10. doi: 10.1179/501100000024. Epub 2015 May 14.

618.	Hepatitis C in Arkansas: updates on epidemiology, testing and treatment
	Beebe A, Quattlebaum T, Gicquelais RE, Zohoori N, Haselow DT, Smith NH. J Ark Med Soc. 2015 May;111(12):248-51.

619.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease

Charlton M1, Everson GT2, Flamm SL3, Kumar P4, Landis C5, Brown RS Jr6, Fried MW7, Terrault NA8, O'Leary JG9, Vargas HE10, Kuo A11, Schiff E12, Sulkowski MS13, Gilroy R14, Watt KD15, Brown K16, Kwo P17, Pungpapong S18, Korenblat KM19, Muir AJ20, Teperman L21, Fontana RJ22, Denning J23, Arterburn S23, Dvory-Sobol H23, Brandt-Sarif T23, Pang PS23, McHutchison JG23, Reddy KR24, Afdhal N25; SOLAR-1 Investigators. Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682-4. doi: 10.1053/j.gastro.2015.05.010. [Epub ahead of print]

620.	Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
	Muir AJ1, Poordad F2, Lalezari J3, Everson G4, Dore GJ5, Herring R6, Sheikh A7, Kwo P8, Hézode C9, Pockros PJ10, Tran A11, Yozviak J12, Reau N13, Ramji A14, Stuart K15, Thompson AJ16, Vierling J17, Freilich B18, Cooper J19, Ghesquiere W20, Yang R21, McPhee F22, Hughes EA21, Swenson ES22, Yin PD22. JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.

621.	Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
	Poordad F1, Sievert W2, Mollison L3, Bennett M4, Tse E5, Bräu N6, Levin J7, Sepe T8, Lee SS9, Angus P10, Conway B11, Pol S12, Boyer N13, Bronowicki JP14, Jacobson I15, Muir AJ16, Reddy KR17, Tam E18, Ortiz-Lasanta G19, de Lédinghen V20, Sulkowski M21, Boparai N22, McPhee F23, Hughes E22, Swenson ES23, Yin PD23; UNITY-1 Study Group. JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.

622.	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials
	Alqahtani SA1, Afdhal N2, Zeuzem S3, Gordon S4, Mangia A5, Kwo P6, Fried M7, Yang JC8, Ding X8, Pang PS8, McHutchison JG8, Pound D9, Reddy KR10, Marcellin P11, Kowdley KV12, Sulkowski M1. Hepatology. 2015 May 11. doi: 10.1002/hep.27890. [Epub ahead of print]

623.	Sorting out cirrhosis: Mechanisms of non-response to hepatitis C therapy
	Al Marzooqi SH1, Feld JJ. Liver Int. 2015 May 2. doi: 10.1111/liv.12861. [Epub ahead of print]

624.	Interferon-free therapy for hepatitis C: The hurdles amid a golden era
	Colombo M1. Dig Liver Dis. 2015 Apr 11. pii: S1590-8658(15)00276-5. doi: 10.1016/j.dld.2015.04.003. [Epub ahead of print]

625.	Increased Incidence of Cancer and Cancer-related Mortality Among Persons with Chronic Hepatitis C Infection, 2006-2010
	Allison RD1, Tong X2, Moorman AC2, Ly KN2, Rupp L3, Xu F2, Gordon SC3, Holmberg SD2; Chronic Hepatitis Cohort Study (CHeCS) Investigators. J Hepatol. 2015 Apr 30. pii: S0168-8278(15)00304-9. doi: 10.1016/j.jhep.2015.04.021. [Epub ahead of print]

626.	Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
	Janardhan SV1, Reau NS1. Hepat Med. 2015 Apr 16;7:11-20. doi:

627.	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients with Hepatitis C, Regardless of Response to Antiviral Therapy
	Lens S1, Rincón D2, García-Retortillo M3, Albillos A4, Calleja JL5, Bañares R2, González-Abraldes J6, Bosch J7, Sanchez-Tapias JM1, Forns X1, García-Pagán JC8. Clin Gastroenterol Hepatol. 2015 Apr 22. pii: S1542-3565(15)00415-2. doi: 10.1016/j.cgh.2015.04.013. [Epub ahead of print]

628.	Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C
	Thibault A1,2, Brissette S3,4, Jutras-Aswad D5,6. Addict Sci Clin Pract. 2015 Feb 24;10(1):6. [Epub ahead of print]

629.	Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial
	Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Ann Intern Med. 2015 Apr 24. doi: 10.7326/M15-0785. [Epub ahead of print]

630.	Implementing Updated Recommendations on Hepatitis C Virus Screening: Translating Federal Guidance Into State Practice
	Martin EG1, Norcott AM, Khalid H, O?Connell DA. J Public Health Manag Pract. 2015 Apr 22. [Epub ahead of print]

631.	Impact of all oral anti-hepatitis C virus therapy: A meta-analysis
	Bansal S1, Singal AK1, McGuire BM1, Anand BS1. World J Hepatol. 2015 Apr 18;7(5):806-13. doi: 10.4254/wjh.v7.i5.806.

632.	From non-A, non-B hepatitis to hepatitis C virus cure
	Pawlotsky JM1, Feld JJ2, Zeuzem S3, Hoofnagle JH4. J Hepatol. 2015 Apr;62(1S):S87-S99. doi: 10.1016/j.jhep.2015.02.006.

633.	Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study
	Verna EC1, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA; for the CRUSH-C Consortium. Transplantation. 2015 Feb 24. [Epub ahead of print]

634.	A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection
	Park H1, Adeyemi A, Henry L, Stepanova M, Younossi Z. J Viral Hepat. 2015 Apr 22. doi: 10.1111/jvh.12413. [Epub ahead of print]

635.	Acquiring hepatitis C in prison: the social organisation of injecting risk
	Treloar C1, McCredie L2, Lloyd AR3; HITS-p investigators. Harm Reduct J. 2015 Apr 24;12(1):10. doi: 10.1186/s12954-015-0045-2.

636.	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade
	Barth H1. World J Hepatol. 2015 Apr 18;7(5):725-37. doi: 10.4254/wjh.v7.i5.725.

637.	Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013
	Jordan AE1, Des Jarlais DC2, Arasteh K2, McKnight C2, Nash D3, Perlman DC4. Drug Alcohol Depend. 2015 Apr 13. pii: S0376-8716(15)00195-7. doi: 10.1016/j.drugalcdep.2015.03.039. [Epub ahead of print]

638.	Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent
	Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print]

639.	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-?-induced protein 10 levels in HBV/HCV-coinfected patients
	Wiegand SB1, Jaroszewicz J2, Potthoff A3, Höner Zu Siederdissen C3, Maasoumy B3, Deterding K3, Manns MP1, Wedemeyer H1, Cornberg M4. Clin Microbiol Infect. 2015 Apr 13. pii: S1198-743X(15)00367-5. doi: 10.1016/j.cmi.2015.03.003. [Epub ahead of print]

640.	Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study
	Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print]

641.	Treatment of hepatitis C in difficult-to-treat patients
	Ferenci P1. Nat Rev Gastroenterol Hepatol. 2015 Apr 21. doi: 10.1038/nrgastro.2015.53. [Epub ahead of print]

642.	Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
	Keating GM1. Drugs. 2015 Apr 3. [Epub ahead of print]

643.	Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study
	Myers RP1, Crotty P2, Town S3, English J3, Fonseca K4, Tellier R4, Swain MG2, McGregor SE3, Heitman SJ3, Hilsden RJ5.

644.	HIV and HCV Medications in End-Stage Renal Disease
	Greenberg KI1, Perazella MA, Atta MG. Semin Dial. 2015 Apr 6. doi: 10.1111/sdi.12367. [Epub ahead of print]

645.	Sofosbuvir for treatment of chronic hepatitis C
	Kattakuzhy S1, Levy R, Kottilil S. Hepatol Int. 2015 Jan 28. [Epub ahead of print]

646.	Chronic hepatitis C - what do the new drugs offer and who should get them first?
	Ryder SD1. Clin Med. 2015 Apr;15(2):197-200. doi: 10.7861/clinmedicine.15-2-197.

647.	Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
	Kirby BJ1, Symonds WT, Kearney BP, Mathias AA. Clin Pharmacokinet. 2015 Mar 31. [Epub ahead of print]

648.	Comparison of Risk-Based Hepatitis C Screening and the True Seroprevalence in an Urban Prison System
	Kuncio DE1, Newbern EC, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. J Urban Health. 2015 Mar 21. [Epub ahead of print]

649.	Post-Liver Transplant Hepatitis C Therapy
	Rahimi RS1, O'Leary JG. Curr Treat Options Gastroenterol. 2015 Mar 27. [Epub ahead of print]

650.	New Medical Treatment Strategies for Nonalcoholic Steatohepatitis
	Fuchs M1. Curr Treat Options Gastroenterol. 2015 Mar 21. [Epub ahead of print]

651.	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
	Younossi ZM1, Stepanova M2, Afdhal N3, Kowdley KV4, Zeuzem S5, Henry L6, Hunt SL7, Marcellin P8. J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192-0. doi: 10.1016/j.jhep.2015.03.014. [Epub ahead of print]

652.	Most patients with HCV-associated lymphoma present with mild liver disease: A call to revise antiviral treatment prioritization
	Torres HA1, Mahale P. Liver Int. 2015 Mar 16. doi: 10.1111/liv.12825. [Epub ahead of print]

653.	A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China
	Wu E1, Chen X, Guan Z, Cao C, Rao H, Feng B, Chan M, Fu S, Lin A, Wei L, Lok AS. Hepatol Int. 2015 Jan;9(1):58-66. doi: 10.1007/s12072-014-9559-z. Epub 2014 Jul 31.

654.	Expanding capacity for hepatitis C treatment in the United States: team-based care and use of nonphysician providers
	Kwong J1, Epstein R2. J Int Assoc Provid AIDS Care. 2015 Mar;14(2):112-5. doi: 10.1177/2325957414560065.

655.	Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
	Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.

656.
	Sep 9;10(3):164-71. doi: 10.1108/IJPH-11-2013-0051.

657.	The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral
	Rein DB1, Wittenborn JS1, Smith BD2, Liffmann DK1, Ward JW2. Clin Infect Dis. 2015 Mar 16. pii: civ220. [Epub ahead of print]

658.	Meal ingestion markedly increases liver stiffness suggesting the need for liver stiffness determination in fasting conditions
	Alvarez D1, Orozco F2, Mella JM2, Anders M2, Antinucci F2, Mastai R3. Gastroenterol Hepatol. 2015 Mar 10. pii: S0210-5705(15)00029-1. doi: 10.1016/j.gastrohep.2015.01.009. [Epub ahead of print]

659.	A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients
	Burgess S1, Partovi N2, Yoshida EM2, Erb SR2, Azalgara VM2, Hussaini T3. Ann Pharmacother. 2015 Mar 13. pii: 1060028015576180. [Epub ahead of print]

660.	Cost-effectiveness of novel regimens for the treatment of hepatitis C virus
	Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.

661.	A Nationwide Reporting System to Satisfy the Ethical Obligation to Prevent Drug Diversion-Related Transmission of Hepatitis C in Healthcare Facilities
	Lahey T1, Nelson WA2. Clin Infect Dis. 2015 Mar 12. pii: civ203. [Epub ahead of print]

662.	Hepatitis C virus therapeutic development: in pursuit of perfectovir
	Dore GJ1, Feld JJ2. Clin Infect Dis. 2015 Mar 11. pii: civ197. [Epub ahead of print]

663.	Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?
	Sengupta S1, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Dig Dis Sci. 2015 Mar 6. [Epub ahead of print]

664.	Hepatitis C virus treatment in the 'real-world': how well do 'real' patients respond?
	Deborah Friedman N1, Green JH2, Weber HM2, Stephen S2, Lane SE3, Ting AY4, Watson JP5. J Clin Exp Hepatol. 2014 Sep;4(3):214-20. doi: 10.1016/j.jceh.2014.07.003. Epub 2014 Jul 25.

665.	Comparison of Rates of Death Having any Death-Certificate Mention of Heart, Kidney, or Liver Disease Among Persons Diagnosed with HIV Infection with those in the General US Population, 2009-2011
	Whiteside YO1, Selik R1, An Q1, Huang T2, Karch D1, Hernandez AL1, Hall HI1. Open AIDS J. 2015 Feb 27;9:14-22. doi: 10.2174/1874613601509010014. eCollection 2015.

666.	An update on the association of vitamin D deficiency with common infectious diseases
	Watkins RR1, Lemonovich TL, Salata RA. Can J Physiol Pharmacol. 2015 Jan 26:1-6. [Epub ahead of print]

667.	Integrated Care Increases Treatment and Improves Outcomes of Patients with Chronic HCV Infection and Psychiatric Illness or Substance Abuse
	Ho SB1, Bräu N2, Cheung R3, Liu L4, Sanchez C5, Sklar M4, Phelps TE6, Marcus SG7, Wasil MM5, Tisi A7, Huynh L6, Robinson SK4, Gifford A8, Asch SM3, Groessl EJ4. Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print]

668.	Protease inhibitors block multiple functions of the NS3/4A protease-helicase during the hepatitis C virus life cycle
	McGivern DR1, Masaki T2, Lovell W2, Hamlett C3, Saalau-Bethell S3, Graham B3. J Virol. 2015 Mar 4. pii: JVI.03188-14. [Epub ahead of print]

669.	A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections
	Beckwith CG1, Kurth AE2, Bazerman LB3, Patry EJ3, Cates A4, Tran L3, Noska A1, Kuo I4. J Public Health (Oxf). 2015 Mar 2. pii: fdv023. [Epub ahead of print]

670.	Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C
	Floreani A1. Expert Opin Pharmacother. 2015 Mar 1:1-4. [Epub ahead of print]

671.	Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection
	Edeghere O1, Verlander NQ2, Aboulhab J3, Costella A4, Harris HE4, Balogun MA4, Ramsay ME4. Public Health. 2015 Feb 25. pii: S0033-3506(15)00043-8. doi: 10.1016/j.puhe.2015.01.024. [Epub ahead of print]

672.

Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

Osinusi A1, Townsend K2, Kohli A3, Nelson A4, Seamon C5, Meissner EG6, Bon D7, Silk R8, Gross C8, Price A8, Sajadi M9, Sidharthan S5, Sims Z5, Herrmann E7, Hogan J10, Teferi G10, Talwani R9, Proschan M11, Jenkins V12, Kleiner DE13, Wood BJ14, Subramanian GM15, Pang PS15, McHutchison JG15, Polis MA2, Fauci AS2, Masur H5, Kottilil S4. JAMA. 2015 Feb 23. doi: 10.1001/jama.2015.1373. [Epub ahead of print]

673.	Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein
	Yu Z, Zhao L, You QD1. Mini Rev Med Chem. 2015 Feb 26. [Epub ahead of print]

674.	A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients
	Patel N1, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. Infect Dis Ther. 2015 Jan 28. [Epub ahead of print]

675.	Ledipasvir/sofosbuvir regimens for chronic hepatits c (chc) infection: insights from a work productivity economic model from the United States
	Younossi Z1, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Hepatology. 2015 Feb 23. doi: 10.1002/hep.27757. [Epub ahead of print]

676.	The hepatitis C genotype 1 paradox: Cost per treatment is increasing, but cost per cure is decreasing
	Shafran SD. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):46-8.

677.	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia
	Treloar C1, Rance J1, Bath N2, Everingham H2, Micallef M3, Day C4, Hazelwood S5, Grebely J3, Dore GJ3. Int J Drug Policy. 2015 Jan 24. pii: S0955-3959(15)00008-0. doi: 10.1016/j.drugpo.2015.01.005. [Epub ahead of print]

678.

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

Jensen D1, Sherman KE2, Hézode C3, Pol S4, Zeuzem S5, Ledinghen V6, Tran A7, Elkhashab M8, Younes ZH9, Kugelmas M10, Mauss S11, Everson G12, Luketic V13, Vierling J14, Serfaty L15, Brunetto M16, Heo J17, Bernstein D18, McPhee F19, Hennicken D20, Mendez P21, Hughes E21, Noviello S21; on behalf of the HALLMARK-QUAD Study Team. J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00125-7. doi: 10.1016/j.jhep.2015.02.018. [Epub ahead of print]

679.	Test, Listen, Cure (TLC) Hepatitis C Community Awareness Campaign
	Coughlin SS1. JMIR Res Protoc. 2015 Feb 6;4(1):e13. doi: 10.2196/resprot.3822.

680.	Hepatitis C virus-associated B-cell non-Hodgkin lymphomas
	Vannata B1, Zucca E1. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):590-8. doi: 10.1182/asheducation-2014.1.590. Epub 2014 Nov 18.

681.	ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients
	Gamal N1, Vitale G, Andreone P. Expert Rev Anti Infect Ther. 2015 Jan 12:1-10. [Epub ahead of print]

682.	Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data
	Konerman MA1, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Hepatology. 2015 Feb 12. doi: 10.1002/hep.27750. [Epub ahead of print]

683.	Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma
	Hibner U1, Grégoire D1.Author information Contemp Oncol (Pozn). 2015;19(1A):A62-7. doi: 10.5114/wo.2014.47132.

684.	Findings from Integrated Behavioral and Biologic Survey among Males Who Inject Drugs (MWID) - Vietnam, 2009-2010: Evidence of the Need for an Integrated Response to HIV, Hepatitis B Virus, and Hepatitis C Virus
	Nadol P1, O'connor S2, Duong H3, Le LV3, Thang PH4, Tram TH4, Ha HT4, Mcconnell MS3, Partridge J5, Kaldor J6, Law M6, Nguyen TA4. PLoS One. 2015 Feb 18;10(2):e0118304. doi: 10.1371/journal.pone.0118304. eCollection 2015.

685.	Hepatitis C
	Webster DP1, Klenerman P2, Dusheiko GM3. Lancet. 2015 Feb 13. pii: S0140-6736(14)62401-6. doi: 10.1016/S0140-6736(14)62401-6. [Epub ahead of print]

686.	Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis
	Maan R1, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12929. [Epub ahead of print]

687.	What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?
	Rowan PJ1. World J Virol. 2015 Feb 12;4(1):13-6. doi: 10.5501/wjv.v4.i1.13.

688.	Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
	Leidner AJ1, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Hepatology. 2015 Feb 11. doi: 10.1002/hep.27736. [Epub ahead of print]

689.	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
	Molina JM1, Orkin C2, Iser DM3, Zamora FX4, Nelson M5, Stephan C6, Massetto B7, Gaggar A7, Ni L7, Svarovskaia E7, Brainard D7, Subramanian GM7, McHutchison JG7, Puoti M8, Rockstroh JK9; for the PHOTON-2 study team. Lancet. 2015 Feb 3. pii: S0140-6736(14)62483-1. doi: 10.1016/S0140-6736(14)62483-1. [Epub ahead of print]

690.	Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir
	Menon R1, Badri P2, Wang T2, Polepally A2, Zha J2, Khatri A2, Wang H2, Hu B2, Coakley E2, Podsadecki T2, Awni W2, Dutta S2. J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00057-4. doi: 10.1016/j.jhep.2015.01.026. [Epub ahead of print]

691.	Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens
	Younossi Z1, Henry L. Aliment Pharmacol Ther. 2015 Jan 23. doi: 10.1111/apt.13090. [Epub ahead of print]

692.	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinical-pathological study
	K-Kutala B1, Bedossa P2, Guedj J3, Asselah T4, Martinot-Peignoux M5, Duval X3, Marcellin P4. Dig Liver Dis. 2014 Dec 25. pii: S1590-8658(14)00842-1. doi: 10.1016/j.dld.2014.12.010. [Epub ahead of print]

693.	Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C
	McEwan P1, Ward T1, Bennett H2, Kalsekar A3, Webster S2, Brenner M4, Yuan Y3. PLoS One. 2015 Jan 30;10(1):e0117334. doi: 10.1371/journal.pone.0117334. eCollection 2015.

694.	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
	Younossi ZM1, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Aliment Pharmacol Ther. 2015 Jan 26. doi: 10.1111/apt.13081. [Epub ahead of print]

695.	All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study
	Nelson DR1, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; on behalf of the ALLY-3 Study Team. Hepatology. 2015 Jan 23. doi: 10.1002/hep.27726. [Epub ahead of print]

696.	Hepatitis C Virus treatment as prevention among injecting drug users: who should we cure first?
	de Vos AS1, Prins M, Kretzschmar ME. Addiction. 2015 Jan 13. doi: 10.1111/add.12842. [Epub ahead of print]

697.	Chronic Hepatitis C Infection as a Risk Factor for Renal Cell Carcinoma
	Gonzalez HC1, Lamerato L, Rogers CG, Gordon SC. Dig Dis Sci. 2015 Jan 17. [Epub ahead of print]

698.	Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin
	Nguyen NH1, McCormack SA, Vutien P, Yee BE, Devaki P, Jencks D, Nguyen MH. Intervirology. 2015 Jan 10;58(1):27-34. [Epub ahead of print]

699.	Hepatitis C Virus (HCV) Antibody Positivity and Predictors among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multi-Site Retrospective Cohort Study
	Smith BD1, Yartel AK2, Krauskopf K3, Massoud OI4, Brown KA5, Fallon MB6, Rein DB7. Clin Infect Dis. 2015 Jan 16. pii: civ002. [Epub ahead of print]

700.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Kohli A1, Osinusi A2, Sims Z3, Nelson A4, Meissner EG4, Barrett LL5, Bon D6, Marti MM4, Silk R7, Kotb C7, Gross C7, Jolley TA4, Sidharthan S3, Petersen T3, Townsend K4, Egerson D7, Kapoor R7, Spurlin E4, Sneller M4, Proschan M8, Herrmann E6, Kwan R4, Teferi G9, Talwani R10, Diaz G11, Kleiner DE12, Wood BJ13, Chavez J9, Abbott S9, Symonds WT14, Subramanian GM14, Pang PS14, McHutchison J14, Polis MA4, Fauci AS4, Masur H3, Kottilil S15. Lancet. 2015 Jan 12. pii: S0140-6736(14)61228-9. doi: 10.1016/S0140-6736(14)61228-9. [Epub ahead of print]

701.	Study of pruritus in chronic hepatitis C patients
	Suzuki K1, Tamano M1, Katayama Y1, Kuniyoshi T1, Kagawa K1, Takada H1, Suzuki K1. World J Gastroenterol. 2014 Dec 21;20(47):17877-82. doi: 10.3748/wjg.v20.i47.17877.

702.	Normocaloric low cholesterol diet modulates th17/treg balance in patients with chronic hepatitis C virus infection
	Maggio R1, Viscomi C2, Andreozzi P3, D'Ettorre G4, Viscogliosi G3, Barbaro B2, Gori M2, Vullo V4, Balsano C1. PLoS One. 2014 Dec 22;9(12):e112346. doi: 10.1371/journal.pone.0112346. eCollection 2014.

703.	Influence of Hepatitis C Virus and IL28B Genotypes on Liver Stiffness
	Lundbo LF1, Clausen LN1, Weis N2, Schønning K3, Rosenørn L4, Benfield T1, Christensen PB5. PLoS One. 2014 Dec 29;9(12):e115882. doi: 10.1371/journal.pone.0115882. eCollection 2014.

704.	Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
	Kayali Z1, Schmidt WN2. Pharmgenomics Pers Med. 2014 Dec 8;7:387-98. doi: 10.2147/PGPM.S52629. eCollection 2014.

705.	Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term
	Macías J1, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA. Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print]

706.	Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans
	Molnar MZ1, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, Kovesdy CP. Hepatology. 2014 Dec 20. doi: 10.1002/hep.27664. [Epub ahead of print]

707.	Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors
	Sacchini D1, Craxì L2, Refolo P3, Minacori R3, Cicchetti A4, Gasbarrini A5, Cammà C6, Spagnolo AG3; on behalf of the WEF Study Group. Dig Liver Dis. 2014 Nov 24. pii: S1590-8658(14)00805-6. doi: 10.1016/j.dld.2014.11.011. [Epub ahead of print]

708.	Metabolic Phenotyping for Enhanced Mechanistic Stratification of Chronic Hepatitis C-Induced Liver Fibrosis
	Sands CJ1, Guha IN2, Kyriakides M1, Wright M3, Beckonert O1, Holmes E1, Rosenberg WM4, Coen M1. Am J Gastroenterol. 2014 Dec 23. doi: 10.1038/ajg.2014.370. [Epub ahead of print]

709.	Cure of HCV related liver disease
	Shiffman ML1, Benhamou Y. Liver Int. 2015 Jan;35 Suppl 1:71-7. doi: 10.1111/liv.12734.

710.	Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients
	Peter J1, Nelson DR. Liver Int. 2015 Jan;35 Suppl 1:65-70. doi: 10.1111/liv.12718.

711.	Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
	Welch NM1, Jensen DM. Liver Int. 2015 Jan;35 Suppl 1:11-7. doi: 10.1111/liv.12715.

712.	The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C
	Younossi Z1, Henry L2. Dig Liver Dis. 2014 Dec 15;46S5:S186-S196. doi: 10.1016/j.dld.2014.09.025. Epub 2014 Nov 10.

713.	Sofosbuvir as backbone of interferon free treatments
	Bourlière M1, Oules V2, Ansaldi C2, Adhoute X2, Castellani P2. Dig Liver Dis. 2014 Dec 15;46S5:S212-S220. doi: 10.1016/j.dld.2014.09.024. Epub 2014 Nov 6.

714.	Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C
	Kumar S1, Jacobson IM2. J Hepatol. 2014 Nov;61(1S):S91-S97. doi: 10.1016/j.jhep.2014.09.006. Epub 2014 Nov 3.

715.	Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
	Lenz O1, Verbinnen T2, Fevery B2, Tambuyzer L2, Vijgen L2, Peeters M2, Buelens A2, Ceulemans H2, Beumont M2, Picchio G3, Meyer SD2. J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00881-2. doi: 10.1016/j.jhep.2014.11.032. [Epub ahead of print]

716.	Extrahepatic manifestations of chronic hepatitis C virus infection
	Cacoub P1, Gragnani L2, Comarmond C3, Zignego AL2. Dig Liver Dis. 2014 Dec 15;46S5:S165-S173. doi: 10.1016/j.dld.2014.10.005. Epub 2014 Nov 8.

717.	Resolute efforts to cure hepatitis C: Understanding patients' reasons for completing antiviral treatment
	Clark JA1, Gifford AL2. Health (London). 2014 Nov 5. pii: 1363459314555237. [Epub ahead of print]

718.	Outcomes in Liver Transplantation: Does Sex Matter?
	Sarkar M1, Watt KD2, Terrault N3, Berenguer M4. J Hepatol. 2014 Nov 26. pii: S0168-8278(14)00872-1. doi: 10.1016/j.jhep.2014.11.023. [Epub ahead of print]

719.	Liver Stiffness Measurement among Patients with Chronic Hepatitis B and C: Results from a 5-Year Prospective Study
	Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. PLoS One. 2014 Nov 4;9(11):e111912. doi: 10.1371/journal.pone.0111912. eCollection 2014.

720.	An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
	Kwo PY1, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X N Engl J Med. 2014 Nov 11. [Epub ahead of print]

721.	A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing
	Baumert TF1, Fauvelle C2, Chen DY3, Lauer GM4. J Hepatol. 2014 Nov;61(1S):S34-S44. doi: 10.1016/j.jhep.2014.09.009. Epub 2014 Nov 3.

722.	Are selective serotonin reuptake inhibitors associated with hepatocellular carcinoma in patients with hepatitis C?
	Pocha C1, Knott A, Rector TS, Dieperink E. J Clin Psychiatry. 2014 Oct;75(10):e1122-6. doi: 10.4088/JCP.13m08877.

723.	The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients
	Younossi Z1, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. Aliment Pharmacol Ther. 2014 Nov 21. doi: 10.1111/apt.13027. [Epub ahead of print]

724.	Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study
	Wu T1, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ. Dig Dis. 2014;32(6):791-9. doi: 10.1159/000368024. Epub 2014 Oct 29.

725.	Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy
	Tada T1, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. J Gastroenterol. 2014 Nov 7. [Epub ahead of print]

726.	Chronic Hepatitis B and Liver Cancer Risks among Asian Immigrants in New York City: Results from a Large, Community-Based Screening, Evaluation, and Treatment Program
	Pollack HJ1, Kwon SC2, Wang SH3, Wyatt LC2, Trinh-Shevrin C2; AAHBP Coalition. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2229-39. doi: 10.1158/1055-9965.EPI-14-0491.

727.	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
	Charlton M1, Gane E2, Manns MP3, Brown RS Jr4, Curry MP5, Kwo PY6, Fontana RJ7, Gilroy R8, Teperman L9, Muir AJ10, McHutchison JG11, Symonds WT11, Brainard D11, Kirby B11, Dvory-Sobol H11, Denning J11, Arterburn S11, Samuel D12, Forns X13, Terrault NA14. Gastroenterology. 2014 Oct 7. pii: S0016-5085(14)01194-9. doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print]

728.	Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
	Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]

729.	Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus
	Yoshida EM1, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead

730.	Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis
	Stine JG1, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG. Dig Dis Sci. 2014 Nov 6. [Epub ahead of print]

731.	Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
	Poordad F1, Agarwal K2, Younes Z3, Cohen D4, Xie W4, Podsadecki T4. Clin Infect Dis. 2014 Nov 2. pii: ciu865. [Epub ahead of print]

732.	Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
	Stirnimann G. Expert Opin Pharmacother. 2014 Dec;15(17):2609-22. doi: 10.1517/14656566.2014.972364. Epub 2014 Oct 27.

733.	The continuum of hepatitis C testing and care
	Viner K1, Kuncio D, Newbern EC, Johnson CC. Hepatology. 2014 Oct 28. doi: 10.1002/hep.27584. [Epub ahead of print]

734.	Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies
	Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]

735.	Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment
	Huang F1, Moschetti V2, Lang B3, Halabi A4, Petersen-Sylla M4, Yong CL5, Elgadi M6. Antimicrob Agents Chemother. 2014 Oct 27. pii: AAC.03359-14. [Epub ahead of print]

736.	Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care
	Muir AJ. Top Antivir Med. 2014 Sep-Oct;22(4):685-9.

737.	Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013
	Kim HY, Kim W. World J Gastroenterol. 2014 Oct 28;20(40):14581-14588.

738.	Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
	Svarovskaia ES1, Dvory-Sobol H1, Parkin N2, Hebner C1, Gontcharova V1, Martin R1, Ouyang W1, Han B1, Xu S1, Ku K1, Chiu S1, Gane E3, Jacobson IM4, Nelson DR5, Lawitz E6, Wyles DL7, Bekele N1, Brainard D1, Symonds WT1, McHutchison JG1, Miller MD1, Mo H1. Clin Infect Dis. 2014 Sep 28. pii: ciu697. [Epub ahead of print]

739.	Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis
	Luo YQ1, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. J Zhejiang Univ Sci B. 2014 Oct;15(10):900-6. doi: 10.1631/jzus.B1400073.

740.	Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares
	Liu Y, Lawrence RH, Falck-Ytter Y, Watts B, Hirsch AA1. Am J Manag Care. 2014 Jul 1;20(7):e257-64.

741.	Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs
	Schackman BR1, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Addiction. 2014 Oct 8. doi: 10.1111/add.12754. [Epub ahead of print]

742.	Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection
	Cresswell FV1, Fisher M2, Hughes DJ1, Shaw SG1, Homer G3, Hassan-Ibrahim MO3. Clin Infect Dis. 2014 Oct 9. pii: ciu782. [Epub ahead of print]

743.	Hepatitis B knowledge and preventive practices of Chinese American immigrants in Southern California
	Zhao X1, Edwards QT, Patel N, Hicks RW. J Am Assoc Nurse Pract. 2014 Oct 6. doi: 10.1002/2327-6924.12173. [Epub ahead of print]

744.	A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection
	Zuo SR1, Zuo XC, Wang CJ, Ma YT, Zhang HY, Li ZJ, Song LY, Deng ZZ, Liu SK. J Clin Pharmacol. 2014 Oct 7. doi: 10.1002/jcph.409. [Epub ahead of print]

745.	Sofosbuvir (Sovaldi) for the treatment of hepatitis C
	Lam B1, Henry L, Younossi Z. Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Epub 2014 Jun 11.

746.	What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
	McDonald SA1, Innes HA2, Hayes PC3, Dillon JF4, Mills PR5, Goldberg DJ6, Barclay S7, Allen S8, Fox R5, Fraser A9, Kennedy N10, Bhattacharyya D11, Hutchinson SJ2. J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00635-7. doi: 10.1016/j.jhep.2014.08.046. [Epub ahead of print]

747.	Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients
	Meissner EG1, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print]

748.	Simeprevir (TMC435) with Peginterferon/Ribavirin in Patients Coinfected with HCV Genotype-1 and HIV-1: A Phase III Study
	Dieterich D1, Rockstroh JK2, Orkin C3, Gutiérrez F4, Klein MB5, Reynes J6, Shukla U7, Jenkins A8, Lenz O9, Ouwerkerk-Mahadevan S10, Peeters M9, De La Rosa G7, Tambuyzer L9, Jessner W9. Clin Infect Dis. 2014 Sep 5. pii: ciu675. [Epub ahead of print]

749.	Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: A concise review
	Yau AH, Yoshida EM. Can J Gastroenterol Hepatol. 2014 Sep;28(8):445-51.

750.	Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach
	Lanini S1, Mammone A, Puro V, Girardi E, Bruzzi P, Ippolito G. New Microbiol. 2014 Jul;37(3):263-76. Epub 2014 Jul 1.

751.	Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection
	Patel R1, Mikuls T, Richards JS, Kerr G, Cannon G, Baker JF. Arthritis Care Res (Hoboken). 2014 Sep 3. doi: 10.1002/acr.22463. [Epub ahead of print]

752.	Current Practices of Screening for Incident Hepatitis C Virus Infection among HIV- Infected, HCV-Uninfected Individuals in Primary Care
	Freiman JM1, Huang W1, White L2, Geng EH3, Hurt CB4, Taylor LE5, Overton ET6, Cachay ER7, Kitahata MM8, Moore RD9, Rodriguez B10, Mayer KH11, Linas BP12. Clin Infect Dis. 2014 Sep 3. pii: ciu698. [Epub ahead of print]

753.	Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C
	Younossi ZM1, Stepanova M2, Henry L3, Gane E4, Jacobson IM5, Lawitz E6, Nelson D7, Gerber L2, Nader F8, Hunt S2. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6.

754.	Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities
	Alvarez KJ1, Befus M2, Herzig CT3, Larson E3. J Infect Public Health. 2014 Aug 30. pii: S1876-0341(14)00118-X. doi: 10.1016/j.jiph.2014.07.018. [Epub ahead of print]

755.	Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis
	Huang H, Kang R, Zhao Z. PLoS One. 2014 Sep 3;9(9):e106376. doi: 10.1371/journal.pone.0106376. eCollection 2014.

756.	Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus
	Summers BB1, Beavers JW, Klibanov OM. J Pharm Pharmacol. 2014 Aug 31. doi: 10.1111/jphp.12294. [Epub ahead of print]

757.	Management of hepatitis C virus and human immunodeficiency virus coinfection
	O'neil CR1, Coffin CS. Minerva Gastroenterol Dietol. 2014 Sep;60(3):165-75.

758.	Follow-up testing for hepatitis C virus infection: an analysis of massachusetts surveillance data, 2007-2010
	Barton K, Church D, Onofrey S, Cocoros N, DeMaria A Jr. Public Health Rep. 2014 Sep;129(5):403-7.

759.	BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion
	Grady BP1, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J. J Viral Hepat. 2014 Sep 1. doi: 10.1111/jvh.12303. [Epub ahead of print]

760.	Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
	Galbraith JW1, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE. Hepatology. 2014 Sep 1. doi: 10.1002/hep.27410. [Epub ahead of print]

761.	Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring-predictors and predictive models of disease progression
	Konerman MA1, Yapali S, Lok AS. Aliment Pharmacol Ther. 2014 Aug 28. doi: 10.1111/apt.12921. [Epub ahead of print]

762.	Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes
	Liu T, Howell GT, Turner L, Corace K, Garber G, Cooper C. Can J Gastroenterol Hepatol. 2014 Jul-Aug;28(7):381-4.

763.	A Pilot Study Examining the Safety and Tolerability of Valacyclovir in Veterans With Hepatitis C Virus/Herpes Simplex Virus Type 2 Coinfection
	Burton MJ1, Penman A, Sunesara I, McGuire BM, Hook EW 3rd. Am J Med Sci. 2014 Aug 26. [Epub ahead of print]

764.	Liver inflammation is a Risk Factor for Prediabetes in At-Risk Latinos with and without Hepatitis C Infection
	Burman BE1, Bacchetti P, Ayala CE, Gelman N, Melgar J, Khalili M. Liver Int. 2014 Aug 23. doi: 10.1111/liv.12676. [Epub ahead of print]

765.	Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection
	Flanagan S1, Crawford-Jones A, Orkin C. Expert Rev Clin Pharmacol. 2014 Sep 11:1-14. [Epub ahead of print]

766.	Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection
	Scott J1, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L.

767.	Treating hepatitis C in the elderly: the future is near?
	Conti F1, Vitale G, Andreone P. Expert Opin Pharmacother. 2014 Oct;15(14):2019-28. doi: 10.1517/14656566.2014.945422. Epub 2014 Aug 26.

768.	An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials
	Wendt A1, Bourlière M2. Ther Adv Infect Dis. 2013 Dec;1(6):191-208. doi: 10.1177/2049936113502647.

769.	Lack of Clinically Significant Pharmacokinetic Interaction Between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir
	Wire MB1, Fang L2, Hussaini A3, Kleha JF4, Theodore D4. Antimicrob Agents Chemother. 2014 Aug 25. pii: AAC.03091-14. [Epub ahead of print]

770.	Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring-predictors and predictive models of disease progression
	Konerman MA1, Yapali S, Lok AS. Aliment Pharmacol Ther. 2014 Aug 28. doi: 10.1111/apt.12921. [Epub ahead of print]

771.	The frequency and determinants of liver stiffness measurement failure: a retrospective study of
	Ji D1, Shao Q1, Han P2, Li F1, Li B1, Zang H3, Niu X1, Li Z1, Xin S3, Chen G1. PLoS One. 2014 Aug 14;9(8):e105183. doi: 10.1371/journal.pone.0105183. eCollection 2014.

772.	Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance
	Chang ML1, Tsou YK2, Hu TH3, Lin CH2, Lin WR2, Sung CM2, Chen TH2, Cheng ML4, Chang KC3, Chiu CT2, Yeh CT2, Pang JH5, Shiao MS4. PLoS One. 2014 Aug 14;9(8):e104783. doi: 10.1371/journal.pone.0104783. eCollection 2014.

773.	Daclatasvir + Asunaprevir: first global approval
	Poole RM. Drugs. 2014 Sep;74(13):1559-71. doi: 10.1007/s40265-014-0279-4.

774.	Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir
	Donaldson EF1, Harrington PR, O'Rear JJ, Naeger LK. Hepatology. 2014 Aug 14. doi: 10.1002/hep.27375. [Epub ahead of print]

775.	Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C
	Evon DM1, Esserman DE2, Howell MA3, Ruffin RA1. Pharmacopsychiatry. 2014 Sep;47(6):195-201. doi: 10.1055/s-0034-1385929. Epub 2014 Aug 14.

776.	Hepatitis C in African Americans
	Saab S1, Jackson Md Facg C2, Nieto DO Facg Facp J3, Francois Md MSc Facg F4. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.243. [Epub ahead of print]

777.	Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
	Hayashi N1, Mobashery N, Izumi N. J Gastroenterol. 2014 Aug 13. [Epub ahead of print]

778.	Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C
	Lawitz E1, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2845. [Epub ahead of print]

779.	The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis c virus
	Eley T1, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M. Clin Drug Investig. 2014 Sep;34(9):661-71. doi: 10.1007/s40261-014-0219-9.

780.	Treatment of hepatitis C: a systematic review
	Kohli A1, Shaffer A2, Sherman A2, Kottilil S2. JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085.

781.	Ending hepatitis C in the United States: the role of screening
	Coffin PO1, Reynolds A2. Hepat Med. 2014 Jul 3;6:79-87. doi: 10.2147/HMER.S40940. eCollection 2014.

782.	Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting
	Price JC1, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Dig Dis Sci. 2014 Aug 8. [Epub ahead of print]

783.	Pegylated-IFN?2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new
	Bichoupan K1, Dieterich DT. Expert Opin Biol Ther. 2014 Sep;14(9):1369-78. doi: 10.1517/14712598.2014.943180.

784.	Modeling viral evolutionary dynamics after telaprevir-based treatment
	Haseltine EL1, De Meyer S2, Dierynck I2, Bartels DJ1, Ghys A2, Davis A1, Zhang EZ1, Tigges AM1, Spanks J1, Picchio G3, Kieffer TL1, Sullivan JC1. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014.

785.	Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott Realtime HCV Genotype II for Detecting Hepatitis C Virus Genotype 6
	Yang R1, Cong X1, Du S1, Fei R1, Rao H1, Wei L2. J Clin Microbiol. 2014 Aug 6. pii: JCM.00882-14. [Epub ahead of print]

786.	The role played by gender in viral hepatitis
	Bernabucci V1, Villa E. Scand J Clin Lab Invest Suppl. 2014;74(244):90-4. doi: 10.3109/00365513.2014.936695.

787.	Global epidemiology and genotype distribution of the hepatitis C virus infection
	Gower E1, Estes C C1, Hindman S1, Razavi-Shearer K1, Razavi H2. J Hepatol. 2014 Jul 30. pii: S0168-8278(14)00526-1. doi: 10.1016/j.jhep.2014.07.027. [Epub ahead of print]

788.	The changing burden of hepatitis C virus infection in the United States: model-based predictions
	Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. Ann Intern Med. 2014 Aug 5;161(3):170-80. doi: 10.7326/M14-0095.

789.	Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir
	Sabo JP1, Kort J1, Ballow C2, Haschke M3, Battegay M3, Fuhr R4, Girlich B5, Schobelock M6, Feifel U7, Lang B8, Li Y1, Elgadi M9. Clin Infect Dis. 2014 Aug 4. pii: ciu616. [Epub ahead of print]

790.	Clinical outcomes of compensated and decompensated cirrhosis: A long term study
	Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504.

791.	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
	Petta S1, Cabibbo G1, Enea M2, Macaluso FS1, Plaia A2, Bruno R3, Gasbarrini A4, Bruno S5, Craxì A1, Cammà C6; on behalf of the WEF study group. Dig Liver Dis. 2014 Jul 22. pii: S1590-8658(14)00422-8. doi: 10.1016/j.dld.2014.06.009. [Epub ahead of print]

792.

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lawitz E1, Sulkowski MS2, Ghalib R3, Rodriguez-Torres M4, Younossi ZM5, Corregidor A6, DeJesus E7, Pearlman B8, Rabinovitz M9, Gitlin N10, Lim JK11, Pockros PJ12, Scott JD13, Fevery B14, Lambrecht T15, Ouwerkerk-Mahadevan S14, Callewaert K14, Symonds WT16, Picchio G17, Lindsay KL17, Beumont M14, Jacobson IM18. Lancet. 2014 Jul 26. pii: S0140-6736(14)61036-9. doi: 10.1016/S0140-6736(14)61036-9. [Epub ahead of print]

793.

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Manns M1, Pol S2, Jacobson IM3, Marcellin P4, Gordon SC5, Peng CY6, Chang TT7, Everson GT8, Heo J9, Gerken G10, Yoffe B11, Towner WJ12, Bourliere M13, Metivier S14, Chu CJ15, Sievert W16, Bronowicki JP17, Thabut D18, Lee YJ19, Kao JH20, McPhee F21, Kopit J21, Mendez P22, Linaberry M22, Hughes E22, Noviello S22; on behalf of the HALLMARK-DUAL Study Team. Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X. [Epub ahead of print]

794.	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
	Saab S1, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Aliment Pharmacol Ther. 2014 Jul 28. doi: 10.1111/apt.12871. [Epub ahead of print]

795.	Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in 5 EU countries
	Marcellin P1, Grotzinger K, Theodore D, Demuth D, Manns M, Bañares Cañizares R, Pike J, Forssen UM. J Gastroenterol Hepatol. 2014 Aug 4. doi: 10.1111/jgh.12698. [Epub ahead of print]

796.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Hézode C1, Hirschfield GM2, Ghesquiere W3, Sievert W4, Rodriguez-Torres M5, Shafran SD6, Thuluvath PJ7, Tatum HA8, Waked I9, Esmat G10, Lawitz EJ11, Rustgi VK12, Pol S13, Weis N14, Pockros PJ15, Bourlière M16, Serfaty L17, Vierling JM18, Fried MW19, Weiland O20, Brunetto MR21, Everson GT22, Zeuzem S23, Kwo PY24, Sulkowski M25, Bräu N26, Hernandez D27, McPhee F27, Wind-Rotolo M28, Liu Z29, Noviello S28, Hughes EA28, Yin PD27, Schnittman S27. Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print]

797.	New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment
	Zimner-Rapuch S1, Janus N, Deray G, Launay-Vacher V. Drugs. 2014 Jul 25. [Epub ahead of print]

798.

Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)

Loras C1, Gisbert JP2, Saro MC3, Piqueras M4, Sánchez-Montes C5, Barrio J6, Ordás I7, Montserrat A8, Ferreiro R9, Zabana Y1, Chaparro M2, Fernández-Bañares F1, Esteve M10; for the REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). J Crohns Colitis. 2014 Jul 19. pii: S1873-9946(14)00206-2. doi: 10.1016/j.crohns.2014.06.009. [Epub ahead of print]

799.	Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response
	Bichoupan K1, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Hepatology. 2014 Jul 28. doi: 10.1002/hep.27340. [Epub ahead of print]

800.	Delivery of treatment for hepatitis C virus infection in the primary care setting
	Baker D1, Alavi M, Erratt A, Hill S, Balcomb A, Hallinan R, Siriragavan S, Richmond D, Smart J, Keats J, Doong N, Marks P, Grebely J, Dore GJ. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1003-9. doi: 10.1097/MEG.0000000000000150.

801.	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
	Gentile I1, Buonomo AR1, Zappulo E1, Minei G1, Morisco F2, Borrelli F1, Coppola N3, Borgia G1. Ther Clin Risk Manag. 2014 Jun 26;10:493-504. doi: 10.2147/TCRM.S66731. eCollection 2014.

802.	Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection
	Sulkowski MS1, Naggie S2, Lalezari J3, Fessel WJ4, Mounzer K5, Shuhart M6, Luetkemeyer AF7, Asmuth D8, Gaggar A9, Ni L9, Svarovskaia E9, Brainard DM9, Symonds WT9, Subramanian GM9, McHutchison JG9, Rodriguez-Torres M10, Dieterich D11; PHOTON-1 Investigators. JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734.

803.	Assessment of Hepatitis C Risk Factors and Infection Prevalence in a Jail Population
	Wenger PJ1, Rottnek F, Crippin JS, Parker T. Am J Public Health. 2014 Jul 17:e1-e6. [Epub ahead of print]

804.	The Effect of HIV-Hepatitis C Co-Infection on Bone Mineral Density and Fracture: A Meta-Analysis
	O'Neill TJ1, Rivera L1, Struchkov V2, Zaheen A3, Thein HH4. PLoS One. 2014 Jul 17;9(7):e101493. doi: 10.1371/journal.pone.0101493. eCollection 2014.

805.	Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients
	Liu X1, Wang Y2, Zhang G1, Li N3, Zhu Q3, Chang H1, Han Q3, Lv Y4, Liu Z5. Int J Antimicrob Agents. 2014 Jun 10. pii: S0924-8579(14)00163-0. doi: 10.1016/j.ijantimicag.2014.04.018. [Epub ahead of print]

806.	Concordance of risk behavior reporting within HCV serodiscordant injecting partnerships of young injection drug users in San Francisco, CA
	Evans JL1, Morris MD2, Yu M2, Page K2, Hahn JA2. Drug Alcohol Depend. 2014 Jul 4. pii: S0376-8716(14)00955-7. doi: 10.1016/j.drugalcdep.2014.06.028. [Epub ahead of print]

807.	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C
	Bronowicki JP1, Ratziu V2, Gadano A3, Thuluvath PJ4, Bessone F5, Martorell CT6, Pol S7, Terg R8, Younes Z9, He B10, Eley T10, Cohen D11, Yu F11, Hernandez D11, McPhee F11, Mendez P10, Hughes E10. J Hepatol. 2014 Jul 16. pii: S0168-8278(14)00480-2. doi: 10.1016/j.jhep.2014.07.011. [Epub ahead of print]

808.	Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965
	Cartwright EJ1, Rentsch C, Rimland D. BMC Res Notes. 2014 Jul 14;7(1):449. doi: 10.1186/1756-0500-7-449.

809.	Antiviral treatment of hepatitis C
	Feeney ER1, Chung RT2. BMJ. 2014 Jul 7;349:g3308. doi: 10.1136/bmj.g3308.

810.	MicroRNA and hepatitis C virus- challenges in investigation and translation: a review of the literature
	Waldron PR1, Holodniy M2. Diagn Microbiol Infect Dis. 2014 Jun 5. pii: S0732-8893(14)00243-0. doi: 10.1016/j.diagmicrobio.2014.05.024. [Epub ahead of print]

811.	An overview of hepatitis C vaccines
	Garcia A, Fernandez S, Toro F, De Sanctis JB1. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):85-91.

812.	Hepatic Retransplant: What Have We Learned?
	Kitchens WH1, Yeh H2, Markmann JF3. Clin Liver Dis. 2014 Aug;18(3):731-751. doi: 10.1016/j.cld.2014.05.010.

813.	Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential
	Lauffenburger JC1, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Eur J Gastroenterol Hepatol. 2014 Jul 10. [Epub ahead of print]

814.	Oral manifestations of hepatitis C virus infection
	Carrozzo M, Scally K. World J Gastroenterol. 2014 Jun 28;20(24):7534-7543.

815.	Association between chronic hepatitis C virus infection and low muscle mass in US adults
	Gowda C1, Compher C, Amorosa VK, Lo Re V 3rd. J Viral Hepat. 2014 Jul 2. doi: 10.1111/jvh.12273. [Epub ahead of print]

816.	Estimating the true prevalence of hepatitis C in rhode island
	Kinnard EN1, Taylor LE2, Galárraga O3, Marshall BD4. R I Med J (2013). 2014 Jul 1;96(7):19-24.

817.	The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis
	Yehia BR1, Schranz AJ2, Umscheid CA3, Lo Re V 3rd4. PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014.

818.	Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis
	García-Álvarez M1, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, Resino S. Hepatology. 2014 Jun 27. doi: 10.1002/hep.27281. [Epub ahead of print]

819.	Viral kinetic modeling: state of the art
	Canini L1, Perelson AS. J Pharmacokinet Pharmacodyn. 2014 Jun 25. [Epub ahead of print]

820.	Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs
	Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, Page K. BMC Public Health. 2014 Jun 25;14(1):645. [Epub ahead of print]

821.	Emerging therapeutic options for the management of hepatitis C infection
	Thompson JR. World J Gastroenterol. 2014 Jun 21;20(23):7079-7088.

822.	Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study
	Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print]

823.	Risk of hepatitis C virus exposure in orthopedic surgery: is universal screening needed?
	DelSole EM, Mercuri JJ, Stachel A, Phillips MS, Zuckerman JD1. Am J Orthop (Belle Mead NJ). 2014 Jun;43(6):E117-23.

824.	Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program
	Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print]

825.	Natural history and management of hepatitis C: does sex play a role?
	Baden R1, Rockstroh JK2, Buti M3. Infect Dis. 2014 Jul 15;209 Suppl 3:S81-5. doi: 10.1093/infdis/jiu057.

826.	Restricting liver transplant recipients to younger donors does not increase wait-list time or drop-out rate: The hepatitis C experience
	Flemming JA1, Vagefi PA, Freise CE, Yao FY, Terrault NA. Liver Transpl. 2014 Jun 25. doi: 10.1002/lt.23937. [Epub ahead of print]

827.	Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study
	Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print]

828.	Risk of hepatitis C virus exposure in orthopedic surgery: is universal screening needed?
	DelSole EM, Mercuri JJ, Stachel A, Phillips MS, Zuckerman JD1. Am J Orthop (Belle Mead NJ). 2014 Jun;43(6):E117-23.

829.	Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program
	Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print]

830.	Natural history and management of hepatitis C: does sex play a role?
	Baden R1, Rockstroh JK2, Buti M3. Infect Dis. 2014 Jul 15;209 Suppl 3:S81-5. doi: 10.1093/infdis/jiu057.

831.	Restricting liver transplant recipients to younger donors does not increase wait-list time or drop-out rate: The hepatitis C experience
	Flemming JA1, Vagefi PA, Freise CE, Yao FY, Terrault NA. Liver Transpl. 2014 Jun 25. doi: 10.1002/lt.23937. [Epub ahead of print]

832.	Incidence and Management of Rash in Telaprevir-Treated Patients: Lessons for Simeprevir?
	Smith MA1, Johnson HJ2, Chopra KB2, Dunn MA2, Ulrich AM2, Mohammad RA3. Ann Pharmacother. 2014 Jun 17. pii: 1060028014539274. [Epub ahead of print]

833.	New insight into the enhanced effect of pegylated IFN-alpha
	Abe H1, Hayes CN, Chayama K. Hepatology. 2014 Jun 18. doi: 10.1002/hep.27269. [Epub ahead of print]

834.	Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model
	Ikeda K1, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Oncology. 2014 Jun 7;86(5-6):295-302. [Epub ahead of print]

835.	High Post-Transplant Virologic Response in Hepatitis C Virus Infected Patients Treated with Pre-Transplant Protease Inhibitor-Based Triple Therapy
	Verna EC1, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. Liver Int. 2014 Jun 6. doi: 10.1111/liv.12616. [Epub ahead of print]

836.	Outbreaks of Infections Associated With Drug Diversion by US Health Care Personnel
	Schaefer MK1, Perz JF2. Mayo Clin Proc. 2014 May 30. pii: S0025-6196(14)00342-5. doi: 10.1016/j.mayocp.2014.04.007. [Epub ahead of print]

837.	Validation of the fatigue severity scale in chronic hepatitis C
	Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J. Health Qual Life Outcomes. 2014 Jun 11;12(1):90. [Epub ahead of print]

838.	IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response
	Lin JC1, Habersetzer F2, Rodriguez-Torres M3, Afdhal N4, Lawitz EJ5, Paulson MS6, Zhu Y6, Subramanian GM6, McHutchison JG6, Sulkowski M7, Wyles DL1, Schooley RT1. J Infect Dis. 2014 Jun 6. pii: jiu325. [Epub ahead of print]

839.	Long term changes in liver histology following treatment of chronic hepatitis C virus
	Shiffman ML1, Sterling RK2, Contos M3, Hubbard S2, Long A1, Luketic VA2, Stravitz RT2, Fuchs M2, Sanyal AJ2. Ann Hepatol. 2014 Jul-Aug;13(4):340-9.

840.	Pushing to a cure by harnessing innate immunity against hepatitis C virus
	Ireton RC1, Gale M Jr2. Antiviral Res. 2014 Jun 4. pii: S0166-3542(14)00149-1. doi: 10.1016/j.antiviral.2014.05.012. [Epub ahead of print]

841.	Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
	Manns M1, Marcellin P2, Poordad F3, de Araujo ES4, Buti M5, Horsmans Y6, Janczewska E7, Villamil F8, Scott J9, Peeters M10, Lenz O10, Ouwerkerk-Mahadevan S11, De La Rosa G12, Kalmeijer R12, Sinha R10, Beumont-Mauviel M10. Lancet. 2014 Jun 3. pii: S0140-6736(14)60538-9. doi: 10.1016/S0140-6736(14)60538-9. [Epub ahead of print]

842.	Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort
	Tracy D1, Hahn JA2, Fuller Lewis C1, Evans J3, Briceño A3, Morris MD3, Lum PJ4, Page K3. BMJ Open. 2014 May 29;4(5):e004988. doi: 10.1136/bmjopen-2014-004988.

843.	Hepatitis C in HIV-Infected Patients: Impact of Direct-Acting Antivirals
	Bichoupan K1, Dieterich DT. Drugs. 2014 May 28. [Epub ahead of print]

844.	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
	Jacobson IM1, Dore GJ2, Foster GR3, Fried MW4, Radu M5, Rafalsky VV6, Moroz L7, Craxi A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, De La Rosa G11, Kalmeijer R11, Scott J12, Sinha R9, Beumont-Mauviel M9. Lancet. 2014 Jun 3. pii: S0140-6736(14)60494-3. doi: 10.1016/S0140-6736(14)60494-3. [Epub ahead of print]

845.	Response-Guided Therapy for Hepatitis C Genotype 2 and 3 in Those with HIV Coinfection
	Win LL1, James P, Wong DK. Dig Dis Sci. 2014 May 21. [Epub ahead of print]

846.	The current state and future prospects of chronic hepatitis C virus infection treatment
	Moore C1, Levitsky J. Curr Infect Dis Rep. 2014 Aug;16(8):413. doi: 10.1007/s11908-014-0413-1.

847.	Response-Guided Therapy in Patients with Genotype 1 HCV: Current Status and Future Prospects
	Lawitz EJ1, Membreno FE. J Gastroenterol Hepatol. 2014 May 22. doi: 10.1111/jgh.12632. [Epub ahead of print]

848.	The hepatitis C cascade of care: identifying priorities to improve clinical outcomes
	Linas BP1, Barter DM2, Leff JA3, Assoumou SA2, Salomon JA4, Weinstein MC5, Kim AY6, Schackman BR3. PLoS One. 2014 May 19;9(5):e97317. doi: 10.1371/journal.pone.0097317. eCollection 2014.

849.	My Treatment Approach to Chronic Hepatitis C Virus
	Shiffman ML1, Long AG2, James A2, Alexander P2. Mayo Clin Proc. 2014 May 24. pii: S0025-6196(14)00372-3. doi: 10.1016/j.mayocp.2014.04.013. [Epub ahead of print]

850.	Resistance to hepatitis C virus protease inhibitors
	Kieffer TL1, George S2. Curr Opin Virol. 2014 May 19;8C:16-21. doi: 10.1016/j.coviro.2014.04.008. [Epub ahead of print]

851.	Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C
	Elkrief L1, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Hepatology. 2014 May 20. doi: 10.1002/hep.27228. [Epub ahead of print]

852.	Advances in newly developing therapy for chronic hepatitis C virus infection
	Pockros PJ. Front Med. 2014 Jun;8(2):166-74. doi: 10.1007/s11684-014-0334-2. Epub 2014 May 29.

853.	Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity
	Flamm SL1, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print]

854.	Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study
	Frimpong JA1, D'Aunno T, Jiang L. Am J Public Health. 2014 Jun;104(6):e75-82. doi: 10.2105/AJPH.2013.301827. Epub 2014 Apr 17.

855.	Is Screening Baby Boomers for HCV Enough? A Call to Screen for Hepatitis C Virus in Persons from Countries of High Endemicity
	Asselah T1, Perumalswami PV, Dieterich D. Liver Int. 2014 May 20. doi: 10.1111/liv.12599. [Epub ahead of print]

856.	Lower life expectancy among people with an HCV notification: a population-based linkage study
	Alavi M1, Law MG, Grebely J, Thein HH, Walter S, Amin J, Dore GJ. J Viral Hepat. 2014 Jun;21(6):e10-8. doi: 10.1111/jvh.12245.

857.	Epidemiology of hepatitis C virus in pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings
	Larney S1, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Am J Public Health. 2014 Jun;104(6):e69-74. doi: 10.2105/AJPH.2014.301943. Epub 2014 Apr 17.

858.	Adherence During Antiviral Treatment Regimens for Chronic Hepatitis C: A Qualitative Study of Patient-reported Facilitators and Barriers
	Evon DM1, Golin CE, Bonner JE, Grodensky C, Velloza J. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print]

859.	Predictors of donor follow-up after living donor liver transplantation
	Brown RS Jr1, Smith A, Dew MA, Gillespie BW, Hill-Callahan M, Ladner DP. Liver Transpl. 2014 May 13. doi: 10.1002/lt.23912. [Epub ahead of print]

860.	Multiplex Protein Analysis to determine Fibrosis Stage and Progression in Patients with Chronic Hepatitis C
	Patel K1, Remlinger KS2, Walker TG3, Leitner P4, Lucas JE5, Gardner SD2, McHutchison JG6, Irving W7, Guha IN7. Clin Gastroenterol Hepatol. 2014 May 7. pii: S1542-3565(14)00672-7. doi: 10.1016/j.cgh.2014.04.037. [Epub ahead of print]

861.	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters
	van der Meer AJ1, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL. Gut. 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print]

862.	ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection
	Andreone P1, Colombo MG2, Enejosa JV3, Koksal I4, Ferenci P5, Maieron A6, Müllhaupt B7, Horsmans Y8, Weiland O9, Reesink HW10, Rodrigues L Jr3, Hu YB3, Podsadecki T3, Bernstein B3. Gastroenterology. 2014 May 9. pii: S0016-5085(14)00603-9. doi: 10.1053/j.gastro.2014.04.045. [Epub ahead of print]

863.	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
	Zeuzem S1, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; the VALENCE Investigators. N Engl J Med. 2014 May 4. [Epub ahead of print]

864.	Next generation sequencing sheds light on the natural history of hepatitis C infection in patients that fail treatment
	Abdelrahman T1, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Hepatology. 2014 May 2. doi: 10.1002/hep.27192. [Epub ahead of print]

865.	Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
	Sofia MJ. Antiviral Res. 2014 May 2. pii: S0166-3542(14)00114-4. doi: 10.1016/j.antiviral.2014.04.008. [Epub ahead of print]

866.	A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy
	Burton JR Jr1, O'Leary JG2, Verna EC3, Saxena V4, Dodge JL4, Stravitz RT5, Levitsky J6, Trotter JF2, Everson GT1, Brown RS Jr3, Terrault NA7. J Hepatol. 2014 May 3. pii: S0168-8278(14)00300-6. doi: 10.1016/j.jhep.2014.04.037. [Epub ahead of print]

867.	Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model - Arizona and utah, 2012-2014
	Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, Box T, Carroll C, Holtzman D, Ward JW; Division of Viral Hepatitis, National Center for National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):393-8.

868.	Frontiers in the treatment of hepatitis C virus infection
	Ahn J, Flamm SL. Gastroenterol Hepatol (N Y). 2014 Feb;10(2):90-100.

869.	Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
	Stedman C. Therap Adv Gastroenterol. 2014 May;7(3):131-140.

870.	All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection
	Wyles DL1, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. Hepatology. 2014 Feb 5. doi: 10.1002/hep.27053. [Epub ahead of print]

871.	Interferon-free strategies with a nucleoside/nucleotide analogue
	Feld JJ. Semin Liver Dis. 2014 Feb;34(1):37-46. doi: 10.1055/s-0034-1371009. Epub 2014 Apr 29.

872.	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
	Hagan LM1, Sulkowski MS, Schinazi RF. Hepatology. 2014 Mar 28. doi: 10.1002/hep.27151. [Epub ahead of print]

873.	ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type
	Matsuura K1, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M. J Viral Hepat. 2013 Sep 3. doi: 10.1111/jvh.12171. [Epub ahead of print]

874.	Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy
	Miller MH1, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Aliment Pharmacol Ther. 2014 Apr 22. doi: 10.1111/apt.12764. [Epub ahead of print]

875.	The role of interferon in the new era of hepatitis C treatments
	Parekh PJ1, Shiffman ML. Expert Rev Gastroenterol Hepatol. 2014 Apr 23. [Epub ahead of print]

876.	Drugs Aging. 2014 May;31(5):339-47. doi: 10.1007/s40266-014-0170-8.
	Malnick S1, Maor Y, Melzer E, Tal S. Drugs Aging. 2014 May;31(5):339-47. doi: 10.1007/s40266-014-0170-8.

877.	CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response
	Joshi D1, Carey I, Foxton M, Al-Freah M, Bruce M, Heaton N, Quaglia A, O'Grady J, Aluvihare V, Agarwal K. Clin Transplant. 2014 Apr 21. doi: 10.1111/ctr.12354. [Epub ahead of print]

878.	Combination of Racial/Ethnic and Etiology/Disease-Specific Factors are associated with Lower Survival following Liver Transplantation in African Americans: An Analysis from UNOS/OPTN Database
	Wong RJ1, Ahmed A. Clin Transplant. 2014 Apr 21. doi: 10.1111/ctr.12374. [Epub ahead of print]

879.	Patient-Reported Outcomes Assessment in Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin: The VALENCE Study
	Younossi ZM1, Stepanova M2, Zeuzem S3, Dusheiko G4, Esteban R5, Hezode C6, Reesink HW7, Weiland O8, Nader F9, Hunt SL2. J Hepatol. 2014 Apr 5. pii: S0168-8278(14)00220-7. doi: 10.1016/j.jhep.2014.04.003. [Epub ahead of print]

880.	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
	Afdhal N1, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; the ION-1 Investigators. N Engl J Med. 2014 Apr 11. [Epub ahead of print]

881.	Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens
	Younossi ZM1, Stepanova M, Nader F, Jacobson IM, Gane E, Nelson D, Lawitz E, Hunt SL. Hepatology. 2014 Apr 8. doi: 10.1002/hep.27161. [Epub ahead of print]

882.	Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
	Afdhal N1, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.

883.	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
	Kowdley KV1, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; the ION-3 Investigators. N Engl J Med. 2014 Apr 10. [Epub ahead of print]

884.	The Rapid Evolution of Treatment Strategies for Hepatitis C
	Muir AJ. Am J Gastroenterol. 2014 Apr 15. doi: 10.1038/ajg.2014.66. [Epub ahead of print]

885.	Curing Chronic Hepatitis C - The Arc of a Medical Triumph
	Chung RT1, Baumert TF. N Engl J Med. 2014 Apr 10. [Epub ahead of print]

886.	How can we improve tracking of transplanted tissue in the United States?
	Mahajan R1, Kuehnert MJ. Cell Tissue Bank. 2013 Nov 27. [Epub ahead of print]

887.	Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study
	Barocas JA1, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Harm Reduct J. 2014 Jan 14;11:1. doi: 10.1186/1477-7517-11-1.

888.	Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission
	Paintsil E1, Binka M, Patel A, Lindenbach BD, Heimer R. J Infect Dis. 2014 Apr;209(8):1205-11. doi: 10.1093/infdis/jit648. Epub 2013 Nov 23.

889.	Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men
	Fierer DS1, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, van Seggelen WO, Hijdra RM, Cassagnol DG; New York Acute Hepatitis C Surveillance Network. Clin Infect Dis. 2014 Mar;58(6):873-9. doi: 10.1093/cid/cit799. Epub 2013 Dec 13.

890.	Maternal-fetal transmission of hepatitis C infection: what is so special about babies?
	Wen JW1, Haber BA. J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):278-82. doi: 10.1097/MPG.0000000000000258.

891.	Impact of Provider Type on Hepatitis C Outcomes With Boceprevir-based and Telaprevir-based Regimens
	Backus LI1, Belperio PS, Shahoumian TA, Mole LA. J Clin Gastroenterol. 2014 Mar 24. [Epub ahead of print]

892.	Hepatitis C virus: a silent killer relevant to dentistry
	Carrozzo M. Oral Dis. 2014 Mar 26. doi: 10.1111/odi.12240. [Epub ahead of print]

893.	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
	Hagan LM1, Sulkowski MS, Schinazi RF. Hepatology. 2014 Mar 28. doi: 10.1002/hep.27151. [Epub ahead of print]

894.	Boceprevir In Liver Transplant Recipients
	Saab S1, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M, Han S, Busuttil RW. Liver Int. 2014 Mar 26. doi: 10.1111/liv.12548. [Epub ahead of print]

895.	Second wave Anti-HCV Protease Inhibitors: Too little too late?
	De Nicola S1, Aghemo A. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12543. [Epub ahead of print]

896.	The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine
	Haznedar J1, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Drug Dev Res. 2013 Dec 26. doi: 10.1002/ddr.21166. [Epub ahead of print]

897.	Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188)
	Deuffic-Burban S1, Schwarzinger M2, Obach D3, Mallet V4, Pol S5, Pageaux GP6, Canva V7, Deltenre P8, Roudot-Thoraval F9, Larrey D10, Dhumeaux D11, Mathurin P12, Yazdanpanah Y13. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155-X. doi: 10.1016/j.jhep.2014.03.011. [Epub ahead of print]

898.	Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study
	Eg Hansen AB1, Haukali Omland L2, Krarup H3, Obel N2; on behalf of the DANVIR cohort study. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00151-2. doi: 10.1016/j.jhep.2014.03.007. [Epub ahead of print]

899.	Barriers to HCV treatment in the era of triple therapy: A prospective multi-centered study in clinical practice
	Crespo J1, Cabezas J, Sacristán B, Olcoz JL, Pérez R, de la Vega J, García R, García-Pajares F, Sáez-Royuela F, González JM, Jiménez F, Rodríguez S, Cuadrado A, López-Arias MJ, García I, Milla A, García-Riesco E, Muñoz M, Sánchez-Antolín G, Jorquera F. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12536. [Epub ahead of print]

900.	Hepatitis C treatment: an incipient therapeutic revolution
	Delemos AS1, Chung RT2. Trends Mol Med. 2014 Mar 10. pii: S1471-4914(14)00023-9. doi: 10.1016/j.molmed.2014.02.002. [Epub ahead of print]

901.

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

Ponziani FR1, Viganò R2, Iemmolo RM3, Donato MF4, Rendina M5, Toniutto P6, Pasulo L7, Morelli MC8, Burra P9, Miglioresi L10, Merli M11, Di Paolo D12, Fagiuoli S7, Gasbarrini A13, Pompili M13; on behalf of AISF RECOLT-C Group, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M. Dig Liver Dis. 2014 Mar 10. pii: S1590-8658(14)00207-2. doi: 10.1016/j.dld.2014.01.157. [Epub ahead of print]

902.	Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis
	Sato M1, Kondo M1, Tateishi R1, Fujiwara N1, Kato N2, Yoshida H1, Taguri M3, Koike K1. PLoS One. 2014 Mar 17;9(3):e91822. doi: 10.1371/journal.pone.0091822. eCollection 2014.

903.	Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients
	Terrault N1, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Am J Transplant. 2014 Mar 17. doi: 10.1111/ajt.12668. [Epub ahead of print]

904.	Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score
	Virlogeux V1, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F. J Viral Hepat. 2014 Feb 25. doi: 10.1111/jvh.12237. [Epub ahead of print]

905.	HCV Genotype 3 is Associated with an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans with HCV
	Kanwal F1, Kramer JR, Ilyas J, Duan Z, El-Serag HB. Hepatology. 2014 Feb 24. doi: 10.1002/hep.27095. [Epub ahead of print]

906.	Review article: HCV genotype 3 - the new treatment challenge
	Ampuero J1, Romero-Gómez M, Reddy KR. Aliment Pharmacol Ther. 2014 Feb 20. doi: 10.1111/apt.12646. [Epub ahead of print]

907.	Prospective evaluation of Fibrotest®, Fibrometer® and Hepascore® for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C
	Leroy V1, Sturm N2, Faure P3, Trocme C4, Marlu A5, Hilleret MN6, Morel F4, Zarski JP6. J Hepatol. 2014 Mar 11. pii: S0168-8278(14)00137-8. doi: 10.1016/j.jhep.2014.02.029. [Epub ahead of print]

908.	Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
	Kumada H1, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Hepatology. 2014 Mar 6. doi: 10.1002/hep.27113. [Epub ahead of print]

909.	Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed After Previous Therapy: a Phase 3 Trial
	Forns X1, Lawitz E2, Zeuzem S3, Gane E4, Bronowicki JP5, Andreone P6, Horban A7, Brown A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, Scott J11, De La Rosa G12, Kalmeijer R12, Sinha R9, Beumont-Mauviel M9. Gastroenterology. 2014 Mar 3. pii: S0016-5085(14)00293-5. doi: 10.1053/j.gastro.2014.02.051. [Epub ahead of print]

910.	Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial
	Su KP1, Lai HC2, Yang HT3, Su WP2, Peng CY2, Chang JP4, Chang HC5, Pariante CM6. Biol Psychiatry. 2014 Jan 24. pii: S0006-3223(14)00047-X. doi: 10.1016/j.biopsych.2014.01.008. [Epub ahead of print]

911.	Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
	Wyles DL1, Gutierrez JA. J Viral Hepat. 2014 Apr;21(4):229-40. doi: 10.1111/jvh.12230.

912.	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy
	Hwang JP1, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok AS. J Oncol Pract. 2014 Mar 4. [Epub ahead of print]

913.	Impact of birth cohort screening for hepatitis C
	Asrani SK1, Davis GL. Curr Gastroenterol Rep. 2014 Apr;16(4):381. doi: 10.1007/s11894-014-0381-5.

914.	Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design
	Ozen A1, Sherman W2, Schiffer CA1. J Chem Theory Comput. 2013 Dec 10;9(12):5693-5705.

915.	Hepatitis C seroprevalence among prison inmates since 2001: still high but declining
	Varan AK1, Mercer DW1, Stein MS1, Spaulding AC2. Public Health Rep. 2014 Mar;129(2):187-95.

916.	Hepatitis C virus: Here comes all-oral treatment
	Dugum M1, O'Shea R. Cleve Clin J Med. 2014 Mar;81(3):159-72. doi: 10.3949/ccjm.81a.13155.

917.	Disease dependent qualitative and quantitative differences in the inflammatory response to ascites occurring in cirrhotics
	Attar BM, George M, Ion-Nedelcu N, Ramadori G, Thiel DH. World J Hepatol. 2014 Feb 27;6(2):85-91. doi: 10.4254/wjh.v6.i2.85.

918.	Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
	Aggarwal J1, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z, Goss TF. J Viral Hepat. 2014 Feb 16. doi: 10.1111/jvh.12227. [Epub ahead of print]

919.	Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence
	Thomas DL. Top Antivir Med. 2013 Dec;21(5):152-6.

920.	Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness
	Sheahan T1, Imanaka N1, Marukian S2, Dorner M1, Liu P1, Ploss A1, Rice CM3. Cell Host Microbe. 2014 Feb 12;15(2):190-202. doi: 10.1016/j.chom.2014.01.007.

921.	The fragile relationship between hepatitis C virus and its human host
	Schooley RT. Top Antivir Med. 2013 Dec;21(5):148-51.

922.	HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex Formation
	Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA. PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.

923.	Transarterial Therapies for Primary Liver Tumors
	Talenfeld AD1, Sista AK1, Madoff DC2. Surg Oncol Clin N Am. 2014 Apr;23(2):323-351. doi: 10.1016/j.soc.2013.11.002.

924.	Hepatitis C virus infection and insulin resistance
	Bose SK, Ray R. World J Diabetes. 2014 Feb 15;5(1):52-58.

925.	Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation
	Schnitzer ME1, Moodie EE, van der Laan MJ, Platt RW, Klein MB. Biometrics. 2013 Nov 13. doi: 10.1111/biom.12105. [Epub ahead of print]

926.	Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003-2010
	Liu G1, Holmberg SD, Kamili S, Xu F. Dig Dis Sci. 2014 Feb 27. [Epub ahead of print

927.	Hepatitis C and Work Impairment: A Review of Current Literature
	Manne V, Sassi K, Allen R, Saab S. J Clin Gastroenterol. 2014 Jan 31. [Epub ahead of print]

928.	Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test
	Tagny CT1, Mbanya D1, Murphy EL2, Lefrère JJ3, Laperche S4. J Virol Methods. 2014 Jan 30. pii: S0166-0934(14)00012-3. doi: 10.1016/j.jviromet.2014.01.002. [Epub ahead of print]

929.	Hepatitis C screening trends in a large integrated health system
	Linas BP1, Hu H2, Barter DM3, Horberg M2. Am J Med. 2014 Jan 28. pii: S0002-9343(14)00078-3. doi: 10.1016/j.amjmed.2014.01.012. [Epub ahead of print]

930.	Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients
	Zeuzem S1, Demasi R2, Baldini A3, Coate B2, Luo D2, Mrus J4, Witek J2. J Hepatol. 2014 Jan 28. pii: S0168-8278(14)00059-2. doi: 10.1016/j.jhep.2014.01.013. [Epub ahead of print]

931.	A New Laboratory Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients with Hepatitis C and Cirrhosis
	El-Serag HB1, Kanwal F2, Davila JA3, Kramer J4, Richardson P5. Gastroenterology. 2014 Jan 23. pii: S0016-5085(14)00104-8. doi: 10.1053/j.gastro.2014.01.045. [Epub ahead of print]

932.	Acute hepatitis C: management in the rapidly evolving world of HCV
	Sharma SA, Feld JJ. Curr Gastroenterol Rep. 2014 Feb;16(2):371. doi: 10.1007/s11894-014-0371-7.

933.	Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection
	Picchio G1, De Meyer S2, Dierynck I2, Ghys A2, Gritz L3, Kieffer TL3, Bartels DJ3, Witek J4, Bengtsson L3, Luo D4, Kauffman RS3, Adda N5, Sarrazin C6. J Clin Virol. 2014 Jan 6. pii: S1386-6532(13)00542-8. doi: 10.1016/j.jcv.2013.12.011. [Epub ahead of print]

934.	Clearance of Hepatitis C infection is associated with early appearance of broad neutralizing antibody responses
	Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Hepatology. 2014 Jan 15. doi: 10.1002/hep.27013. [Epub ahead of print]

935.	Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
	Lok AS1, Gardiner DF2, Hézode C3, Lawitz EJ4, Bourlière M5, Everson GT6, Marcellin P7, Rodriguez-Torres M8, Pol S9, Serfaty L10, Eley T2, Huang SP11, Li J11, Wind-Rotolo M11, Yu F12, McPhee F12, Grasela DM2, Pasquinelli C2. J Hepatol. 2013 Oct 26. pii: S0168-8278(13)00744-7. doi: 10.1016/j.jhep.2013.10.019. [Epub ahead of print]

936.	Acute hepatitis C: A 24 week-course of Peg-Interferon alpha-2b versus a 12 week-course of Peg-Interferon alpha-2b alone or with ribavirin
	Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Perri GD, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Hepatology. 2014 Jan 18. doi: 10.1002/hep.26991. [Epub ahead of print]

937.	Distinct Features in Natural History and Outcomes of Acute Hepatitis C
	Bunchorntavakul C, Jones LM, Kikuchi M, Valiga ME, Kaplan DE, Nunes FA, Aytaman A, Reddy KR, Chang KM. J Clin Gastroenterol. 2014 Jan 22. [Epub ahead of print]

938.	The impact of hepatitis C burden: an evidence-based approach
	Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. Aliment Pharmacol Ther. 2014 Jan 26. doi: 10.1111/apt.12625. [Epub ahead of print]

939.	A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4